#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Disrupted asymmetry of inter- and intra-hemispheric functional connectivity in patients with drug-naive, first-episode schizophrenia and their unaffected siblings
#Text=Background
#Text=Lack of normal asymmetry in the brain has been reported in patients with schizophrenia.
1-1	0-9	Disrupted	_
1-2	10-19	asymmetry	_
1-3	20-22	of	_
1-4	23-28	inter	_
1-5	28-29	-	_
1-6	30-33	and	_
1-7	34-51	intra-hemispheric	_
1-8	52-62	functional	_
1-9	63-75	connectivity	_
1-10	76-78	in	_
1-11	79-87	patients	_
1-12	88-92	with	_
1-13	93-103	drug-naive	_
1-14	103-104	,	_
1-15	105-118	first-episode	_
1-16	119-132	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-17	133-136	and	_
1-18	137-142	their	_
1-19	143-153	unaffected	_
1-20	154-162	siblings	_
1-21	163-173	Background	_
1-22	174-178	Lack	_
1-23	179-181	of	_
1-24	182-188	normal	_
1-25	189-198	asymmetry	_
1-26	199-201	in	_
1-27	202-205	the	_
1-28	206-211	brain	_
1-29	212-215	has	_
1-30	216-220	been	_
1-31	221-229	reported	_
1-32	230-232	in	_
1-33	233-241	patients	_
1-34	242-246	with	_
1-35	247-260	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-36	260-261	.	_

#Text=However, it remains unclear whether disrupted asymmetry originates from inter-hemispheric functional connectivity (FC) and/or intra-hemispheric FC in this patient population.
2-1	262-269	However	_
2-2	269-270	,	_
2-3	271-273	it	_
2-4	274-281	remains	_
2-5	282-289	unclear	_
2-6	290-297	whether	_
2-7	298-307	disrupted	_
2-8	308-317	asymmetry	_
2-9	318-328	originates	_
2-10	329-333	from	_
2-11	334-351	inter-hemispheric	_
2-12	352-362	functional	_
2-13	363-375	connectivity	_
2-14	376-377	(	_
2-15	377-379	FC	_
2-16	379-380	)	_
2-17	381-384	and	_
2-18	384-385	/	_
2-19	385-387	or	_
2-20	388-405	intra-hemispheric	_
2-21	406-408	FC	_
2-22	409-411	in	_
2-23	412-416	this	_
2-24	417-424	patient	_
2-25	425-435	population	_
2-26	435-436	.	_

#Text=Methods
#Text=Forty-four patients with drug-naive, first-episode schizophrenia, 42 unaffected siblings, and 44 healthy controls underwent resting-state functional magnetic resonance imaging (fMRI) scan.
3-1	437-444	Methods	_
3-2	445-455	Forty-four	_
3-3	456-464	patients	_
3-4	465-469	with	_
3-5	470-480	drug-naive	_
3-6	480-481	,	_
3-7	482-495	first-episode	_
3-8	496-509	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-9	509-510	,	_
3-10	511-513	42	_
3-11	514-524	unaffected	_
3-12	525-533	siblings	_
3-13	533-534	,	_
3-14	535-538	and	_
3-15	539-541	44	_
3-16	542-549	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[1]
3-17	550-558	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[1]
3-18	559-568	underwent	_
3-19	569-582	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[2]
3-20	583-593	functional	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[2]
3-21	594-602	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[2]
3-22	603-612	resonance	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[2]
3-23	613-620	imaging	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[2]
3-24	621-622	(	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[2]
3-25	622-626	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[2]
3-26	626-627	)	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[2]
3-27	628-632	scan	_
3-28	632-633	.	_

#Text=The parameter of asymmetry (PAS) and support vector machine (SVM) were used to analyze the data.
4-1	634-637	The	_
4-2	638-647	parameter	_
4-3	648-650	of	_
4-4	651-660	asymmetry	_
4-5	661-662	(	_
4-6	662-665	PAS	_
4-7	665-666	)	_
4-8	667-670	and	_
4-9	671-678	support	_
4-10	679-685	vector	_
4-11	686-693	machine	_
4-12	694-695	(	_
4-13	695-698	SVM	_
4-14	698-699	)	_
4-15	700-704	were	_
4-16	705-709	used	_
4-17	710-712	to	_
4-18	713-720	analyze	_
4-19	721-724	the	_
4-20	725-729	data	_
4-21	729-730	.	_

#Text=Patients were treated with olanzapine for 8 weeks.
5-1	731-739	Patients	_
5-2	740-744	were	_
5-3	745-752	treated	_
5-4	753-757	with	_
5-5	758-768	olanzapine	_
5-6	769-772	for	_
5-7	773-774	8	_
5-8	774-775	 	_
5-9	775-780	weeks	_
5-10	780-781	.	_

#Text=Findings
#Text=Compared with healthy controls, patients showed lower PAS scores in the left middle temporal gyrus (MTG)/inferior temporal gyrus (ITG), left posterior cingulate cortex (PCC)/precuneus and left angular gyrus, and higher PAS scores in the left precentral gyrus/postcentral gyrus.
6-1	782-790	Findings	_
6-2	791-799	Compared	_
6-3	800-804	with	_
6-4	805-812	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]
6-5	813-821	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]
6-6	821-822	,	_
6-7	823-831	patients	_
6-8	832-838	showed	_
6-9	839-844	lower	_
6-10	845-848	PAS	_
6-11	849-855	scores	_
6-12	856-858	in	_
6-13	859-862	the	_
6-14	863-867	left	_
6-15	868-874	middle	_
6-16	875-883	temporal	_
6-17	884-889	gyrus	_
6-18	890-891	(	_
6-19	891-894	MTG	_
6-20	894-895	)	_
6-21	895-896	/	_
6-22	896-904	inferior	_
6-23	905-913	temporal	_
6-24	914-919	gyrus	_
6-25	920-921	(	_
6-26	921-924	ITG	_
6-27	924-925	)	_
6-28	925-926	,	_
6-29	927-931	left	_
6-30	932-941	posterior	_
6-31	942-951	cingulate	_
6-32	952-958	cortex	_
6-33	959-960	(	_
6-34	960-963	PCC	_
6-35	963-964	)	_
6-36	964-965	/	_
6-37	965-974	precuneus	_
6-38	975-978	and	_
6-39	979-983	left	_
6-40	984-991	angular	_
6-41	992-997	gyrus	_
6-42	997-998	,	_
6-43	999-1002	and	_
6-44	1003-1009	higher	_
6-45	1010-1013	PAS	_
6-46	1014-1020	scores	_
6-47	1021-1023	in	_
6-48	1024-1027	the	_
6-49	1028-1032	left	_
6-50	1033-1043	precentral	_
6-51	1044-1049	gyrus	_
6-52	1049-1050	/	_
6-53	1050-1061	postcentral	_
6-54	1062-1067	gyrus	_
6-55	1067-1068	.	_

#Text=Unaffected siblings also showed lower PAS scores in the left MTG/ITG and left PCC/precuneus relative to healthy controls.
7-1	1069-1079	Unaffected	_
7-2	1080-1088	siblings	_
7-3	1089-1093	also	_
7-4	1094-1100	showed	_
7-5	1101-1106	lower	_
7-6	1107-1110	PAS	_
7-7	1111-1117	scores	_
7-8	1118-1120	in	_
7-9	1121-1124	the	_
7-10	1125-1129	left	_
7-11	1130-1133	MTG	_
7-12	1133-1134	/	_
7-13	1134-1137	ITG	_
7-14	1138-1141	and	_
7-15	1142-1146	left	_
7-16	1147-1150	PCC	_
7-17	1150-1151	/	_
7-18	1151-1160	precuneus	_
7-19	1161-1169	relative	_
7-20	1170-1172	to	_
7-21	1173-1180	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[4]
7-22	1181-1189	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[4]
7-23	1189-1190	.	_

#Text=Further, SVM analysis showed that a combination of the PAS scores in these two clusters in patients at baseline was able to predict clinical response after 8 weeks of olanzapine treatment with 77.27% sensitivity, 72.73% specificity, and 75.00% accuracy.
8-1	1191-1198	Further	_
8-2	1198-1199	,	_
8-3	1200-1203	SVM	_
8-4	1204-1212	analysis	_
8-5	1213-1219	showed	_
8-6	1220-1224	that	_
8-7	1225-1226	a	_
8-8	1227-1238	combination	_
8-9	1239-1241	of	_
8-10	1242-1245	the	_
8-11	1246-1249	PAS	_
8-12	1250-1256	scores	_
8-13	1257-1259	in	_
8-14	1260-1265	these	_
8-15	1266-1269	two	_
8-16	1270-1278	clusters	_
8-17	1279-1281	in	_
8-18	1282-1290	patients	_
8-19	1291-1293	at	_
8-20	1294-1302	baseline	_
8-21	1303-1306	was	_
8-22	1307-1311	able	_
8-23	1312-1314	to	_
8-24	1315-1322	predict	_
8-25	1323-1331	clinical	_
8-26	1332-1340	response	_
8-27	1341-1346	after	_
8-28	1347-1348	8	_
8-29	1348-1349	 	_
8-30	1349-1354	weeks	_
8-31	1355-1357	of	_
8-32	1358-1368	olanzapine	_
8-33	1369-1378	treatment	_
8-34	1379-1383	with	_
8-35	1384-1390	77.27%	_
8-36	1391-1402	sensitivity	_
8-37	1402-1403	,	_
8-38	1404-1410	72.73%	_
8-39	1411-1422	specificity	_
8-40	1422-1423	,	_
8-41	1424-1427	and	_
8-42	1428-1434	75.00%	_
8-43	1435-1443	accuracy	_
8-44	1443-1444	.	_

#Text=Interpretation
#Text=The present study suggests disrupted asymmetry of inter- and intra-hemispheric FC in drug-naive, first-episode schizophrenia; in addition, a reduced asymmetry of inter-hemispheric FC in the left MTG/ITG and left PCC/precuneus may serve as an endophenotype for schizophrenia, and may have clinical utility to predict response to olanzapine treatment.
9-1	1445-1459	Interpretation	_
9-2	1460-1463	The	_
9-3	1464-1471	present	_
9-4	1472-1477	study	_
9-5	1478-1486	suggests	_
9-6	1487-1496	disrupted	_
9-7	1497-1506	asymmetry	_
9-8	1507-1509	of	_
9-9	1510-1515	inter	_
9-10	1515-1516	-	_
9-11	1517-1520	and	_
9-12	1521-1538	intra-hemispheric	_
9-13	1539-1541	FC	_
9-14	1542-1544	in	_
9-15	1545-1555	drug-naive	_
9-16	1555-1556	,	_
9-17	1557-1570	first-episode	_
9-18	1571-1584	schizophrenia	_
9-19	1584-1585	;	_
9-20	1586-1588	in	_
9-21	1589-1597	addition	_
9-22	1597-1598	,	_
9-23	1599-1600	a	_
9-24	1601-1608	reduced	_
9-25	1609-1618	asymmetry	_
9-26	1619-1621	of	_
9-27	1622-1639	inter-hemispheric	_
9-28	1640-1642	FC	_
9-29	1643-1645	in	_
9-30	1646-1649	the	_
9-31	1650-1654	left	_
9-32	1655-1658	MTG	_
9-33	1658-1659	/	_
9-34	1659-1662	ITG	_
9-35	1663-1666	and	_
9-36	1667-1671	left	_
9-37	1672-1675	PCC	_
9-38	1675-1676	/	_
9-39	1676-1685	precuneus	_
9-40	1686-1689	may	_
9-41	1690-1695	serve	_
9-42	1696-1698	as	_
9-43	1699-1701	an	_
9-44	1702-1715	endophenotype	_
9-45	1716-1719	for	_
9-46	1720-1733	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
9-47	1733-1734	,	_
9-48	1735-1738	and	_
9-49	1739-1742	may	_
9-50	1743-1747	have	_
9-51	1748-1756	clinical	_
9-52	1757-1764	utility	_
9-53	1765-1767	to	_
9-54	1768-1775	predict	_
9-55	1776-1784	response	_
9-56	1785-1787	to	_
9-57	1788-1798	olanzapine	_
9-58	1799-1808	treatment	_
9-59	1808-1809	.	_

#Text=Fund
#Text=The National Key R&D Program of China and the National Natural Science Foundation of China.
10-1	1810-1814	Fund	_
10-2	1815-1818	The	_
10-3	1819-1827	National	_
10-4	1828-1831	Key	_
10-5	1832-1833	R	_
10-6	1833-1834	&	_
10-7	1834-1835	D	_
10-8	1836-1843	Program	_
10-9	1844-1846	of	_
10-10	1847-1852	China	_
10-11	1853-1856	and	_
10-12	1857-1860	the	_
10-13	1861-1869	National	_
10-14	1870-1877	Natural	_
10-15	1878-1885	Science	_
10-16	1886-1896	Foundation	_
10-17	1897-1899	of	_
10-18	1900-1905	China	_
10-19	1905-1906	.	_

#Text=Research in context
#Text=Evidence before this study
#Text=We searched PubMed from the start of the database until June 24, 2018, for functional asymmetry of resting-state functional connectivity (rsFC) in patients with schizophrenia, with the search terms “schizophrenia”, “functional asymmetry”, and “functional connectivity [Title]”, and “English” [Language].
11-1	1907-1915	Research	_
11-2	1916-1918	in	_
11-3	1919-1926	context	_
11-4	1927-1935	Evidence	_
11-5	1936-1942	before	_
11-6	1943-1947	this	_
11-7	1948-1953	study	_
11-8	1954-1956	We	_
11-9	1957-1965	searched	_
11-10	1966-1972	PubMed	_
11-11	1973-1977	from	_
11-12	1978-1981	the	_
11-13	1982-1987	start	_
11-14	1988-1990	of	_
11-15	1991-1994	the	_
11-16	1995-2003	database	_
11-17	2004-2009	until	_
11-18	2010-2014	June	_
11-19	2015-2017	24	_
11-20	2017-2018	,	_
11-21	2019-2023	2018	_
11-22	2023-2024	,	_
11-23	2025-2028	for	_
11-24	2029-2039	functional	_
11-25	2040-2049	asymmetry	_
11-26	2050-2052	of	_
11-27	2053-2066	resting-state	_
11-28	2067-2077	functional	_
11-29	2078-2090	connectivity	_
11-30	2091-2092	(	_
11-31	2092-2096	rsFC	_
11-32	2096-2097	)	_
11-33	2098-2100	in	_
11-34	2101-2109	patients	_
11-35	2110-2114	with	_
11-36	2115-2128	schizophrenia	_
11-37	2128-2129	,	_
11-38	2130-2134	with	_
11-39	2135-2138	the	_
11-40	2139-2145	search	_
11-41	2146-2151	terms	_
11-42	2152-2153	“	_
11-43	2153-2166	schizophrenia	_
11-44	2166-2167	”	_
11-45	2167-2168	,	_
11-46	2169-2170	“	_
11-47	2170-2180	functional	_
11-48	2181-2190	asymmetry	_
11-49	2190-2191	”	_
11-50	2191-2192	,	_
11-51	2193-2196	and	_
11-52	2197-2198	“	_
11-53	2198-2208	functional	_
11-54	2209-2221	connectivity	_
11-55	2222-2223	[	_
11-56	2223-2228	Title	_
11-57	2228-2229	]	_
11-58	2229-2230	”	_
11-59	2230-2231	,	_
11-60	2232-2235	and	_
11-61	2236-2237	“	_
11-62	2237-2244	English	_
11-63	2244-2245	”	_
11-64	2246-2247	[	_
11-65	2247-2255	Language	_
11-66	2255-2256	]	_
11-67	2256-2257	.	_

#Text=We found three published articles before we initiated the study.
12-1	2258-2260	We	_
12-2	2261-2266	found	_
12-3	2267-2272	three	_
12-4	2273-2282	published	_
12-5	2283-2291	articles	_
12-6	2292-2298	before	_
12-7	2299-2301	we	_
12-8	2302-2311	initiated	_
12-9	2312-2315	the	_
12-10	2316-2321	study	_
12-11	2321-2322	.	_

#Text=In these studies, rsFC strength and independent component analysis (ICA) were used to measure the brain lateralization.
13-1	2323-2325	In	_
13-2	2326-2331	these	_
13-3	2332-2339	studies	_
13-4	2339-2340	,	_
13-5	2341-2345	rsFC	_
13-6	2346-2354	strength	_
13-7	2355-2358	and	_
13-8	2359-2370	independent	_
13-9	2371-2380	component	_
13-10	2381-2389	analysis	_
13-11	2390-2391	(	_
13-12	2391-2394	ICA	_
13-13	2394-2395	)	_
13-14	2396-2400	were	_
13-15	2401-2405	used	_
13-16	2406-2408	to	_
13-17	2409-2416	measure	_
13-18	2417-2420	the	_
13-19	2421-2426	brain	_
13-20	2427-2441	lateralization	_
13-21	2441-2442	.	_

#Text=Human brain demonstrates inter- and intra-hemispheric interactions in response to a stimulus.
14-1	2443-2448	Human	_
14-2	2449-2454	brain	_
14-3	2455-2467	demonstrates	_
14-4	2468-2473	inter	_
14-5	2473-2474	-	_
14-6	2475-2478	and	_
14-7	2479-2496	intra-hemispheric	_
14-8	2497-2509	interactions	_
14-9	2510-2512	in	_
14-10	2513-2521	response	_
14-11	2522-2524	to	_
14-12	2525-2526	a	_
14-13	2527-2535	stimulus	_
14-14	2535-2536	.	_

#Text=Therefore, the brain lateralization may be measured by inter- and intra-hemispheric FCs.
15-1	2537-2546	Therefore	_
15-2	2546-2547	,	_
15-3	2548-2551	the	_
15-4	2552-2557	brain	_
15-5	2558-2572	lateralization	_
15-6	2573-2576	may	_
15-7	2577-2579	be	_
15-8	2580-2588	measured	_
15-9	2589-2591	by	_
15-10	2592-2597	inter	_
15-11	2597-2598	-	_
15-12	2599-2602	and	_
15-13	2603-2620	intra-hemispheric	_
15-14	2621-2624	FCs	_
15-15	2624-2625	.	_

#Text=It still remains unknown to what extent inter- and/or intra-hemispheric FC contribute to disrupted asymmetry in the brain in patients with schizophrenia.
16-1	2626-2628	It	_
16-2	2629-2634	still	_
16-3	2635-2642	remains	_
16-4	2643-2650	unknown	_
16-5	2651-2653	to	_
16-6	2654-2658	what	_
16-7	2659-2665	extent	_
16-8	2666-2671	inter	_
16-9	2671-2672	-	_
16-10	2673-2676	and	_
16-11	2676-2677	/	_
16-12	2677-2679	or	_
16-13	2680-2697	intra-hemispheric	_
16-14	2698-2700	FC	_
16-15	2701-2711	contribute	_
16-16	2712-2714	to	_
16-17	2715-2724	disrupted	_
16-18	2725-2734	asymmetry	_
16-19	2735-2737	in	_
16-20	2738-2741	the	_
16-21	2742-2747	brain	_
16-22	2748-2750	in	_
16-23	2751-2759	patients	_
16-24	2760-2764	with	_
16-25	2765-2778	schizophrenia	_
16-26	2778-2779	.	_

#Text=Added value of this study
#Text=Forty-four patients with drug-naive, first-episode schizophrenia, 42 unaffected siblings, and 44 healthy controls were enrolled in the present study.
17-1	2780-2785	Added	_
17-2	2786-2791	value	_
17-3	2792-2794	of	_
17-4	2795-2799	this	_
17-5	2800-2805	study	_
17-6	2806-2816	Forty-four	_
17-7	2817-2825	patients	_
17-8	2826-2830	with	_
17-9	2831-2841	drug-naive	_
17-10	2841-2842	,	_
17-11	2843-2856	first-episode	_
17-12	2857-2870	schizophrenia	_
17-13	2870-2871	,	_
17-14	2872-2874	42	_
17-15	2875-2885	unaffected	_
17-16	2886-2894	siblings	_
17-17	2894-2895	,	_
17-18	2896-2899	and	_
17-19	2900-2902	44	_
17-20	2903-2910	healthy	_
17-21	2911-2919	controls	_
17-22	2920-2924	were	_
17-23	2925-2933	enrolled	_
17-24	2934-2936	in	_
17-25	2937-2940	the	_
17-26	2941-2948	present	_
17-27	2949-2954	study	_
17-28	2954-2955	.	_

#Text=A quantitative parameter of asymmetry (PAS) was calculated to reflect inter- and/or intra-hemispheric asymmetry.
18-1	2956-2957	A	_
18-2	2958-2970	quantitative	_
18-3	2971-2980	parameter	_
18-4	2981-2983	of	_
18-5	2984-2993	asymmetry	_
18-6	2994-2995	(	_
18-7	2995-2998	PAS	_
18-8	2998-2999	)	_
18-9	3000-3003	was	_
18-10	3004-3014	calculated	_
18-11	3015-3017	to	_
18-12	3018-3025	reflect	_
18-13	3026-3031	inter	_
18-14	3031-3032	-	_
18-15	3033-3036	and	_
18-16	3036-3037	/	_
18-17	3037-3039	or	_
18-18	3040-3057	intra-hemispheric	_
18-19	3058-3067	asymmetry	_
18-20	3067-3068	.	_

#Text=Our study demonstrated disrupted asymmetry in patients with drug naive, first episode schizophrenia and unaffected siblings, which are preferentially within the left hemisphere.
19-1	3069-3072	Our	_
19-2	3073-3078	study	_
19-3	3079-3091	demonstrated	_
19-4	3092-3101	disrupted	_
19-5	3102-3111	asymmetry	_
19-6	3112-3114	in	_
19-7	3115-3123	patients	_
19-8	3124-3128	with	_
19-9	3129-3133	drug	_
19-10	3134-3139	naive	_
19-11	3139-3140	,	_
19-12	3141-3146	first	_
19-13	3147-3154	episode	_
19-14	3155-3168	schizophrenia	_
19-15	3169-3172	and	_
19-16	3173-3183	unaffected	_
19-17	3184-3192	siblings	_
19-18	3192-3193	,	_
19-19	3194-3199	which	_
19-20	3200-3203	are	_
19-21	3204-3218	preferentially	_
19-22	3219-3225	within	_
19-23	3226-3229	the	_
19-24	3230-3234	left	_
19-25	3235-3245	hemisphere	_
19-26	3245-3246	.	_

#Text=A reduced asymmetry of inter-hemispheric FC in the left middle temporal gyrus (MTG)/inferior temporal gyrus (ITG) and left posterior cingulate cortex (PCC)/precuneus may serve as an endophenotype for schizophrenia, and may have clinical utility to predict response to olanzapine treatment.
20-1	3247-3248	A	_
20-2	3249-3256	reduced	_
20-3	3257-3266	asymmetry	_
20-4	3267-3269	of	_
20-5	3270-3287	inter-hemispheric	_
20-6	3288-3290	FC	_
20-7	3291-3293	in	_
20-8	3294-3297	the	_
20-9	3298-3302	left	_
20-10	3303-3309	middle	_
20-11	3310-3318	temporal	_
20-12	3319-3324	gyrus	_
20-13	3325-3326	(	_
20-14	3326-3329	MTG	_
20-15	3329-3330	)	_
20-16	3330-3331	/	_
20-17	3331-3339	inferior	_
20-18	3340-3348	temporal	_
20-19	3349-3354	gyrus	_
20-20	3355-3356	(	_
20-21	3356-3359	ITG	_
20-22	3359-3360	)	_
20-23	3361-3364	and	_
20-24	3365-3369	left	_
20-25	3370-3379	posterior	_
20-26	3380-3389	cingulate	_
20-27	3390-3396	cortex	_
20-28	3397-3398	(	_
20-29	3398-3401	PCC	_
20-30	3401-3402	)	_
20-31	3402-3403	/	_
20-32	3403-3412	precuneus	_
20-33	3413-3416	may	_
20-34	3417-3422	serve	_
20-35	3423-3425	as	_
20-36	3426-3428	an	_
20-37	3429-3442	endophenotype	_
20-38	3443-3446	for	_
20-39	3447-3460	schizophrenia	_
20-40	3460-3461	,	_
20-41	3462-3465	and	_
20-42	3466-3469	may	_
20-43	3470-3474	have	_
20-44	3475-3483	clinical	_
20-45	3484-3491	utility	_
20-46	3492-3494	to	_
20-47	3495-3502	predict	_
20-48	3503-3511	response	_
20-49	3512-3514	to	_
20-50	3515-3525	olanzapine	_
20-51	3526-3535	treatment	_
20-52	3535-3536	.	_

#Text=Implications of all the available evidence
#Text=First, left-sided abnormal functional asymmetry in the brain in drug naive, first episode schizophrenia and unaffected siblings demonstrates that schizophrenia is a brain disorder.
21-1	3537-3549	Implications	_
21-2	3550-3552	of	_
21-3	3553-3556	all	_
21-4	3557-3560	the	_
21-5	3561-3570	available	_
21-6	3571-3579	evidence	_
21-7	3580-3585	First	_
21-8	3585-3586	,	_
21-9	3587-3597	left-sided	_
21-10	3598-3606	abnormal	_
21-11	3607-3617	functional	_
21-12	3618-3627	asymmetry	_
21-13	3628-3630	in	_
21-14	3631-3634	the	_
21-15	3635-3640	brain	_
21-16	3641-3643	in	_
21-17	3644-3648	drug	_
21-18	3649-3654	naive	_
21-19	3654-3655	,	_
21-20	3656-3661	first	_
21-21	3662-3669	episode	_
21-22	3670-3683	schizophrenia	_
21-23	3684-3687	and	_
21-24	3688-3698	unaffected	_
21-25	3699-3707	siblings	_
21-26	3708-3720	demonstrates	_
21-27	3721-3725	that	_
21-28	3726-3739	schizophrenia	_
21-29	3740-3742	is	_
21-30	3743-3744	a	_
21-31	3745-3750	brain	_
21-32	3751-3759	disorder	_
21-33	3759-3760	.	_

#Text=Second, reduced inter-hemispheric FC in the default mode network (DMN) may bear genetic load and serve as an endophenotype for schizophrenia, confirming that schizophrenia is a genetic disorder.
22-1	3761-3767	Second	_
22-2	3767-3768	,	_
22-3	3769-3776	reduced	_
22-4	3777-3794	inter-hemispheric	_
22-5	3795-3797	FC	_
22-6	3798-3800	in	_
22-7	3801-3804	the	_
22-8	3805-3812	default	_
22-9	3813-3817	mode	_
22-10	3818-3825	network	_
22-11	3826-3827	(	_
22-12	3827-3830	DMN	_
22-13	3830-3831	)	_
22-14	3832-3835	may	_
22-15	3836-3840	bear	_
22-16	3841-3848	genetic	_
22-17	3849-3853	load	_
22-18	3854-3857	and	_
22-19	3858-3863	serve	_
22-20	3864-3866	as	_
22-21	3867-3869	an	_
22-22	3870-3883	endophenotype	_
22-23	3884-3887	for	_
22-24	3888-3901	schizophrenia	_
22-25	3901-3902	,	_
22-26	3903-3913	confirming	_
22-27	3914-3918	that	_
22-28	3919-3932	schizophrenia	_
22-29	3933-3935	is	_
22-30	3936-3937	a	_
22-31	3938-3945	genetic	_
22-32	3946-3954	disorder	_
22-33	3954-3955	.	_

#Text=Finally, biomarkers to reflect disrupted functional asymmetry in the brain, such as a combination of the PAS scores of the left MTG/ITG and left PCC/precuneus, may have great clinical implications to help clinicians make individualized treatment decisions for patients.
23-1	3956-3963	Finally	_
23-2	3963-3964	,	_
23-3	3965-3975	biomarkers	_
23-4	3976-3978	to	_
23-5	3979-3986	reflect	_
23-6	3987-3996	disrupted	_
23-7	3997-4007	functional	_
23-8	4008-4017	asymmetry	_
23-9	4018-4020	in	_
23-10	4021-4024	the	_
23-11	4025-4030	brain	_
23-12	4030-4031	,	_
23-13	4032-4036	such	_
23-14	4037-4039	as	_
23-15	4040-4041	a	_
23-16	4042-4053	combination	_
23-17	4054-4056	of	_
23-18	4057-4060	the	_
23-19	4061-4064	PAS	_
23-20	4065-4071	scores	_
23-21	4072-4074	of	_
23-22	4075-4078	the	_
23-23	4079-4083	left	_
23-24	4084-4087	MTG	_
23-25	4087-4088	/	_
23-26	4088-4091	ITG	_
23-27	4092-4095	and	_
23-28	4096-4100	left	_
23-29	4101-4104	PCC	_
23-30	4104-4105	/	_
23-31	4105-4114	precuneus	_
23-32	4114-4115	,	_
23-33	4116-4119	may	_
23-34	4120-4124	have	_
23-35	4125-4130	great	_
23-36	4131-4139	clinical	_
23-37	4140-4152	implications	_
23-38	4153-4155	to	_
23-39	4156-4160	help	_
23-40	4161-4171	clinicians	_
23-41	4172-4176	make	_
23-42	4177-4191	individualized	_
23-43	4192-4201	treatment	_
23-44	4202-4211	decisions	_
23-45	4212-4215	for	_
23-46	4216-4224	patients	_
23-47	4224-4225	.	_

#Text=Alt-text: Unlabelled Box
#Text=Introduction
#Text=Functional asymmetry of inter- and intra-hemispheric interaction exists during the normal development of human brain.
24-1	4226-4234	Alt-text	_
24-2	4234-4235	:	_
24-3	4236-4246	Unlabelled	_
24-4	4247-4250	Box	_
24-5	4251-4263	Introduction	_
24-6	4264-4274	Functional	_
24-7	4275-4284	asymmetry	_
24-8	4285-4287	of	_
24-9	4288-4293	inter	_
24-10	4293-4294	-	_
24-11	4295-4298	and	_
24-12	4299-4316	intra-hemispheric	_
24-13	4317-4328	interaction	_
24-14	4329-4335	exists	_
24-15	4336-4342	during	_
24-16	4343-4346	the	_
24-17	4347-4353	normal	_
24-18	4354-4365	development	_
24-19	4366-4368	of	_
24-20	4369-4374	human	_
24-21	4375-4380	brain	_
24-22	4380-4381	.	_

#Text=For example, the left hemisphere is more specialized for high spatial frequencies; whereas the right hemisphere prefers to process low spatial frequencies.
25-1	4382-4385	For	_
25-2	4386-4393	example	_
25-3	4393-4394	,	_
25-4	4395-4398	the	_
25-5	4399-4403	left	_
25-6	4404-4414	hemisphere	_
25-7	4415-4417	is	_
25-8	4418-4422	more	_
25-9	4423-4434	specialized	_
25-10	4435-4438	for	_
25-11	4439-4443	high	_
25-12	4444-4451	spatial	_
25-13	4452-4463	frequencies	_
25-14	4463-4464	;	_
25-15	4465-4472	whereas	_
25-16	4473-4476	the	_
25-17	4477-4482	right	_
25-18	4483-4493	hemisphere	_
25-19	4494-4501	prefers	_
25-20	4502-4504	to	_
25-21	4505-4512	process	_
25-22	4513-4516	low	_
25-23	4517-4524	spatial	_
25-24	4525-4536	frequencies	_
25-25	4536-4537	.	_

#Text=The right hemisphere is also biased towards processing line bisection, line orientation, and mental rotation compared to the left hemisphere.
26-1	4538-4541	The	_
26-2	4542-4547	right	_
26-3	4548-4558	hemisphere	_
26-4	4559-4561	is	_
26-5	4562-4566	also	_
26-6	4567-4573	biased	_
26-7	4574-4581	towards	_
26-8	4582-4592	processing	_
26-9	4593-4597	line	_
26-10	4598-4607	bisection	_
26-11	4607-4608	,	_
26-12	4609-4613	line	_
26-13	4614-4625	orientation	_
26-14	4625-4626	,	_
26-15	4627-4630	and	_
26-16	4631-4637	mental	_
26-17	4638-4646	rotation	_
26-18	4647-4655	compared	_
26-19	4656-4658	to	_
26-20	4659-4662	the	_
26-21	4663-4667	left	_
26-22	4668-4678	hemisphere	_
26-23	4678-4679	.	_

#Text=The two hemispheres interact with each other via callosal fibers.
27-1	4680-4683	The	_
27-2	4684-4687	two	_
27-3	4688-4699	hemispheres	_
27-4	4700-4708	interact	_
27-5	4709-4713	with	_
27-6	4714-4718	each	_
27-7	4719-4724	other	_
27-8	4725-4728	via	_
27-9	4729-4737	callosal	_
27-10	4738-4744	fibers	_
27-11	4744-4745	.	_

#Text=Healthy individuals benefit from such inter-hemispheric interaction.
28-1	4746-4753	Healthy	_
28-2	4754-4765	individuals	_
28-3	4766-4773	benefit	_
28-4	4774-4778	from	_
28-5	4779-4783	such	_
28-6	4784-4801	inter-hemispheric	_
28-7	4802-4813	interaction	_
28-8	4813-4814	.	_

#Text=Having both hemispheres involved in processing tasks is more advantageous than just one hemisphere, especially when computational complexity increases.
29-1	4815-4821	Having	_
29-2	4822-4826	both	_
29-3	4827-4838	hemispheres	_
29-4	4839-4847	involved	_
29-5	4848-4850	in	_
29-6	4851-4861	processing	_
29-7	4862-4867	tasks	_
29-8	4868-4870	is	_
29-9	4871-4875	more	_
29-10	4876-4888	advantageous	_
29-11	4889-4893	than	_
29-12	4894-4898	just	_
29-13	4899-4902	one	_
29-14	4903-4913	hemisphere	_
29-15	4913-4914	,	_
29-16	4915-4925	especially	_
29-17	4926-4930	when	_
29-18	4931-4944	computational	_
29-19	4945-4955	complexity	_
29-20	4956-4965	increases	_
29-21	4965-4966	.	_

#Text=Further, it has been reported that asymmetry in intra-hemispheric connectivity is associated with language hemispheric dominance.
30-1	4967-4974	Further	_
30-2	4974-4975	,	_
30-3	4976-4978	it	_
30-4	4979-4982	has	_
30-5	4983-4987	been	_
30-6	4988-4996	reported	_
30-7	4997-5001	that	_
30-8	5002-5011	asymmetry	_
30-9	5012-5014	in	_
30-10	5015-5032	intra-hemispheric	_
30-11	5033-5045	connectivity	_
30-12	5046-5048	is	_
30-13	5049-5059	associated	_
30-14	5060-5064	with	_
30-15	5065-5073	language	_
30-16	5074-5085	hemispheric	_
30-17	5086-5095	dominance	_
30-18	5095-5096	.	_

#Text=Even though healthy individuals benefit from normal asymmetry of inter- and intra-hemispheric interactions for efficient information processing, such asymmetry is disrupted in schizophrenia.
31-1	5097-5101	Even	_
31-2	5102-5108	though	_
31-3	5109-5116	healthy	_
31-4	5117-5128	individuals	_
31-5	5129-5136	benefit	_
31-6	5137-5141	from	_
31-7	5142-5148	normal	_
31-8	5149-5158	asymmetry	_
31-9	5159-5161	of	_
31-10	5162-5167	inter	_
31-11	5167-5168	-	_
31-12	5169-5172	and	_
31-13	5173-5190	intra-hemispheric	_
31-14	5191-5203	interactions	_
31-15	5204-5207	for	_
31-16	5208-5217	efficient	_
31-17	5218-5229	information	_
31-18	5230-5240	processing	_
31-19	5240-5241	,	_
31-20	5242-5246	such	_
31-21	5247-5256	asymmetry	_
31-22	5257-5259	is	_
31-23	5260-5269	disrupted	_
31-24	5270-5272	in	_
31-25	5273-5286	schizophrenia	_
31-26	5286-5287	.	_

#Text=Non-right-handed individuals are apt to suffer from schizophrenia than right-handedness, which may suggest a failure to develop brain asymmetry.
32-1	5288-5304	Non-right-handed	_
32-2	5305-5316	individuals	_
32-3	5317-5320	are	_
32-4	5321-5324	apt	_
32-5	5325-5327	to	_
32-6	5328-5334	suffer	_
32-7	5335-5339	from	_
32-8	5340-5353	schizophrenia	_
32-9	5354-5358	than	_
32-10	5359-5375	right-handedness	_
32-11	5375-5376	,	_
32-12	5377-5382	which	_
32-13	5383-5386	may	_
32-14	5387-5394	suggest	_
32-15	5395-5396	a	_
32-16	5397-5404	failure	_
32-17	5405-5407	to	_
32-18	5408-5415	develop	_
32-19	5416-5421	brain	_
32-20	5422-5431	asymmetry	_
32-21	5431-5432	.	_

#Text=Crow et al. has reported that structural magnetic resonance imaging (MRI) abnormalities are highly significantly selective to the left hemisphere in schizophrenia.
33-1	5433-5437	Crow	_
33-2	5438-5440	et	_
33-3	5441-5443	al	_
33-4	5443-5444	.	_
33-5	5445-5448	has	_
33-6	5449-5457	reported	_
33-7	5458-5462	that	_
33-8	5463-5473	structural	_
33-9	5474-5482	magnetic	_
33-10	5483-5492	resonance	_
33-11	5493-5500	imaging	_
33-12	5501-5502	(	_
33-13	5502-5505	MRI	_
33-14	5505-5506	)	_
33-15	5507-5520	abnormalities	_
33-16	5521-5524	are	_
33-17	5525-5531	highly	_
33-18	5532-5545	significantly	_
33-19	5546-5555	selective	_
33-20	5556-5558	to	_
33-21	5559-5562	the	_
33-22	5563-5567	left	_
33-23	5568-5578	hemisphere	_
33-24	5579-5581	in	_
33-25	5582-5595	schizophrenia	_
33-26	5595-5596	.	_

#Text=Our group has found reduced gray matter volume in the left middle temporal gyrus (MTG), but not in the right MTG, in patients with drug naive, first episode schizophrenia and their unaffected siblings.
34-1	5597-5600	Our	_
34-2	5601-5606	group	_
34-3	5607-5610	has	_
34-4	5611-5616	found	_
34-5	5617-5624	reduced	_
34-6	5625-5629	gray	_
34-7	5630-5636	matter	_
34-8	5637-5643	volume	_
34-9	5644-5646	in	_
34-10	5647-5650	the	_
34-11	5651-5655	left	_
34-12	5656-5662	middle	_
34-13	5663-5671	temporal	_
34-14	5672-5677	gyrus	_
34-15	5678-5679	(	_
34-16	5679-5682	MTG	_
34-17	5682-5683	)	_
34-18	5683-5684	,	_
34-19	5685-5688	but	_
34-20	5689-5692	not	_
34-21	5693-5695	in	_
34-22	5696-5699	the	_
34-23	5700-5705	right	_
34-24	5706-5709	MTG	_
34-25	5709-5710	,	_
34-26	5711-5713	in	_
34-27	5714-5722	patients	_
34-28	5723-5727	with	_
34-29	5728-5732	drug	_
34-30	5733-5738	naive	_
34-31	5738-5739	,	_
34-32	5740-5745	first	_
34-33	5746-5753	episode	_
34-34	5754-5767	schizophrenia	_
34-35	5768-5771	and	_
34-36	5772-5777	their	_
34-37	5778-5788	unaffected	_
34-38	5789-5797	siblings	_
34-39	5797-5798	.	_

#Text=Disruption of normal asymmetry in white matter tracts also has been reported in patients with chronic schizophrenia.
35-1	5799-5809	Disruption	_
35-2	5810-5812	of	_
35-3	5813-5819	normal	_
35-4	5820-5829	asymmetry	_
35-5	5830-5832	in	_
35-6	5833-5838	white	_
35-7	5839-5845	matter	_
35-8	5846-5852	tracts	_
35-9	5853-5857	also	_
35-10	5858-5861	has	_
35-11	5862-5866	been	_
35-12	5867-5875	reported	_
35-13	5876-5878	in	_
35-14	5879-5887	patients	_
35-15	5888-5892	with	_
35-16	5893-5900	chronic	_
35-17	5901-5914	schizophrenia	_
35-18	5914-5915	.	_

#Text=In addition, reduced inter-hemispheric connectivity in patients with schizophrenia has been reported by our group and others.
36-1	5916-5918	In	_
36-2	5919-5927	addition	_
36-3	5927-5928	,	_
36-4	5929-5936	reduced	_
36-5	5937-5954	inter-hemispheric	_
36-6	5955-5967	connectivity	_
36-7	5968-5970	in	_
36-8	5971-5979	patients	_
36-9	5980-5984	with	_
36-10	5985-5998	schizophrenia	_
36-11	5999-6002	has	_
36-12	6003-6007	been	_
36-13	6008-6016	reported	_
36-14	6017-6019	by	_
36-15	6020-6023	our	_
36-16	6024-6029	group	_
36-17	6030-6033	and	_
36-18	6034-6040	others	_
36-19	6040-6041	.	_

#Text=Several important questions are still to be answered with regard to disrupted asymmetry in the brain in patients with schizophrenia.
37-1	6042-6049	Several	_
37-2	6050-6059	important	_
37-3	6060-6069	questions	_
37-4	6070-6073	are	_
37-5	6074-6079	still	_
37-6	6080-6082	to	_
37-7	6083-6085	be	_
37-8	6086-6094	answered	_
37-9	6095-6099	with	_
37-10	6100-6106	regard	_
37-11	6107-6109	to	_
37-12	6110-6119	disrupted	_
37-13	6120-6129	asymmetry	_
37-14	6130-6132	in	_
37-15	6133-6136	the	_
37-16	6137-6142	brain	_
37-17	6143-6145	in	_
37-18	6146-6154	patients	_
37-19	6155-6159	with	_
37-20	6160-6173	schizophrenia	_
37-21	6173-6174	.	_

#Text=First, resting-state functional connectivity (rsFC) strength and independent component analysis (ICA) were used to measure the brain lateralization in previous studies.
38-1	6175-6180	First	_
38-2	6180-6181	,	_
38-3	6182-6195	resting-state	_
38-4	6196-6206	functional	_
38-5	6207-6219	connectivity	_
38-6	6220-6221	(	_
38-7	6221-6225	rsFC	_
38-8	6225-6226	)	_
38-9	6227-6235	strength	_
38-10	6236-6239	and	_
38-11	6240-6251	independent	_
38-12	6252-6261	component	_
38-13	6262-6270	analysis	_
38-14	6271-6272	(	_
38-15	6272-6275	ICA	_
38-16	6275-6276	)	_
38-17	6277-6281	were	_
38-18	6282-6286	used	_
38-19	6287-6289	to	_
38-20	6290-6297	measure	_
38-21	6298-6301	the	_
38-22	6302-6307	brain	_
38-23	6308-6322	lateralization	_
38-24	6323-6325	in	_
38-25	6326-6334	previous	_
38-26	6335-6342	studies	_
38-27	6342-6343	.	_

#Text=Human brain demonstrates inter- and intra-hemispheric interactions in response to a stimulus.
39-1	6344-6349	Human	_
39-2	6350-6355	brain	_
39-3	6356-6368	demonstrates	_
39-4	6369-6374	inter	_
39-5	6374-6375	-	_
39-6	6376-6379	and	_
39-7	6380-6397	intra-hemispheric	_
39-8	6398-6410	interactions	_
39-9	6411-6413	in	_
39-10	6414-6422	response	_
39-11	6423-6425	to	_
39-12	6426-6427	a	_
39-13	6428-6436	stimulus	_
39-14	6436-6437	.	_

#Text=Therefore, the brain lateralization may be measured by inter- and intra-hemispheric FCs.
40-1	6438-6447	Therefore	_
40-2	6447-6448	,	_
40-3	6449-6452	the	_
40-4	6453-6458	brain	_
40-5	6459-6473	lateralization	_
40-6	6474-6477	may	_
40-7	6478-6480	be	_
40-8	6481-6489	measured	_
40-9	6490-6492	by	_
40-10	6493-6498	inter	_
40-11	6498-6499	-	_
40-12	6500-6503	and	_
40-13	6504-6521	intra-hemispheric	_
40-14	6522-6525	FCs	_
40-15	6525-6526	.	_

#Text=It still remains unknown to what extent inter- and/or intra-hemispheric FC contributes to disrupted asymmetry in the brain in patients with schizophrenia.
41-1	6527-6529	It	_
41-2	6530-6535	still	_
41-3	6536-6543	remains	_
41-4	6544-6551	unknown	_
41-5	6552-6554	to	_
41-6	6555-6559	what	_
41-7	6560-6566	extent	_
41-8	6567-6572	inter	_
41-9	6572-6573	-	_
41-10	6574-6577	and	_
41-11	6577-6578	/	_
41-12	6578-6580	or	_
41-13	6581-6598	intra-hemispheric	_
41-14	6599-6601	FC	_
41-15	6602-6613	contributes	_
41-16	6614-6616	to	_
41-17	6617-6626	disrupted	_
41-18	6627-6636	asymmetry	_
41-19	6637-6639	in	_
41-20	6640-6643	the	_
41-21	6644-6649	brain	_
41-22	6650-6652	in	_
41-23	6653-6661	patients	_
41-24	6662-6666	with	_
41-25	6667-6680	schizophrenia	_
41-26	6680-6681	.	_

#Text=Second, it is unclear whether such disrupted asymmetry represents an endophenotype for schizophrenia.
42-1	6682-6688	Second	_
42-2	6688-6689	,	_
42-3	6690-6692	it	_
42-4	6693-6695	is	_
42-5	6696-6703	unclear	_
42-6	6704-6711	whether	_
42-7	6712-6716	such	_
42-8	6717-6726	disrupted	_
42-9	6727-6736	asymmetry	_
42-10	6737-6747	represents	_
42-11	6748-6750	an	_
42-12	6751-6764	endophenotype	_
42-13	6765-6768	for	_
42-14	6769-6782	schizophrenia	_
42-15	6782-6783	.	_

#Text=An endophenotype is state independent and heritable, and segregates with known illness loci.
43-1	6784-6786	An	_
43-2	6787-6800	endophenotype	_
43-3	6801-6803	is	_
43-4	6804-6809	state	_
43-5	6810-6821	independent	_
43-6	6822-6825	and	_
43-7	6826-6835	heritable	_
43-8	6835-6836	,	_
43-9	6837-6840	and	_
43-10	6841-6851	segregates	_
43-11	6852-6856	with	_
43-12	6857-6862	known	_
43-13	6863-6870	illness	_
43-14	6871-6875	loci	_
43-15	6875-6876	.	_

#Text=Endophenotype is often observed in unaffected siblings at an increased rate than in the general population.
44-1	6877-6890	Endophenotype	_
44-2	6891-6893	is	_
44-3	6894-6899	often	_
44-4	6900-6908	observed	_
44-5	6909-6911	in	_
44-6	6912-6922	unaffected	_
44-7	6923-6931	siblings	_
44-8	6932-6934	at	_
44-9	6935-6937	an	_
44-10	6938-6947	increased	_
44-11	6948-6952	rate	_
44-12	6953-6957	than	_
44-13	6958-6960	in	_
44-14	6961-6964	the	_
44-15	6965-6972	general	_
44-16	6973-6983	population	_
44-17	6983-6984	.	_

#Text=Third, existing evidence suggests that antipsychotic drugs can alter rsFC patterns; in addition, changes induced by antipsychotic drugs in brain network topology can predict individual treatment response.
45-1	6985-6990	Third	_
45-2	6990-6991	,	_
45-3	6992-7000	existing	_
45-4	7001-7009	evidence	_
45-5	7010-7018	suggests	_
45-6	7019-7023	that	_
45-7	7024-7037	antipsychotic	_
45-8	7038-7043	drugs	_
45-9	7044-7047	can	_
45-10	7048-7053	alter	_
45-11	7054-7058	rsFC	_
45-12	7059-7067	patterns	_
45-13	7067-7068	;	_
45-14	7069-7071	in	_
45-15	7072-7080	addition	_
45-16	7080-7081	,	_
45-17	7082-7089	changes	_
45-18	7090-7097	induced	_
45-19	7098-7100	by	_
45-20	7101-7114	antipsychotic	_
45-21	7115-7120	drugs	_
45-22	7121-7123	in	_
45-23	7124-7129	brain	_
45-24	7130-7137	network	_
45-25	7138-7146	topology	_
45-26	7147-7150	can	_
45-27	7151-7158	predict	_
45-28	7159-7169	individual	_
45-29	7170-7179	treatment	_
45-30	7180-7188	response	_
45-31	7188-7189	.	_

#Text=However, it is still unknown whether disrupted asymmetry in the brain is associated with clinical response to antipsychotic treatment in patients with schizophrenia.
46-1	7190-7197	However	_
46-2	7197-7198	,	_
46-3	7199-7201	it	_
46-4	7202-7204	is	_
46-5	7205-7210	still	_
46-6	7211-7218	unknown	_
46-7	7219-7226	whether	_
46-8	7227-7236	disrupted	_
46-9	7237-7246	asymmetry	_
46-10	7247-7249	in	_
46-11	7250-7253	the	_
46-12	7254-7259	brain	_
46-13	7260-7262	is	_
46-14	7263-7273	associated	_
46-15	7274-7278	with	_
46-16	7279-7287	clinical	_
46-17	7288-7296	response	_
46-18	7297-7299	to	_
46-19	7300-7313	antipsychotic	_
46-20	7314-7323	treatment	_
46-21	7324-7326	in	_
46-22	7327-7335	patients	_
46-23	7336-7340	with	_
46-24	7341-7354	schizophrenia	_
46-25	7354-7355	.	_

#Text=The present study sought to address these questions.
47-1	7356-7359	The	_
47-2	7360-7367	present	_
47-3	7368-7373	study	_
47-4	7374-7380	sought	_
47-5	7381-7383	to	_
47-6	7384-7391	address	_
47-7	7392-7397	these	_
47-8	7398-7407	questions	_
47-9	7407-7408	.	_

#Text=Patients with drug-naive, first-episode schizophrenia, unaffected siblings and healthy controls were recruited in the study.
48-1	7409-7417	Patients	_
48-2	7418-7422	with	_
48-3	7423-7433	drug-naive	_
48-4	7433-7434	,	_
48-5	7435-7448	first-episode	_
48-6	7449-7462	schizophrenia	_
48-7	7462-7463	,	_
48-8	7464-7474	unaffected	_
48-9	7475-7483	siblings	_
48-10	7484-7487	and	_
48-11	7488-7495	healthy	_
48-12	7496-7504	controls	_
48-13	7505-7509	were	_
48-14	7510-7519	recruited	_
48-15	7520-7522	in	_
48-16	7523-7526	the	_
48-17	7527-7532	study	_
48-18	7532-7533	.	_

#Text=Resting-state functional MRI (rs-fMRI) was used to assess voxel-wise inter- and intra-hemispheric FCs.
49-1	7534-7547	Resting-state	_
49-2	7548-7558	functional	_
49-3	7559-7562	MRI	_
49-4	7563-7564	(	_
49-5	7564-7571	rs-fMRI	_
49-6	7571-7572	)	_
49-7	7573-7576	was	_
49-8	7577-7581	used	_
49-9	7582-7584	to	_
49-10	7585-7591	assess	_
49-11	7592-7602	voxel-wise	_
49-12	7603-7608	inter	_
49-13	7608-7609	-	_
49-14	7610-7613	and	_
49-15	7614-7631	intra-hemispheric	_
49-16	7632-7635	FCs	_
49-17	7635-7636	.	_

#Text=Inter- and intra-hemispheric FCs were calculated between a given voxel and other voxels from the opposite hemisphere (inter-hemispheric FCs) and the same hemisphere (intra-hemispheric FCs).
50-1	7637-7642	Inter	_
50-2	7642-7643	-	_
50-3	7644-7647	and	_
50-4	7648-7665	intra-hemispheric	_
50-5	7666-7669	FCs	_
50-6	7670-7674	were	_
50-7	7675-7685	calculated	_
50-8	7686-7693	between	_
50-9	7694-7695	a	_
50-10	7696-7701	given	_
50-11	7702-7707	voxel	_
50-12	7708-7711	and	_
50-13	7712-7717	other	_
50-14	7718-7724	voxels	_
50-15	7725-7729	from	_
50-16	7730-7733	the	_
50-17	7734-7742	opposite	_
50-18	7743-7753	hemisphere	_
50-19	7754-7755	(	_
50-20	7755-7772	inter-hemispheric	_
50-21	7773-7776	FCs	_
50-22	7776-7777	)	_
50-23	7778-7781	and	_
50-24	7782-7785	the	_
50-25	7786-7790	same	_
50-26	7791-7801	hemisphere	_
50-27	7802-7803	(	_
50-28	7803-7820	intra-hemispheric	_
50-29	7821-7824	FCs	_
50-30	7824-7825	)	_
50-31	7825-7826	.	_

#Text=Then, a quantitative parameter of asymmetry (PAS) was calculated to reflect inter- and/or intra-hemispheric asymmetry (PAS = FCinter − FCintra).
51-1	7827-7831	Then	_
51-2	7831-7832	,	_
51-3	7833-7834	a	_
51-4	7835-7847	quantitative	_
51-5	7848-7857	parameter	_
51-6	7858-7860	of	_
51-7	7861-7870	asymmetry	_
51-8	7871-7872	(	_
51-9	7872-7875	PAS	_
51-10	7875-7876	)	_
51-11	7877-7880	was	_
51-12	7881-7891	calculated	_
51-13	7892-7894	to	_
51-14	7895-7902	reflect	_
51-15	7903-7908	inter	_
51-16	7908-7909	-	_
51-17	7910-7913	and	_
51-18	7913-7914	/	_
51-19	7914-7916	or	_
51-20	7917-7934	intra-hemispheric	_
51-21	7935-7944	asymmetry	_
51-22	7945-7946	(	_
51-23	7946-7949	PAS	_
51-24	7949-7950	 	_
51-25	7950-7951	=	_
51-26	7951-7952	 	_
51-27	7952-7959	FCinter	_
51-28	7959-7960	 	_
51-29	7960-7961	−	_
51-30	7961-7962	 	_
51-31	7962-7969	FCintra	_
51-32	7969-7970	)	_
51-33	7970-7971	.	_

#Text=This voxel-wise method does not depend on pre-defined regions of interest (ROIs) in two hemispheres, therefore minimizing potential confounding effects of structural asymmetry and selection bias caused by ROIs.
52-1	7972-7976	This	_
52-2	7977-7987	voxel-wise	_
52-3	7988-7994	method	_
52-4	7995-7999	does	_
52-5	8000-8003	not	_
52-6	8004-8010	depend	_
52-7	8011-8013	on	_
52-8	8014-8025	pre-defined	_
52-9	8026-8033	regions	_
52-10	8034-8036	of	_
52-11	8037-8045	interest	_
52-12	8046-8047	(	_
52-13	8047-8051	ROIs	_
52-14	8051-8052	)	_
52-15	8053-8055	in	_
52-16	8056-8059	two	_
52-17	8060-8071	hemispheres	_
52-18	8071-8072	,	_
52-19	8073-8082	therefore	_
52-20	8083-8093	minimizing	_
52-21	8094-8103	potential	_
52-22	8104-8115	confounding	_
52-23	8116-8123	effects	_
52-24	8124-8126	of	_
52-25	8127-8137	structural	_
52-26	8138-8147	asymmetry	_
52-27	8148-8151	and	_
52-28	8152-8161	selection	_
52-29	8162-8166	bias	_
52-30	8167-8173	caused	_
52-31	8174-8176	by	_
52-32	8177-8181	ROIs	_
52-33	8181-8182	.	_

#Text=Previously, autonomy index (AI), an asymmetry parameter, was calculated by counting the numbers of voxels with abnormal functional asymmetry.
53-1	8183-8193	Previously	_
53-2	8193-8194	,	_
53-3	8195-8203	autonomy	_
53-4	8204-8209	index	_
53-5	8210-8211	(	_
53-6	8211-8213	AI	_
53-7	8213-8214	)	_
53-8	8214-8215	,	_
53-9	8216-8218	an	_
53-10	8219-8228	asymmetry	_
53-11	8229-8238	parameter	_
53-12	8238-8239	,	_
53-13	8240-8243	was	_
53-14	8244-8254	calculated	_
53-15	8255-8257	by	_
53-16	8258-8266	counting	_
53-17	8267-8270	the	_
53-18	8271-8278	numbers	_
53-19	8279-8281	of	_
53-20	8282-8288	voxels	_
53-21	8289-8293	with	_
53-22	8294-8302	abnormal	_
53-23	8303-8313	functional	_
53-24	8314-8323	asymmetry	_
53-25	8323-8324	.	_

#Text=AI is valuable to quantify functional asymmetry.
54-1	8325-8327	AI	_
54-2	8328-8330	is	_
54-3	8331-8339	valuable	_
54-4	8340-8342	to	_
54-5	8343-8351	quantify	_
54-6	8352-8362	functional	_
54-7	8363-8372	asymmetry	_
54-8	8372-8373	.	_

#Text=However, AI ignores the correlation coefficient of each voxel, which is an important characteristic of functional asymmetry.
55-1	8374-8381	However	_
55-2	8381-8382	,	_
55-3	8383-8385	AI	_
55-4	8386-8393	ignores	_
55-5	8394-8397	the	_
55-6	8398-8409	correlation	_
55-7	8410-8421	coefficient	_
55-8	8422-8424	of	_
55-9	8425-8429	each	_
55-10	8430-8435	voxel	_
55-11	8435-8436	,	_
55-12	8437-8442	which	_
55-13	8443-8445	is	_
55-14	8446-8448	an	_
55-15	8449-8458	important	_
55-16	8459-8473	characteristic	_
55-17	8474-8476	of	_
55-18	8477-8487	functional	_
55-19	8488-8497	asymmetry	_
55-20	8497-8498	.	_

#Text=Therefore, we proposed a novel method, PAS, to quantify correlation coefficients of voxels with functional asymmetry in the present study.
56-1	8499-8508	Therefore	_
56-2	8508-8509	,	_
56-3	8510-8512	we	_
56-4	8513-8521	proposed	_
56-5	8522-8523	a	_
56-6	8524-8529	novel	_
56-7	8530-8536	method	_
56-8	8536-8537	,	_
56-9	8538-8541	PAS	_
56-10	8541-8542	,	_
56-11	8543-8545	to	_
56-12	8546-8554	quantify	_
56-13	8555-8566	correlation	_
56-14	8567-8579	coefficients	_
56-15	8580-8582	of	_
56-16	8583-8589	voxels	_
56-17	8590-8594	with	_
56-18	8595-8605	functional	_
56-19	8606-8615	asymmetry	_
56-20	8616-8618	in	_
56-21	8619-8622	the	_
56-22	8623-8630	present	_
56-23	8631-8636	study	_
56-24	8636-8637	.	_

#Text=Unaffected siblings were recruited to examine whether disrupted asymmetry represent an endophenotype for schizophrenia.
57-1	8638-8648	Unaffected	_
57-2	8649-8657	siblings	_
57-3	8658-8662	were	_
57-4	8663-8672	recruited	_
57-5	8673-8675	to	_
57-6	8676-8683	examine	_
57-7	8684-8691	whether	_
57-8	8692-8701	disrupted	_
57-9	8702-8711	asymmetry	_
57-10	8712-8721	represent	_
57-11	8722-8724	an	_
57-12	8725-8738	endophenotype	_
57-13	8739-8742	for	_
57-14	8743-8756	schizophrenia	_
57-15	8756-8757	.	_

#Text=Patients received olanzapine treatment for 8 weeks.
58-1	8758-8766	Patients	_
58-2	8767-8775	received	_
58-3	8776-8786	olanzapine	_
58-4	8787-8796	treatment	_
58-5	8797-8800	for	_
58-6	8801-8802	8	_
58-7	8802-8803	 	_
58-8	8803-8808	weeks	_
58-9	8808-8809	.	_

#Text=Previous univariate analysis could predict clinical response at the group level, which was of little utility to guide treatment decision making for individual patients in the clinical setting.
59-1	8810-8818	Previous	_
59-2	8819-8829	univariate	_
59-3	8830-8838	analysis	_
59-4	8839-8844	could	_
59-5	8845-8852	predict	_
59-6	8853-8861	clinical	_
59-7	8862-8870	response	_
59-8	8871-8873	at	_
59-9	8874-8877	the	_
59-10	8878-8883	group	_
59-11	8884-8889	level	_
59-12	8889-8890	,	_
59-13	8891-8896	which	_
59-14	8897-8900	was	_
59-15	8901-8903	of	_
59-16	8904-8910	little	_
59-17	8911-8918	utility	_
59-18	8919-8921	to	_
59-19	8922-8927	guide	_
59-20	8928-8937	treatment	_
59-21	8938-8946	decision	_
59-22	8947-8953	making	_
59-23	8954-8957	for	_
59-24	8958-8968	individual	_
59-25	8969-8977	patients	_
59-26	8978-8980	in	_
59-27	8981-8984	the	_
59-28	8985-8993	clinical	_
59-29	8994-9001	setting	_
59-30	9001-9002	.	_

#Text=By contrast, pattern classification techniques including support vector machine (SVM) allow prediction at the individual level, which might be helpful in the clinical setting.
60-1	9003-9005	By	_
60-2	9006-9014	contrast	_
60-3	9014-9015	,	_
60-4	9016-9023	pattern	_
60-5	9024-9038	classification	_
60-6	9039-9049	techniques	_
60-7	9050-9059	including	_
60-8	9060-9067	support	_
60-9	9068-9074	vector	_
60-10	9075-9082	machine	_
60-11	9083-9084	(	_
60-12	9084-9087	SVM	_
60-13	9087-9088	)	_
60-14	9089-9094	allow	_
60-15	9095-9105	prediction	_
60-16	9106-9108	at	_
60-17	9109-9112	the	_
60-18	9113-9123	individual	_
60-19	9124-9129	level	_
60-20	9129-9130	,	_
60-21	9131-9136	which	_
60-22	9137-9142	might	_
60-23	9143-9145	be	_
60-24	9146-9153	helpful	_
60-25	9154-9156	in	_
60-26	9157-9160	the	_
60-27	9161-9169	clinical	_
60-28	9170-9177	setting	_
60-29	9177-9178	.	_

#Text=Such methods have been used to differentiate patients with adolescent-onset schizophrenia and healthy controls, and to predict clinical response to electroconvulsive treatment in patients with major depressive disorder.
61-1	9179-9183	Such	_
61-2	9184-9191	methods	_
61-3	9192-9196	have	_
61-4	9197-9201	been	_
61-5	9202-9206	used	_
61-6	9207-9209	to	_
61-7	9210-9223	differentiate	_
61-8	9224-9232	patients	_
61-9	9233-9237	with	_
61-10	9238-9254	adolescent-onset	_
61-11	9255-9268	schizophrenia	_
61-12	9269-9272	and	_
61-13	9273-9280	healthy	_
61-14	9281-9289	controls	_
61-15	9289-9290	,	_
61-16	9291-9294	and	_
61-17	9295-9297	to	_
61-18	9298-9305	predict	_
61-19	9306-9314	clinical	_
61-20	9315-9323	response	_
61-21	9324-9326	to	_
61-22	9327-9344	electroconvulsive	_
61-23	9345-9354	treatment	_
61-24	9355-9357	in	_
61-25	9358-9366	patients	_
61-26	9367-9371	with	_
61-27	9372-9377	major	_
61-28	9378-9388	depressive	_
61-29	9389-9397	disorder	_
61-30	9397-9398	.	_

#Text=The purpose of the present study was to examine whether the baseline PAS scores can predict individual clinical response to olanzapine treatment at week 8 using the SVM method.
62-1	9399-9402	The	_
62-2	9403-9410	purpose	_
62-3	9411-9413	of	_
62-4	9414-9417	the	_
62-5	9418-9425	present	_
62-6	9426-9431	study	_
62-7	9432-9435	was	_
62-8	9436-9438	to	_
62-9	9439-9446	examine	_
62-10	9447-9454	whether	_
62-11	9455-9458	the	_
62-12	9459-9467	baseline	_
62-13	9468-9471	PAS	_
62-14	9472-9478	scores	_
62-15	9479-9482	can	_
62-16	9483-9490	predict	_
62-17	9491-9501	individual	_
62-18	9502-9510	clinical	_
62-19	9511-9519	response	_
62-20	9520-9522	to	_
62-21	9523-9533	olanzapine	_
62-22	9534-9543	treatment	_
62-23	9544-9546	at	_
62-24	9547-9551	week	_
62-25	9552-9553	8	_
62-26	9554-9559	using	_
62-27	9560-9563	the	_
62-28	9564-9567	SVM	_
62-29	9568-9574	method	_
62-30	9574-9575	.	_

#Text=Materials and methods
#Text=Subjects
#Text=Forty-six patients with drug-naive, first-episode schizophrenia and 46 unaffected siblings were recruited from the Mental Health Center, the Second Affiliated Hospital of Guangxi Medical University in China between June 2013 and July 2014; 46 healthy controls were recruited from the local community during the same time period.
63-1	9576-9585	Materials	http://www.case.edu/ProvCaRe/provcare#StudyMethod[5]
63-2	9586-9589	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[5]
63-3	9590-9597	methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[5]
63-4	9598-9606	Subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
63-5	9607-9616	Forty-six	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
63-6	9617-9625	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
63-7	9626-9630	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
63-8	9631-9641	drug-naive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
63-9	9641-9642	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
63-10	9643-9656	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
63-11	9657-9670	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[7]
63-12	9671-9674	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
63-13	9675-9677	46	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
63-14	9678-9688	unaffected	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
63-15	9689-9697	siblings	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
63-16	9698-9702	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
63-17	9703-9712	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
63-18	9713-9717	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
63-19	9718-9721	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
63-20	9722-9728	Mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
63-21	9729-9735	Health	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
63-22	9736-9742	Center	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
63-23	9742-9743	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
63-24	9744-9747	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
63-25	9748-9754	Second	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
63-26	9755-9765	Affiliated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
63-27	9766-9774	Hospital	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
63-28	9775-9777	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
63-29	9778-9785	Guangxi	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
63-30	9786-9793	Medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
63-31	9794-9804	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
63-32	9805-9807	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
63-33	9808-9813	China	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
63-34	9814-9821	between	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
63-35	9822-9826	June	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
63-36	9827-9831	2013	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
63-37	9832-9835	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
63-38	9836-9840	July	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
63-39	9841-9845	2014	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
63-40	9845-9846	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
63-41	9847-9849	46	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
63-42	9850-9857	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[8]
63-43	9858-9866	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[8]
63-44	9867-9871	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
63-45	9872-9881	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
63-46	9882-9886	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
63-47	9887-9890	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
63-48	9891-9896	local	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
63-49	9897-9906	community	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
63-50	9907-9913	during	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
63-51	9914-9917	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
63-52	9918-9922	same	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
63-53	9923-9927	time	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
63-54	9928-9934	period	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
63-55	9934-9935	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]

#Text=All subjects were in the age range 18–37 years old and right handed, and had >6 years of formal education.
64-1	9936-9939	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
64-2	9940-9948	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
64-3	9949-9953	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
64-4	9954-9956	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
64-5	9957-9960	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
64-6	9961-9964	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
64-7	9965-9970	range	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
64-8	9971-9973	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
64-9	9973-9974	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
64-10	9974-9976	37	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
64-11	9976-9977	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
64-12	9977-9982	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
64-13	9983-9986	old	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
64-14	9987-9990	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
64-15	9991-9996	right	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
64-16	9997-10003	handed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
64-17	10003-10004	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
64-18	10005-10008	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
64-19	10009-10012	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
64-20	10013-10014	>	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
64-21	10014-10015	6	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
64-22	10015-10016	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
64-23	10016-10021	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
64-24	10022-10024	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
64-25	10025-10031	formal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
64-26	10032-10041	education	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
64-27	10041-10042	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]

#Text=Patients were diagnosed with schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV).
65-1	10043-10051	Patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
65-2	10052-10056	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
65-3	10057-10066	diagnosed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
65-4	10067-10071	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
65-5	10072-10085	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[11]
65-6	10086-10095	according	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
65-7	10096-10098	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
65-8	10099-10102	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
65-9	10103-10113	Diagnostic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
65-10	10114-10117	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
65-11	10118-10129	Statistical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
65-12	10130-10136	Manual	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
65-13	10137-10139	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
65-14	10140-10146	Mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
65-15	10147-10159	Disorders-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
65-16	10160-10161	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
65-17	10161-10167	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
65-18	10167-10168	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
65-19	10168-10169	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]

#Text=They were never treated with antipsychotic medications or other psychotropic agents.
66-1	10170-10174	They	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
66-2	10175-10179	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
66-3	10180-10185	never	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
66-4	10186-10193	treated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
66-5	10194-10198	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
66-6	10199-10212	antipsychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
66-7	10213-10224	medications	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
66-8	10225-10227	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
66-9	10228-10233	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
66-10	10234-10246	psychotropic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
66-11	10247-10253	agents	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
66-12	10253-10254	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]

#Text=The diagnosis of schizophrenia was further determined by two research psychiatrists (W.G. and Z.Z.) using the Structural Clinical Interview for DSM-IV (SCID), patient version.
67-1	10255-10258	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
67-2	10259-10268	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
67-3	10269-10271	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
67-4	10272-10285	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[14]
67-5	10286-10289	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
67-6	10290-10297	further	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
67-7	10298-10308	determined	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
67-8	10309-10311	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
67-9	10312-10315	two	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
67-10	10316-10324	research	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
67-11	10325-10338	psychiatrists	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
67-12	10339-10340	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
67-13	10340-10343	W.G	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
67-14	10343-10344	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
67-15	10345-10348	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
67-16	10349-10352	Z.Z	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
67-17	10352-10353	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
67-18	10353-10354	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
67-19	10355-10360	using	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
67-20	10361-10364	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
67-21	10365-10375	Structural	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[15]
67-22	10376-10384	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[15]
67-23	10385-10394	Interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[15]
67-24	10395-10398	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[15]
67-25	10399-10405	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[15]
67-26	10406-10407	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[15]
67-27	10407-10411	SCID	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[15]
67-28	10411-10412	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[15]
67-29	10412-10413	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
67-30	10414-10421	patient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
67-31	10422-10429	version	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
67-32	10429-10430	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]

#Text=All patients had a Positive and Negative Syndrome Scale (PANSS) total score of >70 at baseline.
68-1	10431-10434	All	_
68-2	10435-10443	patients	_
68-3	10444-10447	had	_
68-4	10448-10449	a	_
68-5	10450-10458	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[16]
68-6	10459-10462	and	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[16]
68-7	10463-10471	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[16]
68-8	10472-10480	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[16]
68-9	10481-10486	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[16]
68-10	10487-10488	(	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[16]
68-11	10488-10493	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[16]
68-12	10493-10494	)	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[16]
68-13	10495-10500	total	_
68-14	10501-10506	score	_
68-15	10507-10509	of	_
68-16	10510-10511	>	_
68-17	10511-10513	70	_
68-18	10514-10516	at	_
68-19	10517-10525	baseline	_
68-20	10525-10526	.	_

#Text=Exclusion criteria included history of nicotine dependence, alcohol or other substance dependence, or history of brain injury.
69-1	10527-10536	Exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
69-2	10537-10545	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
69-3	10546-10554	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
69-4	10555-10562	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
69-5	10563-10565	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
69-6	10566-10574	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
69-7	10575-10585	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
69-8	10585-10586	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
69-9	10587-10594	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
69-10	10595-10597	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
69-11	10598-10603	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
69-12	10604-10613	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
69-13	10614-10624	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
69-14	10624-10625	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
69-15	10626-10628	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
69-16	10629-10636	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
69-17	10637-10639	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
69-18	10640-10645	brain	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
69-19	10646-10652	injury	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
69-20	10652-10653	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]

#Text=A routine physical examination including review of systems, and routine laboratory tests including complete blood cell count, a comprehensive metabolic panel, thyroid function test, urinalysis, electrocardiography, and chest radiography were performed to exclude any ongoing significant medical conditions.
70-1	10654-10655	A	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-2	10656-10663	routine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-3	10664-10672	physical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-4	10673-10684	examination	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-5	10685-10694	including	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-6	10695-10701	review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-7	10702-10704	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-8	10705-10712	systems	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-9	10712-10713	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-10	10714-10717	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-11	10718-10725	routine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-12	10726-10736	laboratory	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-13	10737-10742	tests	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-14	10743-10752	including	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-15	10753-10761	complete	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-16	10762-10767	blood	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-17	10768-10772	cell	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-18	10773-10778	count	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-19	10778-10779	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-20	10780-10781	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-21	10782-10795	comprehensive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-22	10796-10805	metabolic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-23	10806-10811	panel	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-24	10811-10812	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-25	10813-10820	thyroid	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-26	10821-10829	function	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-27	10830-10834	test	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-28	10834-10835	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-29	10836-10846	urinalysis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-30	10846-10847	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-31	10848-10867	electrocardiography	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-32	10867-10868	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-33	10869-10872	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-34	10873-10878	chest	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-35	10879-10890	radiography	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-36	10891-10895	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-37	10896-10905	performed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-38	10906-10908	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-39	10909-10916	exclude	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-40	10917-10920	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-41	10921-10928	ongoing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-42	10929-10940	significant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-43	10941-10948	medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-44	10949-10959	conditions	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
70-45	10959-10960	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]

#Text=Unaffected siblings and healthy controls were recruited through advertisement.
71-1	10961-10971	Unaffected	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
71-2	10972-10980	siblings	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
71-3	10981-10984	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
71-4	10985-10992	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[20]
71-5	10993-11001	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[20]
71-6	11002-11006	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
71-7	11007-11016	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
71-8	11017-11024	through	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
71-9	11025-11038	advertisement	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
71-10	11038-11039	.	_

#Text=They went through the same physical examination and routine laboratory tests to rule out any medical conditions.
72-1	11040-11044	They	_
72-2	11045-11049	went	_
72-3	11050-11057	through	_
72-4	11058-11061	the	_
72-5	11062-11066	same	_
72-6	11067-11075	physical	_
72-7	11076-11087	examination	_
72-8	11088-11091	and	_
72-9	11092-11099	routine	_
72-10	11100-11110	laboratory	_
72-11	11111-11116	tests	_
72-12	11117-11119	to	_
72-13	11120-11124	rule	_
72-14	11125-11128	out	_
72-15	11129-11132	any	_
72-16	11133-11140	medical	_
72-17	11141-11151	conditions	_
72-18	11151-11152	.	_

#Text=In addition, the same research psychiatrists (W.G. and Z.Z.) conducted a structured clinical interview using the SCID, non-patient version to rule out any psychiatric conditions.
73-1	11153-11155	In	_
73-2	11156-11164	addition	_
73-3	11164-11165	,	_
73-4	11166-11169	the	_
73-5	11170-11174	same	_
73-6	11175-11183	research	_
73-7	11184-11197	psychiatrists	_
73-8	11198-11199	(	_
73-9	11199-11202	W.G	_
73-10	11202-11203	.	_
73-11	11204-11207	and	_
73-12	11208-11211	Z.Z	_
73-13	11211-11212	.	_
73-14	11212-11213	)	_
73-15	11214-11223	conducted	_
73-16	11224-11225	a	_
73-17	11226-11236	structured	_
73-18	11237-11245	clinical	_
73-19	11246-11255	interview	_
73-20	11256-11261	using	_
73-21	11262-11265	the	_
73-22	11266-11270	SCID	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder
73-23	11270-11271	,	_
73-24	11272-11283	non-patient	_
73-25	11284-11291	version	_
73-26	11292-11294	to	_
73-27	11295-11299	rule	_
73-28	11300-11303	out	_
73-29	11304-11307	any	_
73-30	11308-11319	psychiatric	_
73-31	11320-11330	conditions	_
73-32	11330-11331	.	_

#Text=None of them had a history of any psychiatric conditions, nicotine dependence, alcohol or other substance dependence.
74-1	11332-11336	None	_
74-2	11337-11339	of	_
74-3	11340-11344	them	_
74-4	11345-11348	had	_
74-5	11349-11350	a	_
74-6	11351-11358	history	_
74-7	11359-11361	of	_
74-8	11362-11365	any	_
74-9	11366-11377	psychiatric	_
74-10	11378-11388	conditions	_
74-11	11388-11389	,	_
74-12	11390-11398	nicotine	_
74-13	11399-11409	dependence	_
74-14	11409-11410	,	_
74-15	11411-11418	alcohol	_
74-16	11419-11421	or	_
74-17	11422-11427	other	_
74-18	11428-11437	substance	_
74-19	11438-11448	dependence	_
74-20	11448-11449	.	_

#Text=In addition, those who had a first-degree relative diagnosed with psychiatric disorders were not eligible to be healthy controls.
75-1	11450-11452	In	_
75-2	11453-11461	addition	_
75-3	11461-11462	,	_
75-4	11463-11468	those	_
75-5	11469-11472	who	_
75-6	11473-11476	had	_
75-7	11477-11478	a	_
75-8	11479-11491	first-degree	_
75-9	11492-11500	relative	_
75-10	11501-11510	diagnosed	_
75-11	11511-11515	with	_
75-12	11516-11527	psychiatric	_
75-13	11528-11537	disorders	_
75-14	11538-11542	were	_
75-15	11543-11546	not	_
75-16	11547-11555	eligible	_
75-17	11556-11558	to	_
75-18	11559-11561	be	_
75-19	11562-11569	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[21]
75-20	11570-11578	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[21]
75-21	11578-11579	.	_

#Text=Patients were treated with olanzapine (10–30 mg/d with a mean (standard deviation) dose of 18.30 (5.17) mg/d) for 8 weeks.
76-1	11580-11588	Patients	_
76-2	11589-11593	were	_
76-3	11594-11601	treated	_
76-4	11602-11606	with	_
76-5	11607-11617	olanzapine	_
76-6	11618-11619	(	_
76-7	11619-11621	10	_
76-8	11621-11622	–	_
76-9	11622-11624	30	_
76-10	11624-11625	 	_
76-11	11625-11627	mg	_
76-12	11627-11628	/	_
76-13	11628-11629	d	_
76-14	11630-11634	with	_
76-15	11635-11636	a	_
76-16	11637-11641	mean	_
76-17	11642-11643	(	_
76-18	11643-11651	standard	_
76-19	11652-11661	deviation	_
76-20	11661-11662	)	_
76-21	11663-11667	dose	_
76-22	11668-11670	of	_
76-23	11671-11676	18.30	_
76-24	11677-11678	(	_
76-25	11678-11682	5.17	_
76-26	11682-11683	)	_
76-27	11684-11686	mg	_
76-28	11686-11687	/	_
76-29	11687-11688	d	_
76-30	11688-11689	)	_
76-31	11690-11693	for	_
76-32	11694-11695	8	_
76-33	11695-11696	 	_
76-34	11696-11701	weeks	_
76-35	11701-11702	.	_

#Text=The PANSS was repeated at week 8.
77-1	11703-11706	The	_
77-2	11707-11712	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
77-3	11713-11716	was	_
77-4	11717-11725	repeated	_
77-5	11726-11728	at	_
77-6	11729-11733	week	_
77-7	11734-11735	8	_
77-8	11735-11736	.	_

#Text=The study was approved by the ethics committees of the Second Affiliated Hospital of Guangxi Medical University.
78-1	11737-11740	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
78-2	11741-11746	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
78-3	11747-11750	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
78-4	11751-11759	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
78-5	11760-11762	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
78-6	11763-11766	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
78-7	11767-11773	ethics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
78-8	11774-11784	committees	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
78-9	11785-11787	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
78-10	11788-11791	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
78-11	11792-11798	Second	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
78-12	11799-11809	Affiliated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
78-13	11810-11818	Hospital	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
78-14	11819-11821	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
78-15	11822-11829	Guangxi	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
78-16	11830-11837	Medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
78-17	11838-11848	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
78-18	11848-11849	.	_

#Text=All subjects signed a written informed consent.
79-1	11850-11853	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
79-2	11854-11862	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
79-3	11863-11869	signed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
79-4	11870-11871	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
79-5	11872-11879	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
79-6	11880-11888	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
79-7	11889-11896	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
79-8	11896-11897	.	_

#Text=Image acquisition and preprocessing
#Text=Images were obtained using a 3 T MRI scanner (Siemens Verio, Erlangen, Germany).
80-1	11898-11903	Image	_
80-2	11904-11915	acquisition	_
80-3	11916-11919	and	_
80-4	11920-11933	preprocessing	_
80-5	11934-11940	Images	_
80-6	11941-11945	were	_
80-7	11946-11954	obtained	_
80-8	11955-11960	using	_
80-9	11961-11962	a	_
80-10	11963-11964	3	_
80-11	11964-11965	 	_
80-12	11965-11966	T	_
80-13	11967-11970	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
80-14	11971-11978	scanner	_
80-15	11979-11980	(	_
80-16	11980-11987	Siemens	_
80-17	11988-11993	Verio	_
80-18	11993-11994	,	_
80-19	11995-12003	Erlangen	_
80-20	12003-12004	,	_
80-21	12005-12012	Germany	_
80-22	12012-12013	)	_
80-23	12013-12014	.	_

#Text=The images were analyzed using the DPABI software.
81-1	12015-12018	The	_
81-2	12019-12025	images	_
81-3	12026-12030	were	_
81-4	12031-12039	analyzed	_
81-5	12040-12045	using	_
81-6	12046-12049	the	_
81-7	12050-12055	DPABI	_
81-8	12056-12064	software	_
81-9	12064-12065	.	_

#Text=More details about image acquisition and pre-processing can be found in the Supplementary files.
82-1	12066-12070	More	_
82-2	12071-12078	details	_
82-3	12079-12084	about	_
82-4	12085-12090	image	_
82-5	12091-12102	acquisition	_
82-6	12103-12106	and	_
82-7	12107-12121	pre-processing	_
82-8	12122-12125	can	_
82-9	12126-12128	be	_
82-10	12129-12134	found	_
82-11	12135-12137	in	_
82-12	12138-12141	the	_
82-13	12142-12155	Supplementary	_
82-14	12156-12161	files	_
82-15	12161-12162	.	_

#Text=Calculation of the PAS scores
#Text=For each subject, correlation coefficients were calculated between a given voxel and other voxels from the same hemisphere (intra-hemispheric coefficients) or other voxels from the opposite hemisphere (inter-hemispheric coefficients) by using a voxel-wise whole-brain analysis.
83-1	12163-12174	Calculation	_
83-2	12175-12177	of	_
83-3	12178-12181	the	_
83-4	12182-12185	PAS	_
83-5	12186-12192	scores	_
83-6	12193-12196	For	_
83-7	12197-12201	each	_
83-8	12202-12209	subject	_
83-9	12209-12210	,	_
83-10	12211-12222	correlation	_
83-11	12223-12235	coefficients	_
83-12	12236-12240	were	_
83-13	12241-12251	calculated	_
83-14	12252-12259	between	_
83-15	12260-12261	a	_
83-16	12262-12267	given	_
83-17	12268-12273	voxel	_
83-18	12274-12277	and	_
83-19	12278-12283	other	_
83-20	12284-12290	voxels	_
83-21	12291-12295	from	_
83-22	12296-12299	the	_
83-23	12300-12304	same	_
83-24	12305-12315	hemisphere	_
83-25	12316-12317	(	_
83-26	12317-12334	intra-hemispheric	_
83-27	12335-12347	coefficients	_
83-28	12347-12348	)	_
83-29	12349-12351	or	_
83-30	12352-12357	other	_
83-31	12358-12364	voxels	_
83-32	12365-12369	from	_
83-33	12370-12373	the	_
83-34	12374-12382	opposite	_
83-35	12383-12393	hemisphere	_
83-36	12394-12395	(	_
83-37	12395-12412	inter-hemispheric	_
83-38	12413-12425	coefficients	_
83-39	12425-12426	)	_
83-40	12427-12429	by	_
83-41	12430-12435	using	_
83-42	12436-12437	a	_
83-43	12438-12448	voxel-wise	_
83-44	12449-12460	whole-brain	_
83-45	12461-12469	analysis	_
83-46	12469-12470	.	_

#Text=The mean coefficient of this given voxel was termed as the intra-hemispheric FC or inter-hemispheric FC of this voxel.
84-1	12471-12474	The	_
84-2	12475-12479	mean	_
84-3	12480-12491	coefficient	_
84-4	12492-12494	of	_
84-5	12495-12499	this	_
84-6	12500-12505	given	_
84-7	12506-12511	voxel	_
84-8	12512-12515	was	_
84-9	12516-12522	termed	_
84-10	12523-12525	as	_
84-11	12526-12529	the	_
84-12	12530-12547	intra-hemispheric	_
84-13	12548-12550	FC	_
84-14	12551-12553	or	_
84-15	12554-12571	inter-hemispheric	_
84-16	12572-12574	FC	_
84-17	12575-12577	of	_
84-18	12578-12582	this	_
84-19	12583-12588	voxel	_
84-20	12588-12589	.	_

#Text=Because small correlation coefficients between voxels, which were not significantly greater/smaller than zero, might bring in confounding effect on asymmetry analysis, the PAS calculation was conducted based on a pre-defined correlation coefficient threshold (r > 0.2) in order to remove weak correlations likely due to signal noise.
85-1	12590-12597	Because	_
85-2	12598-12603	small	_
85-3	12604-12615	correlation	_
85-4	12616-12628	coefficients	_
85-5	12629-12636	between	_
85-6	12637-12643	voxels	_
85-7	12643-12644	,	_
85-8	12645-12650	which	_
85-9	12651-12655	were	_
85-10	12656-12659	not	_
85-11	12660-12673	significantly	_
85-12	12674-12681	greater	_
85-13	12681-12682	/	_
85-14	12682-12689	smaller	_
85-15	12690-12694	than	_
85-16	12695-12699	zero	_
85-17	12699-12700	,	_
85-18	12701-12706	might	_
85-19	12707-12712	bring	_
85-20	12713-12715	in	_
85-21	12716-12727	confounding	_
85-22	12728-12734	effect	_
85-23	12735-12737	on	_
85-24	12738-12747	asymmetry	_
85-25	12748-12756	analysis	_
85-26	12756-12757	,	_
85-27	12758-12761	the	_
85-28	12762-12765	PAS	_
85-29	12766-12777	calculation	_
85-30	12778-12781	was	_
85-31	12782-12791	conducted	_
85-32	12792-12797	based	_
85-33	12798-12800	on	_
85-34	12801-12802	a	_
85-35	12803-12814	pre-defined	_
85-36	12815-12826	correlation	_
85-37	12827-12838	coefficient	_
85-38	12839-12848	threshold	_
85-39	12849-12850	(	_
85-40	12850-12851	r	_
85-41	12851-12852	 	_
85-42	12852-12853	>	_
85-43	12853-12854	 	_
85-44	12854-12857	0.2	_
85-45	12857-12858	)	_
85-46	12859-12861	in	_
85-47	12862-12867	order	_
85-48	12868-12870	to	_
85-49	12871-12877	remove	_
85-50	12878-12882	weak	_
85-51	12883-12895	correlations	_
85-52	12896-12902	likely	_
85-53	12903-12906	due	_
85-54	12907-12909	to	_
85-55	12910-12916	signal	_
85-56	12917-12922	noise	_
85-57	12922-12923	.	_

#Text=To test whether the choice of correlation coefficient threshold might affect the findings, another correlation coefficient threshold (r > 0.25) was also used according to a previous study.
86-1	12924-12926	To	_
86-2	12927-12931	test	_
86-3	12932-12939	whether	_
86-4	12940-12943	the	_
86-5	12944-12950	choice	_
86-6	12951-12953	of	_
86-7	12954-12965	correlation	_
86-8	12966-12977	coefficient	_
86-9	12978-12987	threshold	_
86-10	12988-12993	might	_
86-11	12994-13000	affect	_
86-12	13001-13004	the	_
86-13	13005-13013	findings	_
86-14	13013-13014	,	_
86-15	13015-13022	another	_
86-16	13023-13034	correlation	_
86-17	13035-13046	coefficient	_
86-18	13047-13056	threshold	_
86-19	13057-13058	(	_
86-20	13058-13059	r	_
86-21	13059-13060	 	_
86-22	13060-13061	>	_
86-23	13061-13062	 	_
86-24	13062-13066	0.25	_
86-25	13066-13067	)	_
86-26	13068-13071	was	_
86-27	13072-13076	also	_
86-28	13077-13081	used	_
86-29	13082-13091	according	_
86-30	13092-13094	to	_
86-31	13095-13096	a	_
86-32	13097-13105	previous	_
86-33	13106-13111	study	_
86-34	13111-13112	.	_

#Text=Given the detrimental effects of negative correlations on test–retest reliability and ambiguous explanation of negative correlations, the PAS calculation was restricted to positive correlations only.
87-1	13113-13118	Given	_
87-2	13119-13122	the	_
87-3	13123-13134	detrimental	_
87-4	13135-13142	effects	_
87-5	13143-13145	of	_
87-6	13146-13154	negative	_
87-7	13155-13167	correlations	_
87-8	13168-13170	on	_
87-9	13171-13182	test–retest	_
87-10	13183-13194	reliability	_
87-11	13195-13198	and	_
87-12	13199-13208	ambiguous	_
87-13	13209-13220	explanation	_
87-14	13221-13223	of	_
87-15	13224-13232	negative	_
87-16	13233-13245	correlations	_
87-17	13245-13246	,	_
87-18	13247-13250	the	_
87-19	13251-13254	PAS	_
87-20	13255-13266	calculation	_
87-21	13267-13270	was	_
87-22	13271-13281	restricted	_
87-23	13282-13284	to	_
87-24	13285-13293	positive	_
87-25	13294-13306	correlations	_
87-26	13307-13311	only	_
87-27	13311-13312	.	_

#Text=The mean coefficients were z transformed as described previously.
88-1	13313-13316	The	_
88-2	13317-13321	mean	_
88-3	13322-13334	coefficients	_
88-4	13335-13339	were	_
88-5	13340-13341	z	_
88-6	13342-13353	transformed	_
88-7	13354-13356	as	_
88-8	13357-13366	described	_
88-9	13367-13377	previously	_
88-10	13377-13378	.	_

#Text=The PAS values were calculated using the formula below:
#Text=FCinter refers to inter-hemispheric FC, and FCintra intra-hemispheric FC.
89-1	13379-13382	The	_
89-2	13383-13386	PAS	_
89-3	13387-13393	values	_
89-4	13394-13398	were	_
89-5	13399-13409	calculated	_
89-6	13410-13415	using	_
89-7	13416-13419	the	_
89-8	13420-13427	formula	_
89-9	13428-13433	below	_
89-10	13433-13434	:	_
89-11	13435-13442	FCinter	_
89-12	13443-13449	refers	_
89-13	13450-13452	to	_
89-14	13453-13470	inter-hemispheric	_
89-15	13471-13473	FC	_
89-16	13473-13474	,	_
89-17	13475-13478	and	_
89-18	13479-13486	FCintra	_
89-19	13487-13504	intra-hemispheric	_
89-20	13505-13507	FC	_
89-21	13507-13508	.	_

#Text=A positive PAS score means that the asymmetry mainly originates from inter-hemispheric FC, whereas a negative PAS score means that the asymmetry primarily results from intra-hemispheric FC.
90-1	13509-13510	A	_
90-2	13511-13519	positive	_
90-3	13520-13523	PAS	_
90-4	13524-13529	score	_
90-5	13530-13535	means	_
90-6	13536-13540	that	_
90-7	13541-13544	the	_
90-8	13545-13554	asymmetry	_
90-9	13555-13561	mainly	_
90-10	13562-13572	originates	_
90-11	13573-13577	from	_
90-12	13578-13595	inter-hemispheric	_
90-13	13596-13598	FC	_
90-14	13598-13599	,	_
90-15	13600-13607	whereas	_
90-16	13608-13609	a	_
90-17	13610-13618	negative	_
90-18	13619-13622	PAS	_
90-19	13623-13628	score	_
90-20	13629-13634	means	_
90-21	13635-13639	that	_
90-22	13640-13643	the	_
90-23	13644-13653	asymmetry	_
90-24	13654-13663	primarily	_
90-25	13664-13671	results	_
90-26	13672-13676	from	_
90-27	13677-13694	intra-hemispheric	_
90-28	13695-13697	FC	_
90-29	13697-13698	.	_

#Text=Based on calculated PAS scores, the PAS maps were generated for further analysis.
91-1	13699-13704	Based	_
91-2	13705-13707	on	_
91-3	13708-13718	calculated	_
91-4	13719-13722	PAS	_
91-5	13723-13729	scores	_
91-6	13729-13730	,	_
91-7	13731-13734	the	_
91-8	13735-13738	PAS	_
91-9	13739-13743	maps	_
91-10	13744-13748	were	_
91-11	13749-13758	generated	_
91-12	13759-13762	for	_
91-13	13763-13770	further	_
91-14	13771-13779	analysis	_
91-15	13779-13780	.	_

#Text=Statistical analyses
#Text=Demographic and clinical data were analyzed using Chi-square test and analysis of variance (ANOVA) as appropriate.
92-1	13781-13792	Statistical	_
92-2	13793-13801	analyses	_
92-3	13802-13813	Demographic	_
92-4	13814-13817	and	_
92-5	13818-13826	clinical	_
92-6	13827-13831	data	_
92-7	13832-13836	were	_
92-8	13837-13845	analyzed	_
92-9	13846-13851	using	_
92-10	13852-13862	Chi-square	_
92-11	13863-13867	test	_
92-12	13868-13871	and	_
92-13	13872-13880	analysis	_
92-14	13881-13883	of	_
92-15	13884-13892	variance	_
92-16	13893-13894	(	_
92-17	13894-13899	ANOVA	_
92-18	13899-13900	)	_
92-19	13901-13903	as	_
92-20	13904-13915	appropriate	_
92-21	13915-13916	.	_

#Text=Framewise displacement (FD) was calculated for each subject using the method described previously.
93-1	13917-13926	Framewise	_
93-2	13927-13939	displacement	_
93-3	13940-13941	(	_
93-4	13941-13943	FD	_
93-5	13943-13944	)	_
93-6	13945-13948	was	_
93-7	13949-13959	calculated	_
93-8	13960-13963	for	_
93-9	13964-13968	each	_
93-10	13969-13976	subject	_
93-11	13977-13982	using	_
93-12	13983-13986	the	_
93-13	13987-13993	method	_
93-14	13994-14003	described	_
93-15	14004-14014	previously	_
93-16	14014-14015	.	_

#Text=For the PAS maps, analysis of covariance (ANCOVA), followed by post hoc t-tests, was used to compare group differences controlling for the mean FD and age.
94-1	14016-14019	For	_
94-2	14020-14023	the	_
94-3	14024-14027	PAS	_
94-4	14028-14032	maps	_
94-5	14032-14033	,	_
94-6	14034-14042	analysis	_
94-7	14043-14045	of	_
94-8	14046-14056	covariance	_
94-9	14057-14058	(	_
94-10	14058-14064	ANCOVA	_
94-11	14064-14065	)	_
94-12	14065-14066	,	_
94-13	14067-14075	followed	_
94-14	14076-14078	by	_
94-15	14079-14083	post	_
94-16	14084-14087	hoc	_
94-17	14088-14095	t-tests	_
94-18	14095-14096	,	_
94-19	14097-14100	was	_
94-20	14101-14105	used	_
94-21	14106-14108	to	_
94-22	14109-14116	compare	_
94-23	14117-14122	group	_
94-24	14123-14134	differences	_
94-25	14135-14146	controlling	_
94-26	14147-14150	for	_
94-27	14151-14154	the	_
94-28	14155-14159	mean	_
94-29	14160-14162	FD	_
94-30	14163-14166	and	_
94-31	14167-14170	age	_
94-32	14170-14171	.	_

#Text=The significance level was set at p < 0.05 corrected by the Gaussian random field (GRF) theory (voxel significance: p < 0.001, cluster significance: p < 0.05) using the REST software.
95-1	14172-14175	The	_
95-2	14176-14188	significance	_
95-3	14189-14194	level	_
95-4	14195-14198	was	_
95-5	14199-14202	set	_
95-6	14203-14205	at	_
95-7	14206-14207	p	_
95-8	14207-14208	 	_
95-9	14208-14209	<	_
95-10	14209-14210	 	_
95-11	14210-14214	0.05	_
95-12	14215-14224	corrected	_
95-13	14225-14227	by	_
95-14	14228-14231	the	_
95-15	14232-14240	Gaussian	_
95-16	14241-14247	random	_
95-17	14248-14253	field	_
95-18	14254-14255	(	_
95-19	14255-14258	GRF	_
95-20	14258-14259	)	_
95-21	14260-14266	theory	_
95-22	14267-14268	(	_
95-23	14268-14273	voxel	_
95-24	14274-14286	significance	_
95-25	14286-14287	:	_
95-26	14288-14289	p	_
95-27	14289-14290	 	_
95-28	14290-14291	<	_
95-29	14291-14292	 	_
95-30	14292-14297	0.001	_
95-31	14297-14298	,	_
95-32	14299-14306	cluster	_
95-33	14307-14319	significance	_
95-34	14319-14320	:	_
95-35	14321-14322	p	_
95-36	14322-14323	 	_
95-37	14323-14324	<	_
95-38	14324-14325	 	_
95-39	14325-14329	0.05	_
95-40	14329-14330	)	_
95-41	14331-14336	using	_
95-42	14337-14340	the	_
95-43	14341-14345	REST	_
95-44	14346-14354	software	_
95-45	14354-14355	.	_

#Text=Once abnormal clusters were identified by group comparisons, the mean PAS scores were extracted from every cluster in the patient group.
96-1	14356-14360	Once	_
96-2	14361-14369	abnormal	_
96-3	14370-14378	clusters	_
96-4	14379-14383	were	_
96-5	14384-14394	identified	_
96-6	14395-14397	by	_
96-7	14398-14403	group	_
96-8	14404-14415	comparisons	_
96-9	14415-14416	,	_
96-10	14417-14420	the	_
96-11	14421-14425	mean	_
96-12	14426-14429	PAS	_
96-13	14430-14436	scores	_
96-14	14437-14441	were	_
96-15	14442-14451	extracted	_
96-16	14452-14456	from	_
96-17	14457-14462	every	_
96-18	14463-14470	cluster	_
96-19	14471-14473	in	_
96-20	14474-14477	the	_
96-21	14478-14485	patient	_
96-22	14486-14491	group	_
96-23	14491-14492	.	_

#Text=Normality test was conducted to confirm that the data for mean PAS scores and clinical variables are in normal distribution.
97-1	14493-14502	Normality	_
97-2	14503-14507	test	_
97-3	14508-14511	was	_
97-4	14512-14521	conducted	_
97-5	14522-14524	to	_
97-6	14525-14532	confirm	_
97-7	14533-14537	that	_
97-8	14538-14541	the	_
97-9	14542-14546	data	_
97-10	14547-14550	for	_
97-11	14551-14555	mean	_
97-12	14556-14559	PAS	_
97-13	14560-14566	scores	_
97-14	14567-14570	and	_
97-15	14571-14579	clinical	_
97-16	14580-14589	variables	_
97-17	14590-14593	are	_
97-18	14594-14596	in	_
97-19	14597-14603	normal	_
97-20	14604-14616	distribution	_
97-21	14616-14617	.	_

#Text=Pearson's correlation analysis was performed within patients to examine the relationship between the mean PAS scores and clinical variables including illness duration and the PANSS total scores.
98-1	14618-14627	Pearson's	_
98-2	14628-14639	correlation	_
98-3	14640-14648	analysis	_
98-4	14649-14652	was	_
98-5	14653-14662	performed	_
98-6	14663-14669	within	_
98-7	14670-14678	patients	_
98-8	14679-14681	to	_
98-9	14682-14689	examine	_
98-10	14690-14693	the	_
98-11	14694-14706	relationship	_
98-12	14707-14714	between	_
98-13	14715-14718	the	_
98-14	14719-14723	mean	_
98-15	14724-14727	PAS	_
98-16	14728-14734	scores	_
98-17	14735-14738	and	_
98-18	14739-14747	clinical	_
98-19	14748-14757	variables	_
98-20	14758-14767	including	_
98-21	14768-14775	illness	_
98-22	14776-14784	duration	_
98-23	14785-14788	and	_
98-24	14789-14792	the	_
98-25	14793-14798	PANSS	_
98-26	14799-14804	total	_
98-27	14805-14811	scores	_
98-28	14811-14812	.	_

#Text=The significance level was set at p < 0.05 after the Bonferroni correction.
99-1	14813-14816	The	_
99-2	14817-14829	significance	_
99-3	14830-14835	level	_
99-4	14836-14839	was	_
99-5	14840-14843	set	_
99-6	14844-14846	at	_
99-7	14847-14848	p	_
99-8	14848-14849	 	_
99-9	14849-14850	<	_
99-10	14850-14851	 	_
99-11	14851-14855	0.05	_
99-12	14856-14861	after	_
99-13	14862-14865	the	_
99-14	14866-14876	Bonferroni	_
99-15	14877-14887	correction	_
99-16	14887-14888	.	_

#Text=SVM analysis
#Text=SVM was performed using the LIBSVM software (http://www.csie.ntu.edu.tw/~cjlin/libsvm/).
100-1	14889-14892	SVM	_
100-2	14893-14901	analysis	_
100-3	14902-14905	SVM	_
100-4	14906-14909	was	_
100-5	14910-14919	performed	_
100-6	14920-14925	using	_
100-7	14926-14929	the	_
100-8	14930-14936	LIBSVM	_
100-9	14937-14945	software	_
100-10	14946-14947	(	_
100-11	14947-14951	http	_
100-12	14951-14952	:	_
100-13	14952-14953	/	_
100-14	14953-14954	/	_
100-15	14954-14973	www.csie.ntu.edu.tw	_
100-16	14973-14974	/	_
100-17	14974-14975	~	_
100-18	14975-14980	cjlin	_
100-19	14980-14981	/	_
100-20	14981-14987	libsvm	_
100-21	14987-14988	/	_
100-22	14988-14989	)	_
100-23	14989-14990	.	_

#Text=Patients were divided into two groups (good response versus poor response) based on the median value of the reduction ratio (RR) of the PANSS total scores after 8 weeks of olanzapine treatment.
101-1	14991-14999	Patients	_
101-2	15000-15004	were	_
101-3	15005-15012	divided	_
101-4	15013-15017	into	_
101-5	15018-15021	two	_
101-6	15022-15028	groups	_
101-7	15029-15030	(	_
101-8	15030-15034	good	_
101-9	15035-15043	response	_
101-10	15044-15050	versus	_
101-11	15051-15055	poor	_
101-12	15056-15064	response	_
101-13	15064-15065	)	_
101-14	15066-15071	based	_
101-15	15072-15074	on	_
101-16	15075-15078	the	_
101-17	15079-15085	median	_
101-18	15086-15091	value	_
101-19	15092-15094	of	_
101-20	15095-15098	the	_
101-21	15099-15108	reduction	_
101-22	15109-15114	ratio	_
101-23	15115-15116	(	_
101-24	15116-15118	RR	_
101-25	15118-15119	)	_
101-26	15120-15122	of	_
101-27	15123-15126	the	_
101-28	15127-15132	PANSS	_
101-29	15133-15138	total	_
101-30	15139-15145	scores	_
101-31	15146-15151	after	_
101-32	15152-15153	8	_
101-33	15153-15154	 	_
101-34	15154-15159	weeks	_
101-35	15160-15162	of	_
101-36	15163-15173	olanzapine	_
101-37	15174-15183	treatment	_
101-38	15183-15184	.	_

#Text=The median value was used to ensure equal numbers of patients between the two groups, which is required for SVM analysis.
102-1	15185-15188	The	_
102-2	15189-15195	median	_
102-3	15196-15201	value	_
102-4	15202-15205	was	_
102-5	15206-15210	used	_
102-6	15211-15213	to	_
102-7	15214-15220	ensure	_
102-8	15221-15226	equal	_
102-9	15227-15234	numbers	_
102-10	15235-15237	of	_
102-11	15238-15246	patients	_
102-12	15247-15254	between	_
102-13	15255-15258	the	_
102-14	15259-15262	two	_
102-15	15263-15269	groups	_
102-16	15269-15270	,	_
102-17	15271-15276	which	_
102-18	15277-15279	is	_
102-19	15280-15288	required	_
102-20	15289-15292	for	_
102-21	15293-15296	SVM	_
102-22	15297-15305	analysis	_
102-23	15305-15306	.	_

#Text=The RR was calculated as follows.
103-1	15307-15310	The	_
103-2	15311-15313	RR	_
103-3	15314-15317	was	_
103-4	15318-15328	calculated	_
103-5	15329-15331	as	_
103-6	15332-15339	follows	_
103-7	15339-15340	.	_

#Text=PANSStotal_0 refers to the PANSS total scores at baseline, whereas PANSStotal_8w is the PANSS total scores after 8 weeks of treatment.
104-1	15341-15351	PANSStotal	_
104-2	15351-15352	_	_
104-3	15352-15353	0	_
104-4	15354-15360	refers	_
104-5	15361-15363	to	_
104-6	15364-15367	the	_
104-7	15368-15373	PANSS	_
104-8	15374-15379	total	_
104-9	15380-15386	scores	_
104-10	15387-15389	at	_
104-11	15390-15398	baseline	_
104-12	15398-15399	,	_
104-13	15400-15407	whereas	_
104-14	15408-15418	PANSStotal	_
104-15	15418-15419	_	_
104-16	15419-15421	8w	_
104-17	15422-15424	is	_
104-18	15425-15428	the	_
104-19	15429-15434	PANSS	_
104-20	15435-15440	total	_
104-21	15441-15447	scores	_
104-22	15448-15453	after	_
104-23	15454-15455	8	_
104-24	15455-15456	 	_
104-25	15456-15461	weeks	_
104-26	15462-15464	of	_
104-27	15465-15474	treatment	_
104-28	15474-15475	.	_

#Text=SVM was used to examine whether the PAS scores at baseline can predict clinical response to olanzapine treatment at week 8.
105-1	15476-15479	SVM	_
105-2	15480-15483	was	_
105-3	15484-15488	used	_
105-4	15489-15491	to	_
105-5	15492-15499	examine	_
105-6	15500-15507	whether	_
105-7	15508-15511	the	_
105-8	15512-15515	PAS	_
105-9	15516-15522	scores	_
105-10	15523-15525	at	_
105-11	15526-15534	baseline	_
105-12	15535-15538	can	_
105-13	15539-15546	predict	_
105-14	15547-15555	clinical	_
105-15	15556-15564	response	_
105-16	15565-15567	to	_
105-17	15568-15578	olanzapine	_
105-18	15579-15588	treatment	_
105-19	15589-15591	at	_
105-20	15592-15596	week	_
105-21	15597-15598	8	_
105-22	15598-15599	.	_

#Text=A “leave-one-out” procedure was applied to perform SVM.
106-1	15600-15601	A	_
106-2	15602-15603	“	_
106-3	15603-15616	leave-one-out	_
106-4	15616-15617	”	_
106-5	15618-15627	procedure	_
106-6	15628-15631	was	_
106-7	15632-15639	applied	_
106-8	15640-15642	to	_
106-9	15643-15650	perform	_
106-10	15651-15654	SVM	_
106-11	15654-15655	.	_

#Text=Results
#Text=Characteristics of the subjects
#Text=The data of 8 subjects (2 patients, 4 siblings, and 2 controls) were discarded due to excessive head motion.
107-1	15656-15663	Results	_
107-2	15664-15679	Characteristics	_
107-3	15680-15682	of	_
107-4	15683-15686	the	_
107-5	15687-15695	subjects	_
107-6	15696-15699	The	_
107-7	15700-15704	data	_
107-8	15705-15707	of	_
107-9	15708-15709	8	_
107-10	15710-15718	subjects	_
107-11	15719-15720	(	_
107-12	15720-15721	2	_
107-13	15722-15730	patients	_
107-14	15730-15731	,	_
107-15	15732-15733	4	_
107-16	15734-15742	siblings	_
107-17	15742-15743	,	_
107-18	15744-15747	and	_
107-19	15748-15749	2	_
107-20	15750-15758	controls	_
107-21	15758-15759	)	_
107-22	15760-15764	were	_
107-23	15765-15774	discarded	_
107-24	15775-15778	due	_
107-25	15779-15781	to	_
107-26	15782-15791	excessive	_
107-27	15792-15796	head	_
107-28	15797-15803	motion	_
107-29	15803-15804	.	_

#Text=Therefore, 44 patients, 42 unaffected siblings, and 44 healthy controls were finally enrolled.
108-1	15805-15814	Therefore	_
108-2	15814-15815	,	_
108-3	15816-15818	44	_
108-4	15819-15827	patients	_
108-5	15827-15828	,	_
108-6	15829-15831	42	_
108-7	15832-15842	unaffected	_
108-8	15843-15851	siblings	_
108-9	15851-15852	,	_
108-10	15853-15856	and	_
108-11	15857-15859	44	_
108-12	15860-15867	healthy	_
108-13	15868-15876	controls	_
108-14	15877-15881	were	_
108-15	15882-15889	finally	_
108-16	15890-15898	enrolled	_
108-17	15898-15899	.	_

#Text=There were no significant differences in age, gender, education level, and the mean FD across groups (eTable 1).
109-1	15900-15905	There	_
109-2	15906-15910	were	_
109-3	15911-15913	no	_
109-4	15914-15925	significant	_
109-5	15926-15937	differences	_
109-6	15938-15940	in	_
109-7	15941-15944	age	_
109-8	15944-15945	,	_
109-9	15946-15952	gender	_
109-10	15952-15953	,	_
109-11	15954-15963	education	_
109-12	15964-15969	level	_
109-13	15969-15970	,	_
109-14	15971-15974	and	_
109-15	15975-15978	the	_
109-16	15979-15983	mean	_
109-17	15984-15986	FD	_
109-18	15987-15993	across	_
109-19	15994-16000	groups	_
109-20	16001-16002	(	_
109-21	16002-16008	eTable	_
109-22	16009-16010	1	_
109-23	16010-16011	)	_
109-24	16011-16012	.	_

#Text=Within patients, the PANSS scores were significantly decreased after 8 weeks of treatment (eTable 2).
110-1	16013-16019	Within	_
110-2	16020-16028	patients	_
110-3	16028-16029	,	_
110-4	16030-16033	the	_
110-5	16034-16039	PANSS	_
110-6	16040-16046	scores	_
110-7	16047-16051	were	_
110-8	16052-16065	significantly	_
110-9	16066-16075	decreased	_
110-10	16076-16081	after	_
110-11	16082-16083	8	_
110-12	16083-16084	 	_
110-13	16084-16089	weeks	_
110-14	16090-16092	of	_
110-15	16093-16102	treatment	_
110-16	16103-16104	(	_
110-17	16104-16110	eTable	_
110-18	16111-16112	2	_
110-19	16112-16113	)	_
110-20	16113-16114	.	_

#Text=As shown in eTable 4, there were no significant differences between the good response group and the poor response group in important demographic and clinical characteristics including age, gender, education level, illness duration, and dosage of olanzapine (p's > 0.05).
111-1	16115-16117	As	_
111-2	16118-16123	shown	_
111-3	16124-16126	in	_
111-4	16127-16133	eTable	_
111-5	16134-16135	4	_
111-6	16135-16136	,	_
111-7	16137-16142	there	_
111-8	16143-16147	were	_
111-9	16148-16150	no	_
111-10	16151-16162	significant	_
111-11	16163-16174	differences	_
111-12	16175-16182	between	_
111-13	16183-16186	the	_
111-14	16187-16191	good	_
111-15	16192-16200	response	_
111-16	16201-16206	group	_
111-17	16207-16210	and	_
111-18	16211-16214	the	_
111-19	16215-16219	poor	_
111-20	16220-16228	response	_
111-21	16229-16234	group	_
111-22	16235-16237	in	_
111-23	16238-16247	important	_
111-24	16248-16259	demographic	_
111-25	16260-16263	and	_
111-26	16264-16272	clinical	_
111-27	16273-16288	characteristics	_
111-28	16289-16298	including	_
111-29	16299-16302	age	_
111-30	16302-16303	,	_
111-31	16304-16310	gender	_
111-32	16310-16311	,	_
111-33	16312-16321	education	_
111-34	16322-16327	level	_
111-35	16327-16328	,	_
111-36	16329-16336	illness	_
111-37	16337-16345	duration	_
111-38	16345-16346	,	_
111-39	16347-16350	and	_
111-40	16351-16357	dosage	_
111-41	16358-16360	of	_
111-42	16361-16371	olanzapine	_
111-43	16372-16373	(	_
111-44	16373-16376	p's	_
111-45	16376-16377	 	_
111-46	16377-16378	>	_
111-47	16378-16379	 	_
111-48	16379-16383	0.05	_
111-49	16383-16384	)	_
111-50	16384-16385	.	_

#Text=Group differences in the PAS scores
#Text=Spatial maps of the PAS scores for each group were presented in eFig. 1.
112-1	16386-16391	Group	_
112-2	16392-16403	differences	_
112-3	16404-16406	in	_
112-4	16407-16410	the	_
112-5	16411-16414	PAS	_
112-6	16415-16421	scores	_
112-7	16422-16429	Spatial	_
112-8	16430-16434	maps	_
112-9	16435-16437	of	_
112-10	16438-16441	the	_
112-11	16442-16445	PAS	_
112-12	16446-16452	scores	_
112-13	16453-16456	for	_
112-14	16457-16461	each	_
112-15	16462-16467	group	_
112-16	16468-16472	were	_
112-17	16473-16482	presented	_
112-18	16483-16485	in	_
112-19	16486-16490	eFig	_
112-20	16490-16491	.	_
112-21	16492-16493	1	_
112-22	16493-16494	.	_

#Text=Increased PAS scores were observed in the lateral prefrontal, lateral parietal, temporal gyri, whereas decreased PAS scores were found in the visual and sensorimotor regions within patients; our results are consistent with the findings from a previous study on hemispheric specialization in schizophrenia.
113-1	16495-16504	Increased	_
113-2	16505-16508	PAS	_
113-3	16509-16515	scores	_
113-4	16516-16520	were	_
113-5	16521-16529	observed	_
113-6	16530-16532	in	_
113-7	16533-16536	the	_
113-8	16537-16544	lateral	_
113-9	16545-16555	prefrontal	_
113-10	16555-16556	,	_
113-11	16557-16564	lateral	_
113-12	16565-16573	parietal	_
113-13	16573-16574	,	_
113-14	16575-16583	temporal	_
113-15	16584-16588	gyri	_
113-16	16588-16589	,	_
113-17	16590-16597	whereas	_
113-18	16598-16607	decreased	_
113-19	16608-16611	PAS	_
113-20	16612-16618	scores	_
113-21	16619-16623	were	_
113-22	16624-16629	found	_
113-23	16630-16632	in	_
113-24	16633-16636	the	_
113-25	16637-16643	visual	_
113-26	16644-16647	and	_
113-27	16648-16660	sensorimotor	_
113-28	16661-16668	regions	_
113-29	16669-16675	within	_
113-30	16676-16684	patients	_
113-31	16684-16685	;	_
113-32	16686-16689	our	_
113-33	16690-16697	results	_
113-34	16698-16701	are	_
113-35	16702-16712	consistent	_
113-36	16713-16717	with	_
113-37	16718-16721	the	_
113-38	16722-16730	findings	_
113-39	16731-16735	from	_
113-40	16736-16737	a	_
113-41	16738-16746	previous	_
113-42	16747-16752	study	_
113-43	16753-16755	on	_
113-44	16756-16767	hemispheric	_
113-45	16768-16782	specialization	_
113-46	16783-16785	in	_
113-47	16786-16799	schizophrenia	_
113-48	16799-16800	.	_

#Text=Moreover, the two hemispheres exhibited different patterns of PAS scores in healthy controls, consistent with the findings from a previous study in 1000 healthy controls.
114-1	16801-16809	Moreover	_
114-2	16809-16810	,	_
114-3	16811-16814	the	_
114-4	16815-16818	two	_
114-5	16819-16830	hemispheres	_
114-6	16831-16840	exhibited	_
114-7	16841-16850	different	_
114-8	16851-16859	patterns	_
114-9	16860-16862	of	_
114-10	16863-16866	PAS	_
114-11	16867-16873	scores	_
114-12	16874-16876	in	_
114-13	16877-16884	healthy	_
114-14	16885-16893	controls	_
114-15	16893-16894	,	_
114-16	16895-16905	consistent	_
114-17	16906-16910	with	_
114-18	16911-16914	the	_
114-19	16915-16923	findings	_
114-20	16924-16928	from	_
114-21	16929-16930	a	_
114-22	16931-16939	previous	_
114-23	16940-16945	study	_
114-24	16946-16948	in	_
114-25	16949-16953	1000	_
114-26	16954-16961	healthy	_
114-27	16962-16970	controls	_
114-28	16970-16971	.	_

#Text=As shown in eFig. 2, the three groups (patients, unaffected siblings and healthy controls) differed in the PAS scores in the frontal, temporal, parietal, and occipital cortices.
115-1	16972-16974	As	_
115-2	16975-16980	shown	_
115-3	16981-16983	in	_
115-4	16984-16988	eFig	_
115-5	16988-16989	.	_
115-6	16990-16991	2	_
115-7	16991-16992	,	_
115-8	16993-16996	the	_
115-9	16997-17002	three	_
115-10	17003-17009	groups	_
115-11	17010-17011	(	_
115-12	17011-17019	patients	_
115-13	17019-17020	,	_
115-14	17021-17031	unaffected	_
115-15	17032-17040	siblings	_
115-16	17041-17044	and	_
115-17	17045-17052	healthy	_
115-18	17053-17061	controls	_
115-19	17061-17062	)	_
115-20	17063-17071	differed	_
115-21	17072-17074	in	_
115-22	17075-17078	the	_
115-23	17079-17082	PAS	_
115-24	17083-17089	scores	_
115-25	17090-17092	in	_
115-26	17093-17096	the	_
115-27	17097-17104	frontal	_
115-28	17104-17105	,	_
115-29	17106-17114	temporal	_
115-30	17114-17115	,	_
115-31	17116-17124	parietal	_
115-32	17124-17125	,	_
115-33	17126-17129	and	_
115-34	17130-17139	occipital	_
115-35	17140-17148	cortices	_
115-36	17148-17149	.	_

#Text=Post hoc t-tests across groups.
116-1	17150-17154	Post	_
116-2	17155-17158	hoc	_
116-3	17159-17166	t-tests	_
116-4	17167-17173	across	_
116-5	17174-17180	groups	_
116-6	17180-17181	.	_

#Text=Upper: Group differences in the PAS scores between patients and healthy controls.
117-1	17182-17187	Upper	_
117-2	17187-17188	:	_
117-3	17189-17194	Group	_
117-4	17195-17206	differences	_
117-5	17207-17209	in	_
117-6	17210-17213	the	_
117-7	17214-17217	PAS	_
117-8	17218-17224	scores	_
117-9	17225-17232	between	_
117-10	17233-17241	patients	_
117-11	17242-17245	and	_
117-12	17246-17253	healthy	_
117-13	17254-17262	controls	_
117-14	17262-17263	.	_

#Text=Bottom: Group differences in the PAS scores between unaffected siblings and healthy controls.
118-1	17264-17270	Bottom	_
118-2	17270-17271	:	_
118-3	17272-17277	Group	_
118-4	17278-17289	differences	_
118-5	17290-17292	in	_
118-6	17293-17296	the	_
118-7	17297-17300	PAS	_
118-8	17301-17307	scores	_
118-9	17308-17315	between	_
118-10	17316-17326	unaffected	_
118-11	17327-17335	siblings	_
118-12	17336-17339	and	_
118-13	17340-17347	healthy	_
118-14	17348-17356	controls	_
118-15	17356-17357	.	_

#Text=PAS = parameter of asymmetry.
119-1	17358-17361	PAS	_
119-2	17361-17362	 	_
119-3	17362-17363	=	_
119-4	17363-17364	 	_
119-5	17364-17373	parameter	_
119-6	17374-17376	of	_
119-7	17377-17386	asymmetry	_
119-8	17386-17387	.	_

#Text=Fig. 1
#Text=Baseline group comparison of the PAS scores using a correlation coefficient thresholdof r > 0.2.
120-1	17388-17391	Fig	_
120-2	17391-17392	.	_
120-3	17393-17394	1	_
120-4	17395-17403	Baseline	_
120-5	17404-17409	group	_
120-6	17410-17420	comparison	_
120-7	17421-17423	of	_
120-8	17424-17427	the	_
120-9	17428-17431	PAS	_
120-10	17432-17438	scores	_
120-11	17439-17444	using	_
120-12	17445-17446	a	_
120-13	17447-17458	correlation	_
120-14	17459-17470	coefficient	_
120-15	17471-17482	thresholdof	_
120-16	17483-17484	r	_
120-17	17484-17485	 	_
120-18	17485-17486	>	_
120-19	17486-17487	 	_
120-20	17487-17490	0.2	_
120-21	17490-17491	.	_

#Text=Table 1\t \t
#Text=Cluster location\tPeak (MNI)\tNumberof voxels\tT value\t \tx\ty\tz\t \tPatients vs Healthy Controls\t \tLeft MTG/ITG\t−60\t−21\t−18\t64\t−4.2399\t \tLeft PCC/Precuneus\t−3\t−45\t33\t170\t−4.3947\t \tLeft Angular Gyrus\t−45\t−69\t33\t45\t−3.9649\t \tLeft Precentral Gyrus/Postcentral Gyrus\t−57\t−6\t36\t70\t4.8099\t \t  \t \tUnaffected Siblings vsHealthy Controls\t \tLeft MTG/ITG\t−66\t−15\t−24\t21\t−4.0102\t \tLeft PCC/Precuneus\t−3\t−48\t12\t22\t−4.2168\t \t
#Text=PAS = parameter of asymmetry; MTG = middle temporal gyrus; ITG = inferior temporal gyrus; PCC = posterior cingulate cortex.
121-1	17492-17497	Table	_
121-2	17498-17499	1	_
121-3	17503-17510	Cluster	_
121-4	17511-17519	location	_
121-5	17520-17524	Peak	_
121-6	17525-17526	(	_
121-7	17526-17529	MNI	_
121-8	17529-17530	)	_
121-9	17531-17539	Numberof	_
121-10	17540-17546	voxels	_
121-11	17547-17548	T	_
121-12	17549-17554	value	_
121-13	17557-17558	x	_
121-14	17559-17560	y	_
121-15	17561-17562	z	_
121-16	17565-17573	Patients	_
121-17	17574-17576	vs	_
121-18	17577-17584	Healthy	_
121-19	17585-17593	Controls	_
121-20	17596-17600	Left	_
121-21	17601-17604	MTG	_
121-22	17604-17605	/	_
121-23	17605-17608	ITG	_
121-24	17609-17610	−	_
121-25	17610-17612	60	_
121-26	17613-17614	−	_
121-27	17614-17616	21	_
121-28	17617-17618	−	_
121-29	17618-17620	18	_
121-30	17621-17623	64	_
121-31	17624-17625	−	_
121-32	17625-17631	4.2399	_
121-33	17634-17638	Left	_
121-34	17639-17642	PCC	_
121-35	17642-17643	/	_
121-36	17643-17652	Precuneus	_
121-37	17653-17654	−	_
121-38	17654-17655	3	_
121-39	17656-17657	−	_
121-40	17657-17659	45	_
121-41	17660-17662	33	_
121-42	17663-17666	170	_
121-43	17667-17668	−	_
121-44	17668-17674	4.3947	_
121-45	17677-17681	Left	_
121-46	17682-17689	Angular	_
121-47	17690-17695	Gyrus	_
121-48	17696-17697	−	_
121-49	17697-17699	45	_
121-50	17700-17701	−	_
121-51	17701-17703	69	_
121-52	17704-17706	33	_
121-53	17707-17709	45	_
121-54	17710-17711	−	_
121-55	17711-17717	3.9649	_
121-56	17720-17724	Left	_
121-57	17725-17735	Precentral	_
121-58	17736-17741	Gyrus	_
121-59	17741-17742	/	_
121-60	17742-17753	Postcentral	_
121-61	17754-17759	Gyrus	_
121-62	17760-17761	−	_
121-63	17761-17763	57	_
121-64	17764-17765	−	_
121-65	17765-17766	6	_
121-66	17767-17769	36	_
121-67	17770-17772	70	_
121-68	17773-17779	4.8099	_
121-69	17787-17797	Unaffected	_
121-70	17798-17806	Siblings	_
121-71	17807-17816	vsHealthy	_
121-72	17817-17825	Controls	_
121-73	17828-17832	Left	_
121-74	17833-17836	MTG	_
121-75	17836-17837	/	_
121-76	17837-17840	ITG	_
121-77	17841-17842	−	_
121-78	17842-17844	66	_
121-79	17845-17846	−	_
121-80	17846-17848	15	_
121-81	17849-17850	−	_
121-82	17850-17852	24	_
121-83	17853-17855	21	_
121-84	17856-17857	−	_
121-85	17857-17863	4.0102	_
121-86	17866-17870	Left	_
121-87	17871-17874	PCC	_
121-88	17874-17875	/	_
121-89	17875-17884	Precuneus	_
121-90	17885-17886	−	_
121-91	17886-17887	3	_
121-92	17888-17889	−	_
121-93	17889-17891	48	_
121-94	17892-17894	12	_
121-95	17895-17897	22	_
121-96	17898-17899	−	_
121-97	17899-17905	4.2168	_
121-98	17909-17912	PAS	_
121-99	17912-17913	 	_
121-100	17913-17914	=	_
121-101	17914-17915	 	_
121-102	17915-17924	parameter	_
121-103	17925-17927	of	_
121-104	17928-17937	asymmetry	_
121-105	17937-17938	;	_
121-106	17939-17942	MTG	_
121-107	17942-17943	 	_
121-108	17943-17944	=	_
121-109	17944-17945	 	_
121-110	17945-17951	middle	_
121-111	17952-17960	temporal	_
121-112	17961-17966	gyrus	_
121-113	17966-17967	;	_
121-114	17968-17971	ITG	_
121-115	17971-17972	 	_
121-116	17972-17973	=	_
121-117	17973-17974	 	_
121-118	17974-17982	inferior	_
121-119	17983-17991	temporal	_
121-120	17992-17997	gyrus	_
121-121	17997-17998	;	_
121-122	17999-18002	PCC	_
121-123	18002-18003	 	_
121-124	18003-18004	=	_
121-125	18004-18005	 	_
121-126	18005-18014	posterior	_
121-127	18015-18024	cingulate	_
121-128	18025-18031	cortex	_
121-129	18031-18032	.	_

#Text=Compared with healthy controls, patients at baseline had significantly lower PAS scores in the left MTG/inferior temporal gyrus (ITG), left posterior cingulate cortex (PCC)/precuneus and left angular gyrus, and significantly higher PAS scores in the left precentral grus/postcentral gyrus (Fig. 1 and Table 1).
122-1	18033-18041	Compared	_
122-2	18042-18046	with	_
122-3	18047-18054	healthy	_
122-4	18055-18063	controls	_
122-5	18063-18064	,	_
122-6	18065-18073	patients	_
122-7	18074-18076	at	_
122-8	18077-18085	baseline	_
122-9	18086-18089	had	_
122-10	18090-18103	significantly	_
122-11	18104-18109	lower	_
122-12	18110-18113	PAS	_
122-13	18114-18120	scores	_
122-14	18121-18123	in	_
122-15	18124-18127	the	_
122-16	18128-18132	left	_
122-17	18133-18136	MTG	_
122-18	18136-18137	/	_
122-19	18137-18145	inferior	_
122-20	18146-18154	temporal	_
122-21	18155-18160	gyrus	_
122-22	18161-18162	(	_
122-23	18162-18165	ITG	_
122-24	18165-18166	)	_
122-25	18166-18167	,	_
122-26	18168-18172	left	_
122-27	18173-18182	posterior	_
122-28	18183-18192	cingulate	_
122-29	18193-18199	cortex	_
122-30	18200-18201	(	_
122-31	18201-18204	PCC	_
122-32	18204-18205	)	_
122-33	18205-18206	/	_
122-34	18206-18215	precuneus	_
122-35	18216-18219	and	_
122-36	18220-18224	left	_
122-37	18225-18232	angular	_
122-38	18233-18238	gyrus	_
122-39	18238-18239	,	_
122-40	18240-18243	and	_
122-41	18244-18257	significantly	_
122-42	18258-18264	higher	_
122-43	18265-18268	PAS	_
122-44	18269-18275	scores	_
122-45	18276-18278	in	_
122-46	18279-18282	the	_
122-47	18283-18287	left	_
122-48	18288-18298	precentral	_
122-49	18299-18303	grus	_
122-50	18303-18304	/	_
122-51	18304-18315	postcentral	_
122-52	18316-18321	gyrus	_
122-53	18322-18323	(	_
122-54	18323-18326	Fig	_
122-55	18326-18327	.	_
122-56	18328-18329	1	_
122-57	18330-18333	and	_
122-58	18334-18339	Table	_
122-59	18340-18341	1	_
122-60	18341-18342	)	_
122-61	18342-18343	.	_

#Text=Unaffected siblings showed significantly lower PAS scores in the left MTG/ITG and left PCC/precuneus relative to healthy controls (Fig. 1 and Table 1).
123-1	18344-18354	Unaffected	_
123-2	18355-18363	siblings	_
123-3	18364-18370	showed	_
123-4	18371-18384	significantly	_
123-5	18385-18390	lower	_
123-6	18391-18394	PAS	_
123-7	18395-18401	scores	_
123-8	18402-18404	in	_
123-9	18405-18408	the	_
123-10	18409-18413	left	_
123-11	18414-18417	MTG	_
123-12	18417-18418	/	_
123-13	18418-18421	ITG	_
123-14	18422-18425	and	_
123-15	18426-18430	left	_
123-16	18431-18434	PCC	_
123-17	18434-18435	/	_
123-18	18435-18444	precuneus	_
123-19	18445-18453	relative	_
123-20	18454-18456	to	_
123-21	18457-18464	healthy	_
123-22	18465-18473	controls	_
123-23	18474-18475	(	_
123-24	18475-18478	Fig	_
123-25	18478-18479	.	_
123-26	18480-18481	1	_
123-27	18482-18485	and	_
123-28	18486-18491	Table	_
123-29	18492-18493	1	_
123-30	18493-18494	)	_
123-31	18494-18495	.	_

#Text=Both patients and unaffected siblings showed lower PAS scores in the left MTG/ITG andleft PCC/precuneus.
124-1	18496-18500	Both	_
124-2	18501-18509	patients	_
124-3	18510-18513	and	_
124-4	18514-18524	unaffected	_
124-5	18525-18533	siblings	_
124-6	18534-18540	showed	_
124-7	18541-18546	lower	_
124-8	18547-18550	PAS	_
124-9	18551-18557	scores	_
124-10	18558-18560	in	_
124-11	18561-18564	the	_
124-12	18565-18569	left	_
124-13	18570-18573	MTG	_
124-14	18573-18574	/	_
124-15	18574-18577	ITG	_
124-16	18578-18585	andleft	_
124-17	18586-18589	PCC	_
124-18	18589-18590	/	_
124-19	18590-18599	precuneus	_
124-20	18599-18600	.	_

#Text=To test whether the choice of correlation coefficient threshold might affect the findings, another correlation coefficient threshold of r > 0.25 was used and resulted in similar findings (eFig. 3 and eTable 3).
125-1	18601-18603	To	_
125-2	18604-18608	test	_
125-3	18609-18616	whether	_
125-4	18617-18620	the	_
125-5	18621-18627	choice	_
125-6	18628-18630	of	_
125-7	18631-18642	correlation	_
125-8	18643-18654	coefficient	_
125-9	18655-18664	threshold	_
125-10	18665-18670	might	_
125-11	18671-18677	affect	_
125-12	18678-18681	the	_
125-13	18682-18690	findings	_
125-14	18690-18691	,	_
125-15	18692-18699	another	_
125-16	18700-18711	correlation	_
125-17	18712-18723	coefficient	_
125-18	18724-18733	threshold	_
125-19	18734-18736	of	_
125-20	18737-18738	r	_
125-21	18738-18739	 	_
125-22	18739-18740	>	_
125-23	18740-18741	 	_
125-24	18741-18745	0.25	_
125-25	18746-18749	was	_
125-26	18750-18754	used	_
125-27	18755-18758	and	_
125-28	18759-18767	resulted	_
125-29	18768-18770	in	_
125-30	18771-18778	similar	_
125-31	18779-18787	findings	_
125-32	18788-18789	(	_
125-33	18789-18793	eFig	_
125-34	18793-18794	.	_
125-35	18795-18796	3	_
125-36	18797-18800	and	_
125-37	18801-18807	eTable	_
125-38	18808-18809	3	_
125-39	18809-18810	)	_
125-40	18810-18811	.	_

#Text=A whole-brain voxel-wise statistical comparison of the PAS scores was conducted between the good response group and the poor response group based on the median RR.
126-1	18812-18813	A	_
126-2	18814-18825	whole-brain	_
126-3	18826-18836	voxel-wise	_
126-4	18837-18848	statistical	_
126-5	18849-18859	comparison	_
126-6	18860-18862	of	_
126-7	18863-18866	the	_
126-8	18867-18870	PAS	_
126-9	18871-18877	scores	_
126-10	18878-18881	was	_
126-11	18882-18891	conducted	_
126-12	18892-18899	between	_
126-13	18900-18903	the	_
126-14	18904-18908	good	_
126-15	18909-18917	response	_
126-16	18918-18923	group	_
126-17	18924-18927	and	_
126-18	18928-18931	the	_
126-19	18932-18936	poor	_
126-20	18937-18945	response	_
126-21	18946-18951	group	_
126-22	18952-18957	based	_
126-23	18958-18960	on	_
126-24	18961-18964	the	_
126-25	18965-18971	median	_
126-26	18972-18974	RR	_
126-27	18974-18975	.	_

#Text=Compared with the poor response group, the good response group showed decreased PAS scores in the left superior parietal lobule and increased PAS scores in the right precentral gyrus/postcentral gyrus (eTable 5 and eFig. 4).
127-1	18976-18984	Compared	_
127-2	18985-18989	with	_
127-3	18990-18993	the	_
127-4	18994-18998	poor	_
127-5	18999-19007	response	_
127-6	19008-19013	group	_
127-7	19013-19014	,	_
127-8	19015-19018	the	_
127-9	19019-19023	good	_
127-10	19024-19032	response	_
127-11	19033-19038	group	_
127-12	19039-19045	showed	_
127-13	19046-19055	decreased	_
127-14	19056-19059	PAS	_
127-15	19060-19066	scores	_
127-16	19067-19069	in	_
127-17	19070-19073	the	_
127-18	19074-19078	left	_
127-19	19079-19087	superior	_
127-20	19088-19096	parietal	_
127-21	19097-19103	lobule	_
127-22	19104-19107	and	_
127-23	19108-19117	increased	_
127-24	19118-19121	PAS	_
127-25	19122-19128	scores	_
127-26	19129-19131	in	_
127-27	19132-19135	the	_
127-28	19136-19141	right	_
127-29	19142-19152	precentral	_
127-30	19153-19158	gyrus	_
127-31	19158-19159	/	_
127-32	19159-19170	postcentral	_
127-33	19171-19176	gyrus	_
127-34	19177-19178	(	_
127-35	19178-19184	eTable	_
127-36	19185-19186	5	_
127-37	19187-19190	and	_
127-38	19191-19195	eFig	_
127-39	19195-19196	.	_
127-40	19197-19198	4	_
127-41	19198-19199	)	_
127-42	19199-19200	.	_

#Text=When the mean RR was used as the cut-off value, similar results were obtained using a whole-brain voxel-wise statistical comparison of the PAS scores between the good response group (25 patients) and the poor response group (19 patients) (eTable 5).
128-1	19201-19205	When	_
128-2	19206-19209	the	_
128-3	19210-19214	mean	_
128-4	19215-19217	RR	_
128-5	19218-19221	was	_
128-6	19222-19226	used	_
128-7	19227-19229	as	_
128-8	19230-19233	the	_
128-9	19234-19241	cut-off	_
128-10	19242-19247	value	_
128-11	19247-19248	,	_
128-12	19249-19256	similar	_
128-13	19257-19264	results	_
128-14	19265-19269	were	_
128-15	19270-19278	obtained	_
128-16	19279-19284	using	_
128-17	19285-19286	a	_
128-18	19287-19298	whole-brain	_
128-19	19299-19309	voxel-wise	_
128-20	19310-19321	statistical	_
128-21	19322-19332	comparison	_
128-22	19333-19335	of	_
128-23	19336-19339	the	_
128-24	19340-19343	PAS	_
128-25	19344-19350	scores	_
128-26	19351-19358	between	_
128-27	19359-19362	the	_
128-28	19363-19367	good	_
128-29	19368-19376	response	_
128-30	19377-19382	group	_
128-31	19383-19384	(	_
128-32	19384-19386	25	_
128-33	19387-19395	patients	_
128-34	19395-19396	)	_
128-35	19397-19400	and	_
128-36	19401-19404	the	_
128-37	19405-19409	poor	_
128-38	19410-19418	response	_
128-39	19419-19424	group	_
128-40	19425-19426	(	_
128-41	19426-19428	19	_
128-42	19429-19437	patients	_
128-43	19437-19438	)	_
128-44	19439-19440	(	_
128-45	19440-19446	eTable	_
128-46	19447-19448	5	_
128-47	19448-19449	)	_
128-48	19449-19450	.	_

#Text=Correlation analysis results
#Text=Within patients, no correlations were found between the PAS scores and the PANSS total scores or the illness duration at baseline.
129-1	19451-19462	Correlation	_
129-2	19463-19471	analysis	_
129-3	19472-19479	results	_
129-4	19480-19486	Within	_
129-5	19487-19495	patients	_
129-6	19495-19496	,	_
129-7	19497-19499	no	_
129-8	19500-19512	correlations	_
129-9	19513-19517	were	_
129-10	19518-19523	found	_
129-11	19524-19531	between	_
129-12	19532-19535	the	_
129-13	19536-19539	PAS	_
129-14	19540-19546	scores	_
129-15	19547-19550	and	_
129-16	19551-19554	the	_
129-17	19555-19560	PANSS	_
129-18	19561-19566	total	_
129-19	19567-19573	scores	_
129-20	19574-19576	or	_
129-21	19577-19580	the	_
129-22	19581-19588	illness	_
129-23	19589-19597	duration	_
129-24	19598-19600	at	_
129-25	19601-19609	baseline	_
129-26	19609-19610	.	_

#Text=SVM analysis results
#Text=SVM analysis using a combination of the PAS scores in the left MTG/ITG and left PCC/precuneus.
130-1	19611-19614	SVM	_
130-2	19615-19623	analysis	_
130-3	19624-19631	results	_
130-4	19632-19635	SVM	_
130-5	19636-19644	analysis	_
130-6	19645-19650	using	_
130-7	19651-19652	a	_
130-8	19653-19664	combination	_
130-9	19665-19667	of	_
130-10	19668-19671	the	_
130-11	19672-19675	PAS	_
130-12	19676-19682	scores	_
130-13	19683-19685	in	_
130-14	19686-19689	the	_
130-15	19690-19694	left	_
130-16	19695-19698	MTG	_
130-17	19698-19699	/	_
130-18	19699-19702	ITG	_
130-19	19703-19706	and	_
130-20	19707-19711	left	_
130-21	19712-19715	PCC	_
130-22	19715-19716	/	_
130-23	19716-19725	precuneus	_
130-24	19725-19726	.	_

#Text=Left: SVM parameters selection result (3D visualization) [Grid Search Method]: Best c = 8; Best g = 2; Right: the visualization of classification: a combination of the PAS scores of the left MTG/ITG and left PCC/precuneus.
131-1	19727-19731	Left	_
131-2	19731-19732	:	_
131-3	19733-19736	SVM	_
131-4	19737-19747	parameters	_
131-5	19748-19757	selection	_
131-6	19758-19764	result	_
131-7	19765-19766	(	_
131-8	19766-19768	3D	_
131-9	19769-19782	visualization	_
131-10	19782-19783	)	_
131-11	19784-19785	[	_
131-12	19785-19789	Grid	_
131-13	19790-19796	Search	_
131-14	19797-19803	Method	_
131-15	19803-19804	]	_
131-16	19804-19805	:	_
131-17	19806-19810	Best	_
131-18	19811-19812	c	_
131-19	19812-19813	 	_
131-20	19813-19814	=	_
131-21	19814-19815	 	_
131-22	19815-19816	8	_
131-23	19816-19817	;	_
131-24	19818-19822	Best	_
131-25	19823-19824	g	_
131-26	19824-19825	 	_
131-27	19825-19826	=	_
131-28	19826-19827	 	_
131-29	19827-19828	2	_
131-30	19828-19829	;	_
131-31	19830-19835	Right	_
131-32	19835-19836	:	_
131-33	19837-19840	the	_
131-34	19841-19854	visualization	_
131-35	19855-19857	of	_
131-36	19858-19872	classification	_
131-37	19872-19873	:	_
131-38	19874-19875	a	_
131-39	19876-19887	combination	_
131-40	19888-19890	of	_
131-41	19891-19894	the	_
131-42	19895-19898	PAS	_
131-43	19899-19905	scores	_
131-44	19906-19908	of	_
131-45	19909-19912	the	_
131-46	19913-19917	left	_
131-47	19918-19921	MTG	_
131-48	19921-19922	/	_
131-49	19922-19925	ITG	_
131-50	19926-19929	and	_
131-51	19930-19934	left	_
131-52	19935-19938	PCC	_
131-53	19938-19939	/	_
131-54	19939-19948	precuneus	_
131-55	19948-19949	.	_

#Text=Demension1 represents the PAS scores in the left PCC/precuneus, whereas dimension2 represents the PAS scores in the left MTG/ITG.
132-1	19950-19960	Demension1	_
132-2	19961-19971	represents	_
132-3	19972-19975	the	_
132-4	19976-19979	PAS	_
132-5	19980-19986	scores	_
132-6	19987-19989	in	_
132-7	19990-19993	the	_
132-8	19994-19998	left	_
132-9	19999-20002	PCC	_
132-10	20002-20003	/	_
132-11	20003-20012	precuneus	_
132-12	20012-20013	,	_
132-13	20014-20021	whereas	_
132-14	20022-20032	dimension2	_
132-15	20033-20043	represents	_
132-16	20044-20047	the	_
132-17	20048-20051	PAS	_
132-18	20052-20058	scores	_
132-19	20059-20061	in	_
132-20	20062-20065	the	_
132-21	20066-20070	left	_
132-22	20071-20074	MTG	_
132-23	20074-20075	/	_
132-24	20075-20078	ITG	_
132-25	20078-20079	.	_

#Text=PAS = parameter of asymmetry; SVM = support vector machine; MTG = middle temporal gyrus; ITG = inferior temporal gyrus; PCC = posterior cingulate cortex.
133-1	20080-20083	PAS	_
133-2	20083-20084	 	_
133-3	20084-20085	=	_
133-4	20085-20086	 	_
133-5	20086-20095	parameter	_
133-6	20096-20098	of	_
133-7	20099-20108	asymmetry	_
133-8	20108-20109	;	_
133-9	20110-20113	SVM	_
133-10	20113-20114	 	_
133-11	20114-20115	=	_
133-12	20115-20116	 	_
133-13	20116-20123	support	_
133-14	20124-20130	vector	_
133-15	20131-20138	machine	_
133-16	20138-20139	;	_
133-17	20140-20143	MTG	_
133-18	20143-20144	 	_
133-19	20144-20145	=	_
133-20	20145-20146	 	_
133-21	20146-20152	middle	_
133-22	20153-20161	temporal	_
133-23	20162-20167	gyrus	_
133-24	20167-20168	;	_
133-25	20169-20172	ITG	_
133-26	20172-20173	 	_
133-27	20173-20174	=	_
133-28	20174-20175	 	_
133-29	20175-20183	inferior	_
133-30	20184-20192	temporal	_
133-31	20193-20198	gyrus	_
133-32	20198-20199	;	_
133-33	20200-20203	PCC	_
133-34	20203-20204	 	_
133-35	20204-20205	=	_
133-36	20205-20206	 	_
133-37	20206-20215	posterior	_
133-38	20216-20225	cingulate	_
133-39	20226-20232	cortex	_
133-40	20232-20233	.	_

#Text=Fig. 2
#Text=Based on the median of the RR of the PANSS total scores (0.580), patients were divided into two groups (good response versus poor response, 22 patients in each group).
134-1	20234-20237	Fig	_
134-2	20237-20238	.	_
134-3	20239-20240	2	_
134-4	20241-20246	Based	_
134-5	20247-20249	on	_
134-6	20250-20253	the	_
134-7	20254-20260	median	_
134-8	20261-20263	of	_
134-9	20264-20267	the	_
134-10	20268-20270	RR	_
134-11	20271-20273	of	_
134-12	20274-20277	the	_
134-13	20278-20283	PANSS	_
134-14	20284-20289	total	_
134-15	20290-20296	scores	_
134-16	20297-20298	(	_
134-17	20298-20303	0.580	_
134-18	20303-20304	)	_
134-19	20304-20305	,	_
134-20	20306-20314	patients	_
134-21	20315-20319	were	_
134-22	20320-20327	divided	_
134-23	20328-20332	into	_
134-24	20333-20336	two	_
134-25	20337-20343	groups	_
134-26	20344-20345	(	_
134-27	20345-20349	good	_
134-28	20350-20358	response	_
134-29	20359-20365	versus	_
134-30	20366-20370	poor	_
134-31	20371-20379	response	_
134-32	20379-20380	,	_
134-33	20381-20383	22	_
134-34	20384-20392	patients	_
134-35	20393-20395	in	_
134-36	20396-20400	each	_
134-37	20401-20406	group	_
134-38	20406-20407	)	_
134-39	20407-20408	.	_

#Text=Because univariate analysis showed that both patients and unaffected siblings had reduced PAS scores in the left MTG/ITG and left PCC/precuneus.
135-1	20409-20416	Because	_
135-2	20417-20427	univariate	_
135-3	20428-20436	analysis	_
135-4	20437-20443	showed	_
135-5	20444-20448	that	_
135-6	20449-20453	both	_
135-7	20454-20462	patients	_
135-8	20463-20466	and	_
135-9	20467-20477	unaffected	_
135-10	20478-20486	siblings	_
135-11	20487-20490	had	_
135-12	20491-20498	reduced	_
135-13	20499-20502	PAS	_
135-14	20503-20509	scores	_
135-15	20510-20512	in	_
135-16	20513-20516	the	_
135-17	20517-20521	left	_
135-18	20522-20525	MTG	_
135-19	20525-20526	/	_
135-20	20526-20529	ITG	_
135-21	20530-20533	and	_
135-22	20534-20538	left	_
135-23	20539-20542	PCC	_
135-24	20542-20543	/	_
135-25	20543-20552	precuneus	_
135-26	20552-20553	.	_

#Text=SVM analysis was performed using the baseline PAS scores in these two clusters: the left MTG/ITG and left PCC/precuneus.
136-1	20554-20557	SVM	_
136-2	20558-20566	analysis	_
136-3	20567-20570	was	_
136-4	20571-20580	performed	_
136-5	20581-20586	using	_
136-6	20587-20590	the	_
136-7	20591-20599	baseline	_
136-8	20600-20603	PAS	_
136-9	20604-20610	scores	_
136-10	20611-20613	in	_
136-11	20614-20619	these	_
136-12	20620-20623	two	_
136-13	20624-20632	clusters	_
136-14	20632-20633	:	_
136-15	20634-20637	the	_
136-16	20638-20642	left	_
136-17	20643-20646	MTG	_
136-18	20646-20647	/	_
136-19	20647-20650	ITG	_
136-20	20651-20654	and	_
136-21	20655-20659	left	_
136-22	20660-20663	PCC	_
136-23	20663-20664	/	_
136-24	20664-20673	precuneus	_
136-25	20673-20674	.	_

#Text=The results showed that the PAS scores from single cluster were not able to predict patients with good response versus those with poor response after 8 weeks of olanzapine treatment.
137-1	20675-20678	The	_
137-2	20679-20686	results	_
137-3	20687-20693	showed	_
137-4	20694-20698	that	_
137-5	20699-20702	the	_
137-6	20703-20706	PAS	_
137-7	20707-20713	scores	_
137-8	20714-20718	from	_
137-9	20719-20725	single	_
137-10	20726-20733	cluster	_
137-11	20734-20738	were	_
137-12	20739-20742	not	_
137-13	20743-20747	able	_
137-14	20748-20750	to	_
137-15	20751-20758	predict	_
137-16	20759-20767	patients	_
137-17	20768-20772	with	_
137-18	20773-20777	good	_
137-19	20778-20786	response	_
137-20	20787-20793	versus	_
137-21	20794-20799	those	_
137-22	20800-20804	with	_
137-23	20805-20809	poor	_
137-24	20810-20818	response	_
137-25	20819-20824	after	_
137-26	20825-20826	8	_
137-27	20826-20827	 	_
137-28	20827-20832	weeks	_
137-29	20833-20835	of	_
137-30	20836-20846	olanzapine	_
137-31	20847-20856	treatment	_
137-32	20856-20857	.	_

#Text=The sensitivity, specificity, and accuracy were 72.73%, 54.55%, and 63.64% respectively in the left MTG/ITG, and 63.64%, 77.27%, and 70.45% respectively in the left PCC/precuneus.
138-1	20858-20861	The	_
138-2	20862-20873	sensitivity	_
138-3	20873-20874	,	_
138-4	20875-20886	specificity	_
138-5	20886-20887	,	_
138-6	20888-20891	and	_
138-7	20892-20900	accuracy	_
138-8	20901-20905	were	_
138-9	20906-20912	72.73%	_
138-10	20912-20913	,	_
138-11	20914-20920	54.55%	_
138-12	20920-20921	,	_
138-13	20922-20925	and	_
138-14	20926-20932	63.64%	_
138-15	20933-20945	respectively	_
138-16	20946-20948	in	_
138-17	20949-20952	the	_
138-18	20953-20957	left	_
138-19	20958-20961	MTG	_
138-20	20961-20962	/	_
138-21	20962-20965	ITG	_
138-22	20965-20966	,	_
138-23	20967-20970	and	_
138-24	20971-20977	63.64%	_
138-25	20977-20978	,	_
138-26	20979-20985	77.27%	_
138-27	20985-20986	,	_
138-28	20987-20990	and	_
138-29	20991-20997	70.45%	_
138-30	20998-21010	respectively	_
138-31	21011-21013	in	_
138-32	21014-21017	the	_
138-33	21018-21022	left	_
138-34	21023-21026	PCC	_
138-35	21026-21027	/	_
138-36	21027-21036	precuneus	_
138-37	21036-21037	.	_

#Text=However, a combination of the PAS scores of these two clusters was able to predict clinical response to olanzapine treatment with 77.27% sensitivity, 72.73% specificity, and 75.00% accuracy (Fig. 2).
139-1	21038-21045	However	_
139-2	21045-21046	,	_
139-3	21047-21048	a	_
139-4	21049-21060	combination	_
139-5	21061-21063	of	_
139-6	21064-21067	the	_
139-7	21068-21071	PAS	_
139-8	21072-21078	scores	_
139-9	21079-21081	of	_
139-10	21082-21087	these	_
139-11	21088-21091	two	_
139-12	21092-21100	clusters	_
139-13	21101-21104	was	_
139-14	21105-21109	able	_
139-15	21110-21112	to	_
139-16	21113-21120	predict	_
139-17	21121-21129	clinical	_
139-18	21130-21138	response	_
139-19	21139-21141	to	_
139-20	21142-21152	olanzapine	_
139-21	21153-21162	treatment	_
139-22	21163-21167	with	_
139-23	21168-21174	77.27%	_
139-24	21175-21186	sensitivity	_
139-25	21186-21187	,	_
139-26	21188-21194	72.73%	_
139-27	21195-21206	specificity	_
139-28	21206-21207	,	_
139-29	21208-21211	and	_
139-30	21212-21218	75.00%	_
139-31	21219-21227	accuracy	_
139-32	21228-21229	(	_
139-33	21229-21232	Fig	_
139-34	21232-21233	.	_
139-35	21234-21235	2	_
139-36	21235-21236	)	_
139-37	21236-21237	.	_

#Text=In addition, SVM analysis showed that the PAS scores of the left superior parietal lobule, right precentral gyrus/postcentral gyrus, and the combination of the two clusters could discriminate the good response patients from the poor response patients with sensitivities of 77.27%, 90.91%, and 86.36%, specificities of 77.27%, 86.36%, and 100%, and accuracies of 77.27%, 88.64%, and 93.18%, respectively.
140-1	21238-21240	In	_
140-2	21241-21249	addition	_
140-3	21249-21250	,	_
140-4	21251-21254	SVM	_
140-5	21255-21263	analysis	_
140-6	21264-21270	showed	_
140-7	21271-21275	that	_
140-8	21276-21279	the	_
140-9	21280-21283	PAS	_
140-10	21284-21290	scores	_
140-11	21291-21293	of	_
140-12	21294-21297	the	_
140-13	21298-21302	left	_
140-14	21303-21311	superior	_
140-15	21312-21320	parietal	_
140-16	21321-21327	lobule	_
140-17	21327-21328	,	_
140-18	21329-21334	right	_
140-19	21335-21345	precentral	_
140-20	21346-21351	gyrus	_
140-21	21351-21352	/	_
140-22	21352-21363	postcentral	_
140-23	21364-21369	gyrus	_
140-24	21369-21370	,	_
140-25	21371-21374	and	_
140-26	21375-21378	the	_
140-27	21379-21390	combination	_
140-28	21391-21393	of	_
140-29	21394-21397	the	_
140-30	21398-21401	two	_
140-31	21402-21410	clusters	_
140-32	21411-21416	could	_
140-33	21417-21429	discriminate	_
140-34	21430-21433	the	_
140-35	21434-21438	good	_
140-36	21439-21447	response	_
140-37	21448-21456	patients	_
140-38	21457-21461	from	_
140-39	21462-21465	the	_
140-40	21466-21470	poor	_
140-41	21471-21479	response	_
140-42	21480-21488	patients	_
140-43	21489-21493	with	_
140-44	21494-21507	sensitivities	_
140-45	21508-21510	of	_
140-46	21511-21517	77.27%	_
140-47	21517-21518	,	_
140-48	21519-21525	90.91%	_
140-49	21525-21526	,	_
140-50	21527-21530	and	_
140-51	21531-21537	86.36%	_
140-52	21537-21538	,	_
140-53	21539-21552	specificities	_
140-54	21553-21555	of	_
140-55	21556-21562	77.27%	_
140-56	21562-21563	,	_
140-57	21564-21570	86.36%	_
140-58	21570-21571	,	_
140-59	21572-21575	and	_
140-60	21576-21580	100%	_
140-61	21580-21581	,	_
140-62	21582-21585	and	_
140-63	21586-21596	accuracies	_
140-64	21597-21599	of	_
140-65	21600-21606	77.27%	_
140-66	21606-21607	,	_
140-67	21608-21614	88.64%	_
140-68	21614-21615	,	_
140-69	21616-21619	and	_
140-70	21620-21626	93.18%	_
140-71	21626-21627	,	_
140-72	21628-21640	respectively	_
140-73	21640-21641	.	_

#Text=Discussion
#Text=To our knowledge, the present study is the first to examine functional asymmetry in first-episode, drug-naive schizophrenia and unaffected siblings using a voxel-wise whole-brain analysis.
141-1	21642-21652	Discussion	_
141-2	21653-21655	To	_
141-3	21656-21659	our	_
141-4	21660-21669	knowledge	_
141-5	21669-21670	,	_
141-6	21671-21674	the	_
141-7	21675-21682	present	_
141-8	21683-21688	study	_
141-9	21689-21691	is	_
141-10	21692-21695	the	_
141-11	21696-21701	first	_
141-12	21702-21704	to	_
141-13	21705-21712	examine	_
141-14	21713-21723	functional	_
141-15	21724-21733	asymmetry	_
141-16	21734-21736	in	_
141-17	21737-21750	first-episode	_
141-18	21750-21751	,	_
141-19	21752-21762	drug-naive	_
141-20	21763-21776	schizophrenia	_
141-21	21777-21780	and	_
141-22	21781-21791	unaffected	_
141-23	21792-21800	siblings	_
141-24	21801-21806	using	_
141-25	21807-21808	a	_
141-26	21809-21819	voxel-wise	_
141-27	21820-21831	whole-brain	_
141-28	21832-21840	analysis	_
141-29	21840-21841	.	_

#Text=We found that disrupted asymmetry in schizophrenia is preferentially within the left hemisphere as reflected by reduced inter-hemispheric FC in brain regions of the default-mode network (DMN, including the left MTG/ITG,left PCC/precuneus, and left angular gyrus) and elevated inter-hemispheric FC in the sensorimotor region (including the left precentral gyrus/postcentral gyrus).
142-1	21842-21844	We	_
142-2	21845-21850	found	_
142-3	21851-21855	that	_
142-4	21856-21865	disrupted	_
142-5	21866-21875	asymmetry	_
142-6	21876-21878	in	_
142-7	21879-21892	schizophrenia	_
142-8	21893-21895	is	_
142-9	21896-21910	preferentially	_
142-10	21911-21917	within	_
142-11	21918-21921	the	_
142-12	21922-21926	left	_
142-13	21927-21937	hemisphere	_
142-14	21938-21940	as	_
142-15	21941-21950	reflected	_
142-16	21951-21953	by	_
142-17	21954-21961	reduced	_
142-18	21962-21979	inter-hemispheric	_
142-19	21980-21982	FC	_
142-20	21983-21985	in	_
142-21	21986-21991	brain	_
142-22	21992-21999	regions	_
142-23	22000-22002	of	_
142-24	22003-22006	the	_
142-25	22007-22019	default-mode	_
142-26	22020-22027	network	_
142-27	22028-22029	(	_
142-28	22029-22032	DMN	_
142-29	22032-22033	,	_
142-30	22034-22043	including	_
142-31	22044-22047	the	_
142-32	22048-22052	left	_
142-33	22053-22056	MTG	_
142-34	22056-22057	/	_
142-35	22057-22060	ITG	_
142-36	22060-22061	,	_
142-37	22061-22065	left	_
142-38	22066-22069	PCC	_
142-39	22069-22070	/	_
142-40	22070-22079	precuneus	_
142-41	22079-22080	,	_
142-42	22081-22084	and	_
142-43	22085-22089	left	_
142-44	22090-22097	angular	_
142-45	22098-22103	gyrus	_
142-46	22103-22104	)	_
142-47	22105-22108	and	_
142-48	22109-22117	elevated	_
142-49	22118-22135	inter-hemispheric	_
142-50	22136-22138	FC	_
142-51	22139-22141	in	_
142-52	22142-22145	the	_
142-53	22146-22158	sensorimotor	_
142-54	22159-22165	region	_
142-55	22166-22167	(	_
142-56	22167-22176	including	_
142-57	22177-22180	the	_
142-58	22181-22185	left	_
142-59	22186-22196	precentral	_
142-60	22197-22202	gyrus	_
142-61	22202-22203	/	_
142-62	22203-22214	postcentral	_
142-63	22215-22220	gyrus	_
142-64	22220-22221	)	_
142-65	22221-22222	.	_

#Text=Patients and unaffected siblings shared reduced inter-hemispheric FC in brain regions of the DMN (including the left MTG/ITG and left PCC/precuneus), which may serve as an endophenotype for schizophrenia.
143-1	22223-22231	Patients	_
143-2	22232-22235	and	_
143-3	22236-22246	unaffected	_
143-4	22247-22255	siblings	_
143-5	22256-22262	shared	_
143-6	22263-22270	reduced	_
143-7	22271-22288	inter-hemispheric	_
143-8	22289-22291	FC	_
143-9	22292-22294	in	_
143-10	22295-22300	brain	_
143-11	22301-22308	regions	_
143-12	22309-22311	of	_
143-13	22312-22315	the	_
143-14	22316-22319	DMN	_
143-15	22320-22321	(	_
143-16	22321-22330	including	_
143-17	22331-22334	the	_
143-18	22335-22339	left	_
143-19	22340-22343	MTG	_
143-20	22343-22344	/	_
143-21	22344-22347	ITG	_
143-22	22348-22351	and	_
143-23	22352-22356	left	_
143-24	22357-22360	PCC	_
143-25	22360-22361	/	_
143-26	22361-22370	precuneus	_
143-27	22370-22371	)	_
143-28	22371-22372	,	_
143-29	22373-22378	which	_
143-30	22379-22382	may	_
143-31	22383-22388	serve	_
143-32	22389-22391	as	_
143-33	22392-22394	an	_
143-34	22395-22408	endophenotype	_
143-35	22409-22412	for	_
143-36	22413-22426	schizophrenia	_
143-37	22426-22427	.	_

#Text=Furthermore, SVM analysis suggests that, within patients, a combination of the PAS scores of these two clusters may predict clinical response to olanzapine treatment; the prediction was unlikely confounded by age, gender, education level, illness duration or daily dosage of olanzapine.
144-1	22428-22439	Furthermore	_
144-2	22439-22440	,	_
144-3	22441-22444	SVM	_
144-4	22445-22453	analysis	_
144-5	22454-22462	suggests	_
144-6	22463-22467	that	_
144-7	22467-22468	,	_
144-8	22469-22475	within	_
144-9	22476-22484	patients	_
144-10	22484-22485	,	_
144-11	22486-22487	a	_
144-12	22488-22499	combination	_
144-13	22500-22502	of	_
144-14	22503-22506	the	_
144-15	22507-22510	PAS	_
144-16	22511-22517	scores	_
144-17	22518-22520	of	_
144-18	22521-22526	these	_
144-19	22527-22530	two	_
144-20	22531-22539	clusters	_
144-21	22540-22543	may	_
144-22	22544-22551	predict	_
144-23	22552-22560	clinical	_
144-24	22561-22569	response	_
144-25	22570-22572	to	_
144-26	22573-22583	olanzapine	_
144-27	22584-22593	treatment	_
144-28	22593-22594	;	_
144-29	22595-22598	the	_
144-30	22599-22609	prediction	_
144-31	22610-22613	was	_
144-32	22614-22622	unlikely	_
144-33	22623-22633	confounded	_
144-34	22634-22636	by	_
144-35	22637-22640	age	_
144-36	22640-22641	,	_
144-37	22642-22648	gender	_
144-38	22648-22649	,	_
144-39	22650-22659	education	_
144-40	22660-22665	level	_
144-41	22665-22666	,	_
144-42	22667-22674	illness	_
144-43	22675-22683	duration	_
144-44	22684-22686	or	_
144-45	22687-22692	daily	_
144-46	22693-22699	dosage	_
144-47	22700-22702	of	_
144-48	22703-22713	olanzapine	_
144-49	22713-22714	.	_

#Text=Our group has previously reported abnormal DMN homogeneity in patients with schizophrenia.
145-1	22715-22718	Our	_
145-2	22719-22724	group	_
145-3	22725-22728	has	_
145-4	22729-22739	previously	_
145-5	22740-22748	reported	_
145-6	22749-22757	abnormal	_
145-7	22758-22761	DMN	_
145-8	22762-22773	homogeneity	_
145-9	22774-22776	in	_
145-10	22777-22785	patients	_
145-11	22786-22790	with	_
145-12	22791-22804	schizophrenia	_
145-13	22804-22805	.	_

#Text=In addition, reduced rsFC within the DMN in patients with schizophrenia has been reported by other groups.
146-1	22806-22808	In	_
146-2	22809-22817	addition	_
146-3	22817-22818	,	_
146-4	22819-22826	reduced	_
146-5	22827-22831	rsFC	_
146-6	22832-22838	within	_
146-7	22839-22842	the	_
146-8	22843-22846	DMN	_
146-9	22847-22849	in	_
146-10	22850-22858	patients	_
146-11	22859-22863	with	_
146-12	22864-22877	schizophrenia	_
146-13	22878-22881	has	_
146-14	22882-22886	been	_
146-15	22887-22895	reported	_
146-16	22896-22898	by	_
146-17	22899-22904	other	_
146-18	22905-22911	groups	_
146-19	22911-22912	.	_

#Text=However, these studies did not examine whether disrupted FC in the DMN is primarily contributed by abnormal inter-hemispheric FC and/or intra-hemispheric FC.
147-1	22913-22920	However	_
147-2	22920-22921	,	_
147-3	22922-22927	these	_
147-4	22928-22935	studies	_
147-5	22936-22939	did	_
147-6	22940-22943	not	_
147-7	22944-22951	examine	_
147-8	22952-22959	whether	_
147-9	22960-22969	disrupted	_
147-10	22970-22972	FC	_
147-11	22973-22975	in	_
147-12	22976-22979	the	_
147-13	22980-22983	DMN	_
147-14	22984-22986	is	_
147-15	22987-22996	primarily	_
147-16	22997-23008	contributed	_
147-17	23009-23011	by	_
147-18	23012-23020	abnormal	_
147-19	23021-23038	inter-hemispheric	_
147-20	23039-23041	FC	_
147-21	23042-23045	and	_
147-22	23045-23046	/	_
147-23	23046-23048	or	_
147-24	23049-23066	intra-hemispheric	_
147-25	23067-23069	FC	_
147-26	23069-23070	.	_

#Text=In the present study, the whole-brain FC was divided into inter-hemispheric FC and intra-hemispheric FC.
148-1	23071-23073	In	_
148-2	23074-23077	the	_
148-3	23078-23085	present	_
148-4	23086-23091	study	_
148-5	23091-23092	,	_
148-6	23093-23096	the	_
148-7	23097-23108	whole-brain	_
148-8	23109-23111	FC	_
148-9	23112-23115	was	_
148-10	23116-23123	divided	_
148-11	23124-23128	into	_
148-12	23129-23146	inter-hemispheric	_
148-13	23147-23149	FC	_
148-14	23150-23153	and	_
148-15	23154-23171	intra-hemispheric	_
148-16	23172-23174	FC	_
148-17	23174-23175	.	_

#Text=Our findings suggest that abnormal FC in brain regions of the DMN might be related to reduced inter-hemispheric FC within the left hemisphere.
149-1	23176-23179	Our	_
149-2	23180-23188	findings	_
149-3	23189-23196	suggest	_
149-4	23197-23201	that	_
149-5	23202-23210	abnormal	_
149-6	23211-23213	FC	_
149-7	23214-23216	in	_
149-8	23217-23222	brain	_
149-9	23223-23230	regions	_
149-10	23231-23233	of	_
149-11	23234-23237	the	_
149-12	23238-23241	DMN	_
149-13	23242-23247	might	_
149-14	23248-23250	be	_
149-15	23251-23258	related	_
149-16	23259-23261	to	_
149-17	23262-23269	reduced	_
149-18	23270-23287	inter-hemispheric	_
149-19	23288-23290	FC	_
149-20	23291-23297	within	_
149-21	23298-23301	the	_
149-22	23302-23306	left	_
149-23	23307-23317	hemisphere	_
149-24	23317-23318	.	_

#Text=Interestingly, unaffected siblings also showed reduced inter-hemispheric FC in the DMN (including the left MTG/ITG and left PCC/precuneus) in our study.
150-1	23319-23332	Interestingly	_
150-2	23332-23333	,	_
150-3	23334-23344	unaffected	_
150-4	23345-23353	siblings	_
150-5	23354-23358	also	_
150-6	23359-23365	showed	_
150-7	23366-23373	reduced	_
150-8	23374-23391	inter-hemispheric	_
150-9	23392-23394	FC	_
150-10	23395-23397	in	_
150-11	23398-23401	the	_
150-12	23402-23405	DMN	_
150-13	23406-23407	(	_
150-14	23407-23416	including	_
150-15	23417-23420	the	_
150-16	23421-23425	left	_
150-17	23426-23429	MTG	_
150-18	23429-23430	/	_
150-19	23430-23433	ITG	_
150-20	23434-23437	and	_
150-21	23438-23442	left	_
150-22	23443-23446	PCC	_
150-23	23446-23447	/	_
150-24	23447-23456	precuneus	_
150-25	23456-23457	)	_
150-26	23458-23460	in	_
150-27	23461-23464	our	_
150-28	23465-23470	study	_
150-29	23470-23471	.	_

#Text=According to the definition of endophenotype, reduced inter-hemispheric FC in the left MTG/ITG and left PCC/precuneus may represent an endophenotype for schizophrenia.
151-1	23472-23481	According	_
151-2	23482-23484	to	_
151-3	23485-23488	the	_
151-4	23489-23499	definition	_
151-5	23500-23502	of	_
151-6	23503-23516	endophenotype	_
151-7	23516-23517	,	_
151-8	23518-23525	reduced	_
151-9	23526-23543	inter-hemispheric	_
151-10	23544-23546	FC	_
151-11	23547-23549	in	_
151-12	23550-23553	the	_
151-13	23554-23558	left	_
151-14	23559-23562	MTG	_
151-15	23562-23563	/	_
151-16	23563-23566	ITG	_
151-17	23567-23570	and	_
151-18	23571-23575	left	_
151-19	23576-23579	PCC	_
151-20	23579-23580	/	_
151-21	23580-23589	precuneus	_
151-22	23590-23593	may	_
151-23	23594-23603	represent	_
151-24	23604-23606	an	_
151-25	23607-23620	endophenotype	_
151-26	23621-23624	for	_
151-27	23625-23638	schizophrenia	_
151-28	23638-23639	.	_

#Text=Previously, our group has reported reduced DMN homogeneity in unaffected siblings of patients with schizophrenia.
152-1	23640-23650	Previously	_
152-2	23650-23651	,	_
152-3	23652-23655	our	_
152-4	23656-23661	group	_
152-5	23662-23665	has	_
152-6	23666-23674	reported	_
152-7	23675-23682	reduced	_
152-8	23683-23686	DMN	_
152-9	23687-23698	homogeneity	_
152-10	23699-23701	in	_
152-11	23702-23712	unaffected	_
152-12	23713-23721	siblings	_
152-13	23722-23724	of	_
152-14	23725-23733	patients	_
152-15	23734-23738	with	_
152-16	23739-23752	schizophrenia	_
152-17	23752-23753	.	_

#Text=We also reported reduced gray matter volume in the left MTG in both patients and their unaffected siblings.
153-1	23754-23756	We	_
153-2	23757-23761	also	_
153-3	23762-23770	reported	_
153-4	23771-23778	reduced	_
153-5	23779-23783	gray	_
153-6	23784-23790	matter	_
153-7	23791-23797	volume	_
153-8	23798-23800	in	_
153-9	23801-23804	the	_
153-10	23805-23809	left	_
153-11	23810-23813	MTG	_
153-12	23814-23816	in	_
153-13	23817-23821	both	_
153-14	23822-23830	patients	_
153-15	23831-23834	and	_
153-16	23835-23840	their	_
153-17	23841-23851	unaffected	_
153-18	23852-23860	siblings	_
153-19	23860-23861	.	_

#Text=SVM analysis in the present study suggested that a combination of the PAS scores of these two clusters was able to predict clinical response to olanzapine treatment with acceptable sensitivity, specificity, and accuracy.
154-1	23862-23865	SVM	_
154-2	23866-23874	analysis	_
154-3	23875-23877	in	_
154-4	23878-23881	the	_
154-5	23882-23889	present	_
154-6	23890-23895	study	_
154-7	23896-23905	suggested	_
154-8	23906-23910	that	_
154-9	23911-23912	a	_
154-10	23913-23924	combination	_
154-11	23925-23927	of	_
154-12	23928-23931	the	_
154-13	23932-23935	PAS	_
154-14	23936-23942	scores	_
154-15	23943-23945	of	_
154-16	23946-23951	these	_
154-17	23952-23955	two	_
154-18	23956-23964	clusters	_
154-19	23965-23968	was	_
154-20	23969-23973	able	_
154-21	23974-23976	to	_
154-22	23977-23984	predict	_
154-23	23985-23993	clinical	_
154-24	23994-24002	response	_
154-25	24003-24005	to	_
154-26	24006-24016	olanzapine	_
154-27	24017-24026	treatment	_
154-28	24027-24031	with	_
154-29	24032-24042	acceptable	_
154-30	24043-24054	sensitivity	_
154-31	24054-24055	,	_
154-32	24056-24067	specificity	_
154-33	24067-24068	,	_
154-34	24069-24072	and	_
154-35	24073-24081	accuracy	_
154-36	24081-24082	.	_

#Text=Genes may play a critical role in the reduced inter-hemispheric FC in the DMN.
155-1	24083-24088	Genes	_
155-2	24089-24092	may	_
155-3	24093-24097	play	_
155-4	24098-24099	a	_
155-5	24100-24108	critical	_
155-6	24109-24113	role	_
155-7	24114-24116	in	_
155-8	24117-24120	the	_
155-9	24121-24128	reduced	_
155-10	24129-24146	inter-hemispheric	_
155-11	24147-24149	FC	_
155-12	24150-24152	in	_
155-13	24153-24156	the	_
155-14	24157-24160	DMN	_
155-15	24160-24161	.	_

#Text=For example, additive genetic effects on the degree of gray matter volume loss in the temporal gyrus over five years have been observed in patients with schizophrenia and unaffected co-twins.
156-1	24162-24165	For	_
156-2	24166-24173	example	_
156-3	24173-24174	,	_
156-4	24175-24183	additive	_
156-5	24184-24191	genetic	_
156-6	24192-24199	effects	_
156-7	24200-24202	on	_
156-8	24203-24206	the	_
156-9	24207-24213	degree	_
156-10	24214-24216	of	_
156-11	24217-24221	gray	_
156-12	24222-24228	matter	_
156-13	24229-24235	volume	_
156-14	24236-24240	loss	_
156-15	24241-24243	in	_
156-16	24244-24247	the	_
156-17	24248-24256	temporal	_
156-18	24257-24262	gyrus	_
156-19	24263-24267	over	_
156-20	24268-24272	five	_
156-21	24273-24278	years	_
156-22	24279-24283	have	_
156-23	24284-24288	been	_
156-24	24289-24297	observed	_
156-25	24298-24300	in	_
156-26	24301-24309	patients	_
156-27	24310-24314	with	_
156-28	24315-24328	schizophrenia	_
156-29	24329-24332	and	_
156-30	24333-24343	unaffected	_
156-31	24344-24352	co-twins	_
156-32	24352-24353	.	_

#Text=Decreased volume in the MTG has been related to Val allele homozygosity in chronic schizophrenia.
157-1	24354-24363	Decreased	_
157-2	24364-24370	volume	_
157-3	24371-24373	in	_
157-4	24374-24377	the	_
157-5	24378-24381	MTG	_
157-6	24382-24385	has	_
157-7	24386-24390	been	_
157-8	24391-24398	related	_
157-9	24399-24401	to	_
157-10	24402-24405	Val	_
157-11	24406-24412	allele	_
157-12	24413-24425	homozygosity	_
157-13	24426-24428	in	_
157-14	24429-24436	chronic	_
157-15	24437-24450	schizophrenia	_
157-16	24450-24451	.	_

#Text=Reduced FC in the DMN has been associated with psychopathology in patients with high genetic loading for schizophrenia.
158-1	24452-24459	Reduced	_
158-2	24460-24462	FC	_
158-3	24463-24465	in	_
158-4	24466-24469	the	_
158-5	24470-24473	DMN	_
158-6	24474-24477	has	_
158-7	24478-24482	been	_
158-8	24483-24493	associated	_
158-9	24494-24498	with	_
158-10	24499-24514	psychopathology	_
158-11	24515-24517	in	_
158-12	24518-24526	patients	_
158-13	24527-24531	with	_
158-14	24532-24536	high	_
158-15	24537-24544	genetic	_
158-16	24545-24552	loading	_
158-17	24553-24556	for	_
158-18	24557-24570	schizophrenia	_
158-19	24570-24571	.	_

#Text=Therefore, reduced inter-hemispheric FC in the DMN may bear genetic load and serve as an endophenotype for schizophrenia.
159-1	24572-24581	Therefore	_
159-2	24581-24582	,	_
159-3	24583-24590	reduced	_
159-4	24591-24608	inter-hemispheric	_
159-5	24609-24611	FC	_
159-6	24612-24614	in	_
159-7	24615-24618	the	_
159-8	24619-24622	DMN	_
159-9	24623-24626	may	_
159-10	24627-24631	bear	_
159-11	24632-24639	genetic	_
159-12	24640-24644	load	_
159-13	24645-24648	and	_
159-14	24649-24654	serve	_
159-15	24655-24657	as	_
159-16	24658-24660	an	_
159-17	24661-24674	endophenotype	_
159-18	24675-24678	for	_
159-19	24679-24692	schizophrenia	_
159-20	24692-24693	.	_

#Text=Decreased activity in the right precentral gyrus has been observed in schizophrenia; this finding is consistent with reported functional deficits in the sensorimotor regions in patients with schizophrenia.
160-1	24694-24703	Decreased	_
160-2	24704-24712	activity	_
160-3	24713-24715	in	_
160-4	24716-24719	the	_
160-5	24720-24725	right	_
160-6	24726-24736	precentral	_
160-7	24737-24742	gyrus	_
160-8	24743-24746	has	_
160-9	24747-24751	been	_
160-10	24752-24760	observed	_
160-11	24761-24763	in	_
160-12	24764-24777	schizophrenia	_
160-13	24777-24778	;	_
160-14	24779-24783	this	_
160-15	24784-24791	finding	_
160-16	24792-24794	is	_
160-17	24795-24805	consistent	_
160-18	24806-24810	with	_
160-19	24811-24819	reported	_
160-20	24820-24830	functional	_
160-21	24831-24839	deficits	_
160-22	24840-24842	in	_
160-23	24843-24846	the	_
160-24	24847-24859	sensorimotor	_
160-25	24860-24867	regions	_
160-26	24868-24870	in	_
160-27	24871-24879	patients	_
160-28	24880-24884	with	_
160-29	24885-24898	schizophrenia	_
160-30	24898-24899	.	_

#Text=Increased FC is usually considered as compensatory reallocation or dedifferentiation to functional deficits in the sensorimotor regions.
161-1	24900-24909	Increased	_
161-2	24910-24912	FC	_
161-3	24913-24915	is	_
161-4	24916-24923	usually	_
161-5	24924-24934	considered	_
161-6	24935-24937	as	_
161-7	24938-24950	compensatory	_
161-8	24951-24963	reallocation	_
161-9	24964-24966	or	_
161-10	24967-24984	dedifferentiation	_
161-11	24985-24987	to	_
161-12	24988-24998	functional	_
161-13	24999-25007	deficits	_
161-14	25008-25010	in	_
161-15	25011-25014	the	_
161-16	25015-25027	sensorimotor	_
161-17	25028-25035	regions	_
161-18	25035-25036	.	_

#Text=The precentral gyrus is the primary motor cortex; whereas the primary somatosensory cortex is located in the postcentral gyrus.
162-1	25037-25040	The	_
162-2	25041-25051	precentral	_
162-3	25052-25057	gyrus	_
162-4	25058-25060	is	_
162-5	25061-25064	the	_
162-6	25065-25072	primary	_
162-7	25073-25078	motor	_
162-8	25079-25085	cortex	_
162-9	25085-25086	;	_
162-10	25087-25094	whereas	_
162-11	25095-25098	the	_
162-12	25099-25106	primary	_
162-13	25107-25120	somatosensory	_
162-14	25121-25127	cortex	_
162-15	25128-25130	is	_
162-16	25131-25138	located	_
162-17	25139-25141	in	_
162-18	25142-25145	the	_
162-19	25146-25157	postcentral	_
162-20	25158-25163	gyrus	_
162-21	25163-25164	.	_

#Text=Therefore, increased inter-hemispheric FC in the left precentral grus/postcentral gyrus in the present study may be a compensatory effort to functional deficits in these regions.
163-1	25165-25174	Therefore	_
163-2	25174-25175	,	_
163-3	25176-25185	increased	_
163-4	25186-25203	inter-hemispheric	_
163-5	25204-25206	FC	_
163-6	25207-25209	in	_
163-7	25210-25213	the	_
163-8	25214-25218	left	_
163-9	25219-25229	precentral	_
163-10	25230-25234	grus	_
163-11	25234-25235	/	_
163-12	25235-25246	postcentral	_
163-13	25247-25252	gyrus	_
163-14	25253-25255	in	_
163-15	25256-25259	the	_
163-16	25260-25267	present	_
163-17	25268-25273	study	_
163-18	25274-25277	may	_
163-19	25278-25280	be	_
163-20	25281-25282	a	_
163-21	25283-25295	compensatory	_
163-22	25296-25302	effort	_
163-23	25303-25305	to	_
163-24	25306-25316	functional	_
163-25	25317-25325	deficits	_
163-26	25326-25328	in	_
163-27	25329-25334	these	_
163-28	25335-25342	regions	_
163-29	25342-25343	.	_

#Text=The present study has several novel aspects.
164-1	25344-25347	The	_
164-2	25348-25355	present	_
164-3	25356-25361	study	_
164-4	25362-25365	has	_
164-5	25366-25373	several	_
164-6	25374-25379	novel	_
164-7	25380-25387	aspects	_
164-8	25387-25388	.	_

#Text=First, the whole brain FC was divided into inter-hemispheric FC and intra-hemispheric FC, which are helpful for us to understand whether abnormal FC originates from inter-hemispheric FC and/or intra-hemispheric FC in schizophrenia.
165-1	25389-25394	First	_
165-2	25394-25395	,	_
165-3	25396-25399	the	_
165-4	25400-25405	whole	_
165-5	25406-25411	brain	_
165-6	25412-25414	FC	_
165-7	25415-25418	was	_
165-8	25419-25426	divided	_
165-9	25427-25431	into	_
165-10	25432-25449	inter-hemispheric	_
165-11	25450-25452	FC	_
165-12	25453-25456	and	_
165-13	25457-25474	intra-hemispheric	_
165-14	25475-25477	FC	_
165-15	25477-25478	,	_
165-16	25479-25484	which	_
165-17	25485-25488	are	_
165-18	25489-25496	helpful	_
165-19	25497-25500	for	_
165-20	25501-25503	us	_
165-21	25504-25506	to	_
165-22	25507-25517	understand	_
165-23	25518-25525	whether	_
165-24	25526-25534	abnormal	_
165-25	25535-25537	FC	_
165-26	25538-25548	originates	_
165-27	25549-25553	from	_
165-28	25554-25571	inter-hemispheric	_
165-29	25572-25574	FC	_
165-30	25575-25578	and	_
165-31	25578-25579	/	_
165-32	25579-25581	or	_
165-33	25582-25599	intra-hemispheric	_
165-34	25600-25602	FC	_
165-35	25603-25605	in	_
165-36	25606-25619	schizophrenia	_
165-37	25619-25620	.	_

#Text=Second, unaffected siblings were included in the present study; this allowed us to explore potential endophenotypes for schizophrenia.
166-1	25621-25627	Second	_
166-2	25627-25628	,	_
166-3	25629-25639	unaffected	_
166-4	25640-25648	siblings	_
166-5	25649-25653	were	_
166-6	25654-25662	included	_
166-7	25663-25665	in	_
166-8	25666-25669	the	_
166-9	25670-25677	present	_
166-10	25678-25683	study	_
166-11	25683-25684	;	_
166-12	25685-25689	this	_
166-13	25690-25697	allowed	_
166-14	25698-25700	us	_
166-15	25701-25703	to	_
166-16	25704-25711	explore	_
166-17	25712-25721	potential	_
166-18	25722-25736	endophenotypes	_
166-19	25737-25740	for	_
166-20	25741-25754	schizophrenia	_
166-21	25754-25755	.	_

#Text=Third, SVM analysis was used to explore whether asymmetry of inter- and/or intra-hemispheric FC can serve as biomarkers to predict clinical response to medication treatment at the individual level; such biomarkers may have great clinical implications as they can help clinicians to make individualized treatment decisions for patients.
167-1	25756-25761	Third	_
167-2	25761-25762	,	_
167-3	25763-25766	SVM	_
167-4	25767-25775	analysis	_
167-5	25776-25779	was	_
167-6	25780-25784	used	_
167-7	25785-25787	to	_
167-8	25788-25795	explore	_
167-9	25796-25803	whether	_
167-10	25804-25813	asymmetry	_
167-11	25814-25816	of	_
167-12	25817-25822	inter	_
167-13	25822-25823	-	_
167-14	25824-25827	and	_
167-15	25827-25828	/	_
167-16	25828-25830	or	_
167-17	25831-25848	intra-hemispheric	_
167-18	25849-25851	FC	_
167-19	25852-25855	can	_
167-20	25856-25861	serve	_
167-21	25862-25864	as	_
167-22	25865-25875	biomarkers	_
167-23	25876-25878	to	_
167-24	25879-25886	predict	_
167-25	25887-25895	clinical	_
167-26	25896-25904	response	_
167-27	25905-25907	to	_
167-28	25908-25918	medication	_
167-29	25919-25928	treatment	_
167-30	25929-25931	at	_
167-31	25932-25935	the	_
167-32	25936-25946	individual	_
167-33	25947-25952	level	_
167-34	25952-25953	;	_
167-35	25954-25958	such	_
167-36	25959-25969	biomarkers	_
167-37	25970-25973	may	_
167-38	25974-25978	have	_
167-39	25979-25984	great	_
167-40	25985-25993	clinical	_
167-41	25994-26006	implications	_
167-42	26007-26009	as	_
167-43	26010-26014	they	_
167-44	26015-26018	can	_
167-45	26019-26023	help	_
167-46	26024-26034	clinicians	_
167-47	26035-26037	to	_
167-48	26038-26042	make	_
167-49	26043-26057	individualized	_
167-50	26058-26067	treatment	_
167-51	26068-26077	decisions	_
167-52	26078-26081	for	_
167-53	26082-26090	patients	_
167-54	26090-26091	.	_

#Text=Finally, drug-naive, first-episode patients were recruited in the present study, eliminating possible confounding effects of prior medication exposure and the heterogeneity of illness course on brain function.
168-1	26092-26099	Finally	_
168-2	26099-26100	,	_
168-3	26101-26111	drug-naive	_
168-4	26111-26112	,	_
168-5	26113-26126	first-episode	_
168-6	26127-26135	patients	_
168-7	26136-26140	were	_
168-8	26141-26150	recruited	_
168-9	26151-26153	in	_
168-10	26154-26157	the	_
168-11	26158-26165	present	_
168-12	26166-26171	study	_
168-13	26171-26172	,	_
168-14	26173-26184	eliminating	_
168-15	26185-26193	possible	_
168-16	26194-26205	confounding	_
168-17	26206-26213	effects	_
168-18	26214-26216	of	_
168-19	26217-26222	prior	_
168-20	26223-26233	medication	_
168-21	26234-26242	exposure	_
168-22	26243-26246	and	_
168-23	26247-26250	the	_
168-24	26251-26264	heterogeneity	_
168-25	26265-26267	of	_
168-26	26268-26275	illness	_
168-27	26276-26282	course	_
168-28	26283-26285	on	_
168-29	26286-26291	brain	_
168-30	26292-26300	function	_
168-31	26300-26301	.	_

#Text=In addition to the relatively small study sample size, the study has some other limitations.
169-1	26302-26304	In	_
169-2	26305-26313	addition	_
169-3	26314-26316	to	_
169-4	26317-26320	the	_
169-5	26321-26331	relatively	_
169-6	26332-26337	small	_
169-7	26338-26343	study	_
169-8	26344-26350	sample	_
169-9	26351-26355	size	_
169-10	26355-26356	,	_
169-11	26357-26360	the	_
169-12	26361-26366	study	_
169-13	26367-26370	has	_
169-14	26371-26375	some	_
169-15	26376-26381	other	_
169-16	26382-26393	limitations	_
169-17	26393-26394	.	_

#Text=First, within patients, the imaging scans were not repeated after 8 weeks of olanzapine treatment.
170-1	26395-26400	First	_
170-2	26400-26401	,	_
170-3	26402-26408	within	_
170-4	26409-26417	patients	_
170-5	26417-26418	,	_
170-6	26419-26422	the	_
170-7	26423-26430	imaging	_
170-8	26431-26436	scans	_
170-9	26437-26441	were	_
170-10	26442-26445	not	_
170-11	26446-26454	repeated	_
170-12	26455-26460	after	_
170-13	26461-26462	8	_
170-14	26462-26463	 	_
170-15	26463-26468	weeks	_
170-16	26469-26471	of	_
170-17	26472-26482	olanzapine	_
170-18	26483-26492	treatment	_
170-19	26492-26493	.	_

#Text=Therefore, the medication treatment effect on functional asymmetry in schizophrenia remains unclear.
171-1	26494-26503	Therefore	_
171-2	26503-26504	,	_
171-3	26505-26508	the	_
171-4	26509-26519	medication	_
171-5	26520-26529	treatment	_
171-6	26530-26536	effect	_
171-7	26537-26539	on	_
171-8	26540-26550	functional	_
171-9	26551-26560	asymmetry	_
171-10	26561-26563	in	_
171-11	26564-26577	schizophrenia	_
171-12	26578-26585	remains	_
171-13	26586-26593	unclear	_
171-14	26593-26594	.	_

#Text=Second, all patients were treated with olanzapine.
172-1	26595-26601	Second	_
172-2	26601-26602	,	_
172-3	26603-26606	all	_
172-4	26607-26615	patients	_
172-5	26616-26620	were	_
172-6	26621-26628	treated	_
172-7	26629-26633	with	_
172-8	26634-26644	olanzapine	_
172-9	26644-26645	.	_

#Text=Having patients on the same antipsychotic medication olanzapine was helpful to minimize the confounding effects caused by the use of different antipsychotic medications as they may cause differential effects on brain function; however, this also comprised the generalizability of the study findings to patients on antipsychotic medications other than olanzapine.
173-1	26646-26652	Having	_
173-2	26653-26661	patients	_
173-3	26662-26664	on	_
173-4	26665-26668	the	_
173-5	26669-26673	same	_
173-6	26674-26687	antipsychotic	_
173-7	26688-26698	medication	_
173-8	26699-26709	olanzapine	_
173-9	26710-26713	was	_
173-10	26714-26721	helpful	_
173-11	26722-26724	to	_
173-12	26725-26733	minimize	_
173-13	26734-26737	the	_
173-14	26738-26749	confounding	_
173-15	26750-26757	effects	_
173-16	26758-26764	caused	_
173-17	26765-26767	by	_
173-18	26768-26771	the	_
173-19	26772-26775	use	_
173-20	26776-26778	of	_
173-21	26779-26788	different	_
173-22	26789-26802	antipsychotic	_
173-23	26803-26814	medications	_
173-24	26815-26817	as	_
173-25	26818-26822	they	_
173-26	26823-26826	may	_
173-27	26827-26832	cause	_
173-28	26833-26845	differential	_
173-29	26846-26853	effects	_
173-30	26854-26856	on	_
173-31	26857-26862	brain	_
173-32	26863-26871	function	_
173-33	26871-26872	;	_
173-34	26873-26880	however	_
173-35	26880-26881	,	_
173-36	26882-26886	this	_
173-37	26887-26891	also	_
173-38	26892-26901	comprised	_
173-39	26902-26905	the	_
173-40	26906-26922	generalizability	_
173-41	26923-26925	of	_
173-42	26926-26929	the	_
173-43	26930-26935	study	_
173-44	26936-26944	findings	_
173-45	26945-26947	to	_
173-46	26948-26956	patients	_
173-47	26957-26959	on	_
173-48	26960-26973	antipsychotic	_
173-49	26974-26985	medications	_
173-50	26986-26991	other	_
173-51	26992-26996	than	_
173-52	26997-27007	olanzapine	_
173-53	27007-27008	.	_

#Text=Third, a correlation coefficient threshold of r > 0.2 was used to calculate the PAS scores.
174-1	27009-27014	Third	_
174-2	27014-27015	,	_
174-3	27016-27017	a	_
174-4	27018-27029	correlation	_
174-5	27030-27041	coefficient	_
174-6	27042-27051	threshold	_
174-7	27052-27054	of	_
174-8	27055-27056	r	_
174-9	27056-27057	 	_
174-10	27057-27058	>	_
174-11	27058-27059	 	_
174-12	27059-27062	0.2	_
174-13	27063-27066	was	_
174-14	27067-27071	used	_
174-15	27072-27074	to	_
174-16	27075-27084	calculate	_
174-17	27085-27088	the	_
174-18	27089-27092	PAS	_
174-19	27093-27099	scores	_
174-20	27099-27100	.	_

#Text=The choice of such a threshold might affect the findings.
175-1	27101-27104	The	_
175-2	27105-27111	choice	_
175-3	27112-27114	of	_
175-4	27115-27119	such	_
175-5	27120-27121	a	_
175-6	27122-27131	threshold	_
175-7	27132-27137	might	_
175-8	27138-27144	affect	_
175-9	27145-27148	the	_
175-10	27149-27157	findings	_
175-11	27157-27158	.	_

#Text=However, another threshold of r > 0.25 was tested and led to similar findings.
176-1	27159-27166	However	_
176-2	27166-27167	,	_
176-3	27168-27175	another	_
176-4	27176-27185	threshold	_
176-5	27186-27188	of	_
176-6	27189-27190	r	_
176-7	27190-27191	 	_
176-8	27191-27192	>	_
176-9	27192-27193	 	_
176-10	27193-27197	0.25	_
176-11	27198-27201	was	_
176-12	27202-27208	tested	_
176-13	27209-27212	and	_
176-14	27213-27216	led	_
176-15	27217-27219	to	_
176-16	27220-27227	similar	_
176-17	27228-27236	findings	_
176-18	27236-27237	.	_

#Text=Fourth, although a symmetrical standard template was used to process the data, the influence of potential brain size asymmetry between two hemispheres may not be eliminated completely in the calculation of PAS index.
177-1	27238-27244	Fourth	_
177-2	27244-27245	,	_
177-3	27246-27254	although	_
177-4	27255-27256	a	_
177-5	27257-27268	symmetrical	_
177-6	27269-27277	standard	_
177-7	27278-27286	template	_
177-8	27287-27290	was	_
177-9	27291-27295	used	_
177-10	27296-27298	to	_
177-11	27299-27306	process	_
177-12	27307-27310	the	_
177-13	27311-27315	data	_
177-14	27315-27316	,	_
177-15	27317-27320	the	_
177-16	27321-27330	influence	_
177-17	27331-27333	of	_
177-18	27334-27343	potential	_
177-19	27344-27349	brain	_
177-20	27350-27354	size	_
177-21	27355-27364	asymmetry	_
177-22	27365-27372	between	_
177-23	27373-27376	two	_
177-24	27377-27388	hemispheres	_
177-25	27389-27392	may	_
177-26	27393-27396	not	_
177-27	27397-27399	be	_
177-28	27400-27410	eliminated	_
177-29	27411-27421	completely	_
177-30	27422-27424	in	_
177-31	27425-27428	the	_
177-32	27429-27440	calculation	_
177-33	27441-27443	of	_
177-34	27444-27447	PAS	_
177-35	27448-27453	index	_
177-36	27453-27454	.	_

#Text=Finally, although a number of strategies were applied to minimize the effect caused by head motion, such an effect may not be eliminated completely in the present study.
178-1	27455-27462	Finally	_
178-2	27462-27463	,	_
178-3	27464-27472	although	_
178-4	27473-27474	a	_
178-5	27475-27481	number	_
178-6	27482-27484	of	_
178-7	27485-27495	strategies	_
178-8	27496-27500	were	_
178-9	27501-27508	applied	_
178-10	27509-27511	to	_
178-11	27512-27520	minimize	_
178-12	27521-27524	the	_
178-13	27525-27531	effect	_
178-14	27532-27538	caused	_
178-15	27539-27541	by	_
178-16	27542-27546	head	_
178-17	27547-27553	motion	_
178-18	27553-27554	,	_
178-19	27555-27559	such	_
178-20	27560-27562	an	_
178-21	27563-27569	effect	_
178-22	27570-27573	may	_
178-23	27574-27577	not	_
178-24	27578-27580	be	_
178-25	27581-27591	eliminated	_
178-26	27592-27602	completely	_
178-27	27603-27605	in	_
178-28	27606-27609	the	_
178-29	27610-27617	present	_
178-30	27618-27623	study	_
178-31	27623-27624	.	_

#Text=In summary, the present study found reduced inter-hemispheric FC in the DMN and elevated inter-hemispheric FC in the sensorimotor regions in drug naive, first episode schizophrenia, which were preferentially within the left hemisphere.
179-1	27625-27627	In	_
179-2	27628-27635	summary	_
179-3	27635-27636	,	_
179-4	27637-27640	the	_
179-5	27641-27648	present	_
179-6	27649-27654	study	_
179-7	27655-27660	found	_
179-8	27661-27668	reduced	_
179-9	27669-27686	inter-hemispheric	_
179-10	27687-27689	FC	_
179-11	27690-27692	in	_
179-12	27693-27696	the	_
179-13	27697-27700	DMN	_
179-14	27701-27704	and	_
179-15	27705-27713	elevated	_
179-16	27714-27731	inter-hemispheric	_
179-17	27732-27734	FC	_
179-18	27735-27737	in	_
179-19	27738-27741	the	_
179-20	27742-27754	sensorimotor	_
179-21	27755-27762	regions	_
179-22	27763-27765	in	_
179-23	27766-27770	drug	_
179-24	27771-27776	naive	_
179-25	27776-27777	,	_
179-26	27778-27783	first	_
179-27	27784-27791	episode	_
179-28	27792-27805	schizophrenia	_
179-29	27805-27806	,	_
179-30	27807-27812	which	_
179-31	27813-27817	were	_
179-32	27818-27832	preferentially	_
179-33	27833-27839	within	_
179-34	27840-27843	the	_
179-35	27844-27848	left	_
179-36	27849-27859	hemisphere	_
179-37	27859-27860	.	_

#Text=Reduced inter-hemispheric FC in the DMN might serve as an endophenotype for schizophrenia and a predictor for clinical response to olanzapine treatment.
180-1	27861-27868	Reduced	_
180-2	27869-27886	inter-hemispheric	_
180-3	27887-27889	FC	_
180-4	27890-27892	in	_
180-5	27893-27896	the	_
180-6	27897-27900	DMN	_
180-7	27901-27906	might	_
180-8	27907-27912	serve	_
180-9	27913-27915	as	_
180-10	27916-27918	an	_
180-11	27919-27932	endophenotype	_
180-12	27933-27936	for	_
180-13	27937-27950	schizophrenia	_
180-14	27951-27954	and	_
180-15	27955-27956	a	_
180-16	27957-27966	predictor	_
180-17	27967-27970	for	_
180-18	27971-27979	clinical	_
180-19	27980-27988	response	_
180-20	27989-27991	to	_
180-21	27992-28002	olanzapine	_
180-22	28003-28012	treatment	_
180-23	28012-28013	.	_

#Text=Future studies to address the limitations described above and further examine the clinical utility of using disrupted asymmetry of inter- and/or intra-hemispheric FC as a biomarker to predict treatment response in patients with schizophrenia in the clinical settings are warranted.
181-1	28014-28020	Future	_
181-2	28021-28028	studies	_
181-3	28029-28031	to	_
181-4	28032-28039	address	_
181-5	28040-28043	the	_
181-6	28044-28055	limitations	_
181-7	28056-28065	described	_
181-8	28066-28071	above	_
181-9	28072-28075	and	_
181-10	28076-28083	further	_
181-11	28084-28091	examine	_
181-12	28092-28095	the	_
181-13	28096-28104	clinical	_
181-14	28105-28112	utility	_
181-15	28113-28115	of	_
181-16	28116-28121	using	_
181-17	28122-28131	disrupted	_
181-18	28132-28141	asymmetry	_
181-19	28142-28144	of	_
181-20	28145-28150	inter	_
181-21	28150-28151	-	_
181-22	28152-28155	and	_
181-23	28155-28156	/	_
181-24	28156-28158	or	_
181-25	28159-28176	intra-hemispheric	_
181-26	28177-28179	FC	_
181-27	28180-28182	as	_
181-28	28183-28184	a	_
181-29	28185-28194	biomarker	_
181-30	28195-28197	to	_
181-31	28198-28205	predict	_
181-32	28206-28215	treatment	_
181-33	28216-28224	response	_
181-34	28225-28227	in	_
181-35	28228-28236	patients	_
181-36	28237-28241	with	_
181-37	28242-28255	schizophrenia	_
181-38	28256-28258	in	_
181-39	28259-28262	the	_
181-40	28263-28271	clinical	_
181-41	28272-28280	settings	_
181-42	28281-28284	are	_
181-43	28285-28294	warranted	_
181-44	28294-28295	.	_

#Text=Role of the funding source
#Text=The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
182-1	28296-28300	Role	_
182-2	28301-28303	of	_
182-3	28304-28307	the	_
182-4	28308-28315	funding	_
182-5	28316-28322	source	_
182-6	28323-28326	The	_
182-7	28327-28334	funding	_
182-8	28335-28342	sources	_
182-9	28343-28346	had	_
182-10	28347-28349	no	_
182-11	28350-28354	role	_
182-12	28355-28357	in	_
182-13	28358-28361	the	_
182-14	28362-28368	design	_
182-15	28369-28372	and	_
182-16	28373-28380	conduct	_
182-17	28381-28383	of	_
182-18	28384-28387	the	_
182-19	28388-28393	study	_
182-20	28393-28394	;	_
182-21	28395-28405	collection	_
182-22	28405-28406	,	_
182-23	28407-28417	management	_
182-24	28417-28418	,	_
182-25	28419-28427	analysis	_
182-26	28427-28428	,	_
182-27	28429-28432	and	_
182-28	28433-28447	interpretation	_
182-29	28448-28450	of	_
182-30	28451-28454	the	_
182-31	28455-28459	data	_
182-32	28459-28460	;	_
182-33	28461-28472	preparation	_
182-34	28472-28473	,	_
182-35	28474-28480	review	_
182-36	28480-28481	,	_
182-37	28482-28484	or	_
182-38	28485-28493	approval	_
182-39	28494-28496	of	_
182-40	28497-28500	the	_
182-41	28501-28511	manuscript	_
182-42	28511-28512	;	_
182-43	28513-28516	and	_
182-44	28517-28525	decision	_
182-45	28526-28528	to	_
182-46	28529-28535	submit	_
182-47	28536-28539	the	_
182-48	28540-28550	manuscript	_
182-49	28551-28554	for	_
182-50	28555-28566	publication	_
182-51	28566-28567	.	_

#Text=Dr.
183-1	28568-28570	Dr	_
183-2	28570-28571	.	_

#Text=Wenbin Guo had access to all the data in the study and had final responsibility for the decision to submit for publication.
184-1	28572-28578	Wenbin	_
184-2	28579-28582	Guo	_
184-3	28583-28586	had	_
184-4	28587-28593	access	_
184-5	28594-28596	to	_
184-6	28597-28600	all	_
184-7	28601-28604	the	_
184-8	28605-28609	data	_
184-9	28610-28612	in	_
184-10	28613-28616	the	_
184-11	28617-28622	study	_
184-12	28623-28626	and	_
184-13	28627-28630	had	_
184-14	28631-28636	final	_
184-15	28637-28651	responsibility	_
184-16	28652-28655	for	_
184-17	28656-28659	the	_
184-18	28660-28668	decision	_
184-19	28669-28671	to	_
184-20	28672-28678	submit	_
184-21	28679-28682	for	_
184-22	28683-28694	publication	_
184-23	28694-28695	.	_

#Text=Declaration of interests
#Text=Dr.
185-1	28696-28707	Declaration	_
185-2	28708-28710	of	_
185-3	28711-28720	interests	_
185-4	28721-28723	Dr	_
185-5	28723-28724	.	_

#Text=Fan reports receiving research support from the National Institute on Alcohol Abuse and Alcoholism, National Institute on Drug Abuse, the Stanley Medical Research Institute, the Baer Foundation, the Shine Foundation, the Vanguard Group, Janssen, Avanir Pharmaceuticals, Neurocrine, Otsuka, Boehringer Ingelheim, and Alkermes, and reports receiving honoraria for serving on an advisory board for Allergen.
186-1	28725-28728	Fan	_
186-2	28729-28736	reports	_
186-3	28737-28746	receiving	_
186-4	28747-28755	research	_
186-5	28756-28763	support	_
186-6	28764-28768	from	_
186-7	28769-28772	the	_
186-8	28773-28781	National	_
186-9	28782-28791	Institute	_
186-10	28792-28794	on	_
186-11	28795-28802	Alcohol	_
186-12	28803-28808	Abuse	_
186-13	28809-28812	and	_
186-14	28813-28823	Alcoholism	_
186-15	28823-28824	,	_
186-16	28825-28833	National	_
186-17	28834-28843	Institute	_
186-18	28844-28846	on	_
186-19	28847-28851	Drug	_
186-20	28852-28857	Abuse	_
186-21	28857-28858	,	_
186-22	28859-28862	the	_
186-23	28863-28870	Stanley	_
186-24	28871-28878	Medical	_
186-25	28879-28887	Research	_
186-26	28888-28897	Institute	_
186-27	28897-28898	,	_
186-28	28899-28902	the	_
186-29	28903-28907	Baer	_
186-30	28908-28918	Foundation	_
186-31	28918-28919	,	_
186-32	28920-28923	the	_
186-33	28924-28929	Shine	_
186-34	28930-28940	Foundation	_
186-35	28940-28941	,	_
186-36	28942-28945	the	_
186-37	28946-28954	Vanguard	_
186-38	28955-28960	Group	_
186-39	28960-28961	,	_
186-40	28962-28969	Janssen	_
186-41	28969-28970	,	_
186-42	28971-28977	Avanir	_
186-43	28978-28993	Pharmaceuticals	_
186-44	28993-28994	,	_
186-45	28995-29005	Neurocrine	_
186-46	29005-29006	,	_
186-47	29007-29013	Otsuka	_
186-48	29013-29014	,	_
186-49	29015-29025	Boehringer	_
186-50	29026-29035	Ingelheim	_
186-51	29035-29036	,	_
186-52	29037-29040	and	_
186-53	29041-29049	Alkermes	_
186-54	29049-29050	,	_
186-55	29051-29054	and	_
186-56	29055-29062	reports	_
186-57	29063-29072	receiving	_
186-58	29073-29082	honoraria	_
186-59	29083-29086	for	_
186-60	29087-29094	serving	_
186-61	29095-29097	on	_
186-62	29098-29100	an	_
186-63	29101-29109	advisory	_
186-64	29110-29115	board	_
186-65	29116-29119	for	_
186-66	29120-29128	Allergen	_
186-67	29128-29129	.	_

#Text=Other authors have nothing to disclose.
187-1	29130-29135	Other	_
187-2	29136-29143	authors	_
187-3	29144-29148	have	_
187-4	29149-29156	nothing	_
187-5	29157-29159	to	_
187-6	29160-29168	disclose	_
187-7	29168-29169	.	_

#Text=Contributors
#Text=Study concept and design: Wenbin Guo, Xiaoduo Fan, Jingping Zhao.
188-1	29170-29182	Contributors	_
188-2	29183-29188	Study	_
188-3	29189-29196	concept	_
188-4	29197-29200	and	_
188-5	29201-29207	design	_
188-6	29207-29208	:	_
188-7	29209-29215	Wenbin	_
188-8	29216-29219	Guo	_
188-9	29219-29220	,	_
188-10	29221-29228	Xiaoduo	_
188-11	29229-29232	Fan	_
188-12	29232-29233	,	_
188-13	29234-29242	Jingping	_
188-14	29243-29247	Zhao	_
188-15	29247-29248	.	_

#Text=Acquisition, analysis, or interpretation of data: Feng Liu, Jindong Chen, Qinji Su, Zhikun Zhang, Huabing Li, Furong Zhu.
189-1	29249-29260	Acquisition	_
189-2	29260-29261	,	_
189-3	29262-29270	analysis	_
189-4	29270-29271	,	_
189-5	29272-29274	or	_
189-6	29275-29289	interpretation	_
189-7	29290-29292	of	_
189-8	29293-29297	data	_
189-9	29297-29298	:	_
189-10	29299-29303	Feng	_
189-11	29304-29307	Liu	_
189-12	29307-29308	,	_
189-13	29309-29316	Jindong	_
189-14	29317-29321	Chen	_
189-15	29321-29322	,	_
189-16	29323-29328	Qinji	_
189-17	29329-29331	Su	_
189-18	29331-29332	,	_
189-19	29333-29339	Zhikun	_
189-20	29340-29345	Zhang	_
189-21	29345-29346	,	_
189-22	29347-29354	Huabing	_
189-23	29355-29357	Li	_
189-24	29357-29358	,	_
189-25	29359-29365	Furong	_
189-26	29366-29369	Zhu	_
189-27	29369-29370	.	_

#Text=Drafting of the manuscript: Furong Zhu, Wenbin Guo, Xiaoduo Fan.
190-1	29371-29379	Drafting	_
190-2	29380-29382	of	_
190-3	29383-29386	the	_
190-4	29387-29397	manuscript	_
190-5	29397-29398	:	_
190-6	29399-29405	Furong	_
190-7	29406-29409	Zhu	_
190-8	29409-29410	,	_
190-9	29411-29417	Wenbin	_
190-10	29418-29421	Guo	_
190-11	29421-29422	,	_
190-12	29423-29430	Xiaoduo	_
190-13	29431-29434	Fan	_
190-14	29434-29435	.	_

#Text=Critical revision of the manuscript for important intellectual content: WenbinGuo, Xiaoduo Fan, Feng Liu.
191-1	29436-29444	Critical	_
191-2	29445-29453	revision	_
191-3	29454-29456	of	_
191-4	29457-29460	the	_
191-5	29461-29471	manuscript	_
191-6	29472-29475	for	_
191-7	29476-29485	important	_
191-8	29486-29498	intellectual	_
191-9	29499-29506	content	_
191-10	29506-29507	:	_
191-11	29508-29517	WenbinGuo	_
191-12	29517-29518	,	_
191-13	29519-29526	Xiaoduo	_
191-14	29527-29530	Fan	_
191-15	29530-29531	,	_
191-16	29532-29536	Feng	_
191-17	29537-29540	Liu	_
191-18	29540-29541	.	_

#Text=Statistical analysis: Wenbin Guo, Feng Liu.
192-1	29542-29553	Statistical	_
192-2	29554-29562	analysis	_
192-3	29562-29563	:	_
192-4	29564-29570	Wenbin	_
192-5	29571-29574	Guo	_
192-6	29574-29575	,	_
192-7	29576-29580	Feng	_
192-8	29581-29584	Liu	_
192-9	29584-29585	.	_

#Text=Obtained funding: Wenbin Guo, Jingping Zhao.
193-1	29586-29594	Obtained	_
193-2	29595-29602	funding	_
193-3	29602-29603	:	_
193-4	29604-29610	Wenbin	_
193-5	29611-29614	Guo	_
193-6	29614-29615	,	_
193-7	29616-29624	Jingping	_
193-8	29625-29629	Zhao	_
193-9	29629-29630	.	_

#Text=Administrative, technical, or material support: Wenbin Guo, Feng Liu, Jindong Chen, Qinji Su, Zhikun Zhang, Huabing Li, Furong Zhu, Jingping Zhao.
194-1	29631-29645	Administrative	_
194-2	29645-29646	,	_
194-3	29647-29656	technical	_
194-4	29656-29657	,	_
194-5	29658-29660	or	_
194-6	29661-29669	material	_
194-7	29670-29677	support	_
194-8	29677-29678	:	_
194-9	29679-29685	Wenbin	_
194-10	29686-29689	Guo	_
194-11	29689-29690	,	_
194-12	29691-29695	Feng	_
194-13	29696-29699	Liu	_
194-14	29699-29700	,	_
194-15	29701-29708	Jindong	_
194-16	29709-29713	Chen	_
194-17	29713-29714	,	_
194-18	29715-29720	Qinji	_
194-19	29721-29723	Su	_
194-20	29723-29724	,	_
194-21	29725-29731	Zhikun	_
194-22	29732-29737	Zhang	_
194-23	29737-29738	,	_
194-24	29739-29746	Huabing	_
194-25	29747-29749	Li	_
194-26	29749-29750	,	_
194-27	29751-29757	Furong	_
194-28	29758-29761	Zhu	_
194-29	29761-29762	,	_
194-30	29763-29771	Jingping	_
194-31	29772-29776	Zhao	_
194-32	29776-29777	.	_

#Text=Study supervision: Wenbin Guo, Xiaoduo Fan, Jingping Zhao.
195-1	29778-29783	Study	_
195-2	29784-29795	supervision	_
195-3	29795-29796	:	_
195-4	29797-29803	Wenbin	_
195-5	29804-29807	Guo	_
195-6	29807-29808	,	_
195-7	29809-29816	Xiaoduo	_
195-8	29817-29820	Fan	_
195-9	29820-29821	,	_
195-10	29822-29830	Jingping	_
195-11	29831-29835	Zhao	_
195-12	29835-29836	.	_

#Text=References
#Text=Differential hemispheric processing of faces: methodological considerations and reinterpretation
#Text=Right hemisphere control of visuospatial attention: line-bisection judgments evaluated with high-density electrical mapping and source analysis
#Text=Hemispheric differences in the discrimination of line orientation
#Text=Reference frames in mental rotation
#Text=Cytological and quantitative characteristics of four cerebral commissures in the rhesus monkey
#Text=Interhemispheric interaction affected by computational complexity
#Text=The cerebral hemispheres cooperate to perform complex but not simple tasks
#Text=Intra-hemispheric intrinsic connectivity asymmetry and its relationships with handedness and language Lateralization
#Text=Handedness, language lateralisation and anatomical asymmetry in schizophrenia: meta-analysis
#Text=Schizophrenia as an anomaly of development of cerebral asymmetry.
196-1	29837-29847	References	_
196-2	29848-29860	Differential	_
196-3	29861-29872	hemispheric	_
196-4	29873-29883	processing	_
196-5	29884-29886	of	_
196-6	29887-29892	faces	_
196-7	29892-29893	:	_
196-8	29894-29908	methodological	_
196-9	29909-29923	considerations	_
196-10	29924-29927	and	_
196-11	29928-29944	reinterpretation	_
196-12	29945-29950	Right	_
196-13	29951-29961	hemisphere	_
196-14	29962-29969	control	_
196-15	29970-29972	of	_
196-16	29973-29985	visuospatial	_
196-17	29986-29995	attention	_
196-18	29995-29996	:	_
196-19	29997-30011	line-bisection	_
196-20	30012-30021	judgments	_
196-21	30022-30031	evaluated	_
196-22	30032-30036	with	_
196-23	30037-30049	high-density	_
196-24	30050-30060	electrical	_
196-25	30061-30068	mapping	_
196-26	30069-30072	and	_
196-27	30073-30079	source	_
196-28	30080-30088	analysis	_
196-29	30089-30100	Hemispheric	_
196-30	30101-30112	differences	_
196-31	30113-30115	in	_
196-32	30116-30119	the	_
196-33	30120-30134	discrimination	_
196-34	30135-30137	of	_
196-35	30138-30142	line	_
196-36	30143-30154	orientation	_
196-37	30155-30164	Reference	_
196-38	30165-30171	frames	_
196-39	30172-30174	in	_
196-40	30175-30181	mental	_
196-41	30182-30190	rotation	_
196-42	30191-30202	Cytological	_
196-43	30203-30206	and	_
196-44	30207-30219	quantitative	_
196-45	30220-30235	characteristics	_
196-46	30236-30238	of	_
196-47	30239-30243	four	_
196-48	30244-30252	cerebral	_
196-49	30253-30264	commissures	_
196-50	30265-30267	in	_
196-51	30268-30271	the	_
196-52	30272-30278	rhesus	_
196-53	30279-30285	monkey	_
196-54	30286-30302	Interhemispheric	_
196-55	30303-30314	interaction	_
196-56	30315-30323	affected	_
196-57	30324-30326	by	_
196-58	30327-30340	computational	_
196-59	30341-30351	complexity	_
196-60	30352-30355	The	_
196-61	30356-30364	cerebral	_
196-62	30365-30376	hemispheres	_
196-63	30377-30386	cooperate	_
196-64	30387-30389	to	_
196-65	30390-30397	perform	_
196-66	30398-30405	complex	_
196-67	30406-30409	but	_
196-68	30410-30413	not	_
196-69	30414-30420	simple	_
196-70	30421-30426	tasks	_
196-71	30427-30444	Intra-hemispheric	_
196-72	30445-30454	intrinsic	_
196-73	30455-30467	connectivity	_
196-74	30468-30477	asymmetry	_
196-75	30478-30481	and	_
196-76	30482-30485	its	_
196-77	30486-30499	relationships	_
196-78	30500-30504	with	_
196-79	30505-30515	handedness	_
196-80	30516-30519	and	_
196-81	30520-30528	language	_
196-82	30529-30543	Lateralization	_
196-83	30544-30554	Handedness	_
196-84	30554-30555	,	_
196-85	30556-30564	language	_
196-86	30565-30579	lateralisation	_
196-87	30580-30583	and	_
196-88	30584-30594	anatomical	_
196-89	30595-30604	asymmetry	_
196-90	30605-30607	in	_
196-91	30608-30621	schizophrenia	_
196-92	30621-30622	:	_
196-93	30623-30636	meta-analysis	_
196-94	30637-30650	Schizophrenia	_
196-95	30651-30653	as	_
196-96	30654-30656	an	_
196-97	30657-30664	anomaly	_
196-98	30665-30667	of	_
196-99	30668-30679	development	_
196-100	30680-30682	of	_
196-101	30683-30691	cerebral	_
196-102	30692-30701	asymmetry	_
196-103	30701-30702	.	_

#Text=A postmortem study and a proposal concerning the genetic basis of the disease
#Text=Decreased left middle temporal gyrus volume in antipsychotic drug-naive, first-episode schizophrenia patients and their healthy unaffected siblings
#Text=Decreased gray matter volume in the left middle temporal gyrus as a candidate biomarker for schizophrenia: a study of drug naive, first-episode schizophrenia patients and unaffected siblings
#Text=Uncinate fasciculus findings in schizophrenia: a magnetic resonance diffusion tensor imaging study
#Text=Decreased resting-state interhemispheric coordination in first-episode, drug-naive paranoid schizophrenia
#Text=Decreased interhemispheric coordination in schizophrenia: a resting state fMRI study
#Text=The endophenotype concept in psychiatry: etymology and strategic intentions
#Text=Ventral tegmental area/midbrain functional connectivity and response to antipsychotic medication in schizophrenia
#Text=Olanzapine modulation of long- and short-range functional connectivity in the resting brain in a sample of patients with schizophrenia
#Text=Olanzapine modulates the default-mode network homogeneity in recurrent drug-free schizophrenia at rest
#Text=Treatment effects of olanzapine on homotopic connectivity in drug-free schizophrenia at rest
#Text=Change in brain network topology as a function of treatment response in schizophrenia: a longitudinal resting-state fMRI study using graph theory
#Text=Abnormalities in hemispheric specialization of caudate nucleus connectivity in schizophrenia
#Text=Poor outcome in chronic schizophrenia is associated with progressive loss of volume of the putamen
#Text=Abnormal long- and short-range functional connectivity in adolescent-onset schizophrenia patients: a resting-state fMRI study
#Text=Prediction of individual response to electroconvulsive therapy via machine learning on structural magnetic resonance imaging data
#Text=
#Text=DPABI: data processing & analysis for (resting-state) brain imaging
#Text=Overlapping and segregated resting-state functional connectivity in patients with major depressive disorder with and without childhood neglect
#Text=Disrupted cortical hubs in functional brain networks in social anxiety disorder
#Text=Graph theoretical analysis of functional brain networks: test-retest evaluation on short- and long-term resting-state functional MRI data
#Text=The global signal and observed anticorrelated resting state brain networks
#Text=The impact of global signal regression on resting state correlations: are anti-correlated networks introduced?
197-1	30703-30704	A	_
197-2	30705-30715	postmortem	_
197-3	30716-30721	study	_
197-4	30722-30725	and	_
197-5	30726-30727	a	_
197-6	30728-30736	proposal	_
197-7	30737-30747	concerning	_
197-8	30748-30751	the	_
197-9	30752-30759	genetic	_
197-10	30760-30765	basis	_
197-11	30766-30768	of	_
197-12	30769-30772	the	_
197-13	30773-30780	disease	_
197-14	30781-30790	Decreased	_
197-15	30791-30795	left	_
197-16	30796-30802	middle	_
197-17	30803-30811	temporal	_
197-18	30812-30817	gyrus	_
197-19	30818-30824	volume	_
197-20	30825-30827	in	_
197-21	30828-30841	antipsychotic	_
197-22	30842-30852	drug-naive	_
197-23	30852-30853	,	_
197-24	30854-30867	first-episode	_
197-25	30868-30881	schizophrenia	_
197-26	30882-30890	patients	_
197-27	30891-30894	and	_
197-28	30895-30900	their	_
197-29	30901-30908	healthy	_
197-30	30909-30919	unaffected	_
197-31	30920-30928	siblings	_
197-32	30929-30938	Decreased	_
197-33	30939-30943	gray	_
197-34	30944-30950	matter	_
197-35	30951-30957	volume	_
197-36	30958-30960	in	_
197-37	30961-30964	the	_
197-38	30965-30969	left	_
197-39	30970-30976	middle	_
197-40	30977-30985	temporal	_
197-41	30986-30991	gyrus	_
197-42	30992-30994	as	_
197-43	30995-30996	a	_
197-44	30997-31006	candidate	_
197-45	31007-31016	biomarker	_
197-46	31017-31020	for	_
197-47	31021-31034	schizophrenia	_
197-48	31034-31035	:	_
197-49	31036-31037	a	_
197-50	31038-31043	study	_
197-51	31044-31046	of	_
197-52	31047-31051	drug	_
197-53	31052-31057	naive	_
197-54	31057-31058	,	_
197-55	31059-31072	first-episode	_
197-56	31073-31086	schizophrenia	_
197-57	31087-31095	patients	_
197-58	31096-31099	and	_
197-59	31100-31110	unaffected	_
197-60	31111-31119	siblings	_
197-61	31120-31128	Uncinate	_
197-62	31129-31139	fasciculus	_
197-63	31140-31148	findings	_
197-64	31149-31151	in	_
197-65	31152-31165	schizophrenia	_
197-66	31165-31166	:	_
197-67	31167-31168	a	_
197-68	31169-31177	magnetic	_
197-69	31178-31187	resonance	_
197-70	31188-31197	diffusion	_
197-71	31198-31204	tensor	_
197-72	31205-31212	imaging	_
197-73	31213-31218	study	_
197-74	31219-31228	Decreased	_
197-75	31229-31242	resting-state	_
197-76	31243-31259	interhemispheric	_
197-77	31260-31272	coordination	_
197-78	31273-31275	in	_
197-79	31276-31289	first-episode	_
197-80	31289-31290	,	_
197-81	31291-31301	drug-naive	_
197-82	31302-31310	paranoid	_
197-83	31311-31324	schizophrenia	_
197-84	31325-31334	Decreased	_
197-85	31335-31351	interhemispheric	_
197-86	31352-31364	coordination	_
197-87	31365-31367	in	_
197-88	31368-31381	schizophrenia	_
197-89	31381-31382	:	_
197-90	31383-31384	a	_
197-91	31385-31392	resting	_
197-92	31393-31398	state	_
197-93	31399-31403	fMRI	_
197-94	31404-31409	study	_
197-95	31410-31413	The	_
197-96	31414-31427	endophenotype	_
197-97	31428-31435	concept	_
197-98	31436-31438	in	_
197-99	31439-31449	psychiatry	_
197-100	31449-31450	:	_
197-101	31451-31460	etymology	_
197-102	31461-31464	and	_
197-103	31465-31474	strategic	_
197-104	31475-31485	intentions	_
197-105	31486-31493	Ventral	_
197-106	31494-31503	tegmental	_
197-107	31504-31508	area	_
197-108	31508-31509	/	_
197-109	31509-31517	midbrain	_
197-110	31518-31528	functional	_
197-111	31529-31541	connectivity	_
197-112	31542-31545	and	_
197-113	31546-31554	response	_
197-114	31555-31557	to	_
197-115	31558-31571	antipsychotic	_
197-116	31572-31582	medication	_
197-117	31583-31585	in	_
197-118	31586-31599	schizophrenia	_
197-119	31600-31610	Olanzapine	_
197-120	31611-31621	modulation	_
197-121	31622-31624	of	_
197-122	31625-31629	long	_
197-123	31629-31630	-	_
197-124	31631-31634	and	_
197-125	31635-31646	short-range	_
197-126	31647-31657	functional	_
197-127	31658-31670	connectivity	_
197-128	31671-31673	in	_
197-129	31674-31677	the	_
197-130	31678-31685	resting	_
197-131	31686-31691	brain	_
197-132	31692-31694	in	_
197-133	31695-31696	a	_
197-134	31697-31703	sample	_
197-135	31704-31706	of	_
197-136	31707-31715	patients	_
197-137	31716-31720	with	_
197-138	31721-31734	schizophrenia	_
197-139	31735-31745	Olanzapine	_
197-140	31746-31755	modulates	_
197-141	31756-31759	the	_
197-142	31760-31772	default-mode	_
197-143	31773-31780	network	_
197-144	31781-31792	homogeneity	_
197-145	31793-31795	in	_
197-146	31796-31805	recurrent	_
197-147	31806-31815	drug-free	_
197-148	31816-31829	schizophrenia	_
197-149	31830-31832	at	_
197-150	31833-31837	rest	_
197-151	31838-31847	Treatment	_
197-152	31848-31855	effects	_
197-153	31856-31858	of	_
197-154	31859-31869	olanzapine	_
197-155	31870-31872	on	_
197-156	31873-31882	homotopic	_
197-157	31883-31895	connectivity	_
197-158	31896-31898	in	_
197-159	31899-31908	drug-free	_
197-160	31909-31922	schizophrenia	_
197-161	31923-31925	at	_
197-162	31926-31930	rest	_
197-163	31931-31937	Change	_
197-164	31938-31940	in	_
197-165	31941-31946	brain	_
197-166	31947-31954	network	_
197-167	31955-31963	topology	_
197-168	31964-31966	as	_
197-169	31967-31968	a	_
197-170	31969-31977	function	_
197-171	31978-31980	of	_
197-172	31981-31990	treatment	_
197-173	31991-31999	response	_
197-174	32000-32002	in	_
197-175	32003-32016	schizophrenia	_
197-176	32016-32017	:	_
197-177	32018-32019	a	_
197-178	32020-32032	longitudinal	_
197-179	32033-32046	resting-state	_
197-180	32047-32051	fMRI	_
197-181	32052-32057	study	_
197-182	32058-32063	using	_
197-183	32064-32069	graph	_
197-184	32070-32076	theory	_
197-185	32077-32090	Abnormalities	_
197-186	32091-32093	in	_
197-187	32094-32105	hemispheric	_
197-188	32106-32120	specialization	_
197-189	32121-32123	of	_
197-190	32124-32131	caudate	_
197-191	32132-32139	nucleus	_
197-192	32140-32152	connectivity	_
197-193	32153-32155	in	_
197-194	32156-32169	schizophrenia	_
197-195	32170-32174	Poor	_
197-196	32175-32182	outcome	_
197-197	32183-32185	in	_
197-198	32186-32193	chronic	_
197-199	32194-32207	schizophrenia	_
197-200	32208-32210	is	_
197-201	32211-32221	associated	_
197-202	32222-32226	with	_
197-203	32227-32238	progressive	_
197-204	32239-32243	loss	_
197-205	32244-32246	of	_
197-206	32247-32253	volume	_
197-207	32254-32256	of	_
197-208	32257-32260	the	_
197-209	32261-32268	putamen	_
197-210	32269-32277	Abnormal	_
197-211	32278-32282	long	_
197-212	32282-32283	-	_
197-213	32284-32287	and	_
197-214	32288-32299	short-range	_
197-215	32300-32310	functional	_
197-216	32311-32323	connectivity	_
197-217	32324-32326	in	_
197-218	32327-32343	adolescent-onset	_
197-219	32344-32357	schizophrenia	_
197-220	32358-32366	patients	_
197-221	32366-32367	:	_
197-222	32368-32369	a	_
197-223	32370-32383	resting-state	_
197-224	32384-32388	fMRI	_
197-225	32389-32394	study	_
197-226	32395-32405	Prediction	_
197-227	32406-32408	of	_
197-228	32409-32419	individual	_
197-229	32420-32428	response	_
197-230	32429-32431	to	_
197-231	32432-32449	electroconvulsive	_
197-232	32450-32457	therapy	_
197-233	32458-32461	via	_
197-234	32462-32469	machine	_
197-235	32470-32478	learning	_
197-236	32479-32481	on	_
197-237	32482-32492	structural	_
197-238	32493-32501	magnetic	_
197-239	32502-32511	resonance	_
197-240	32512-32519	imaging	_
197-241	32520-32524	data	_
197-242	32526-32531	DPABI	_
197-243	32531-32532	:	_
197-244	32533-32537	data	_
197-245	32538-32548	processing	_
197-246	32549-32550	&	_
197-247	32551-32559	analysis	_
197-248	32560-32563	for	_
197-249	32564-32565	(	_
197-250	32565-32578	resting-state	_
197-251	32578-32579	)	_
197-252	32580-32585	brain	_
197-253	32586-32593	imaging	_
197-254	32594-32605	Overlapping	_
197-255	32606-32609	and	_
197-256	32610-32620	segregated	_
197-257	32621-32634	resting-state	_
197-258	32635-32645	functional	_
197-259	32646-32658	connectivity	_
197-260	32659-32661	in	_
197-261	32662-32670	patients	_
197-262	32671-32675	with	_
197-263	32676-32681	major	_
197-264	32682-32692	depressive	_
197-265	32693-32701	disorder	_
197-266	32702-32706	with	_
197-267	32707-32710	and	_
197-268	32711-32718	without	_
197-269	32719-32728	childhood	_
197-270	32729-32736	neglect	_
197-271	32737-32746	Disrupted	_
197-272	32747-32755	cortical	_
197-273	32756-32760	hubs	_
197-274	32761-32763	in	_
197-275	32764-32774	functional	_
197-276	32775-32780	brain	_
197-277	32781-32789	networks	_
197-278	32790-32792	in	_
197-279	32793-32799	social	_
197-280	32800-32807	anxiety	_
197-281	32808-32816	disorder	_
197-282	32817-32822	Graph	_
197-283	32823-32834	theoretical	_
197-284	32835-32843	analysis	_
197-285	32844-32846	of	_
197-286	32847-32857	functional	_
197-287	32858-32863	brain	_
197-288	32864-32872	networks	_
197-289	32872-32873	:	_
197-290	32874-32885	test-retest	_
197-291	32886-32896	evaluation	_
197-292	32897-32899	on	_
197-293	32900-32905	short	_
197-294	32905-32906	-	_
197-295	32907-32910	and	_
197-296	32911-32920	long-term	_
197-297	32921-32934	resting-state	_
197-298	32935-32945	functional	_
197-299	32946-32949	MRI	_
197-300	32950-32954	data	_
197-301	32955-32958	The	_
197-302	32959-32965	global	_
197-303	32966-32972	signal	_
197-304	32973-32976	and	_
197-305	32977-32985	observed	_
197-306	32986-33000	anticorrelated	_
197-307	33001-33008	resting	_
197-308	33009-33014	state	_
197-309	33015-33020	brain	_
197-310	33021-33029	networks	_
197-311	33030-33033	The	_
197-312	33034-33040	impact	_
197-313	33041-33043	of	_
197-314	33044-33050	global	_
197-315	33051-33057	signal	_
197-316	33058-33068	regression	_
197-317	33069-33071	on	_
197-318	33072-33079	resting	_
197-319	33080-33085	state	_
197-320	33086-33098	correlations	_
197-321	33098-33099	:	_
197-322	33100-33103	are	_
197-323	33104-33119	anti-correlated	_
197-324	33120-33128	networks	_
197-325	33129-33139	introduced	_
197-326	33139-33140	?	_

#Text=Correlations and anticorrelations in resting-state functional connectivity MRI: a quantitative comparison of preprocessing strategies
#Text=Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease
#Text=Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion
#Text=REST: a toolkit for resting-state functional magnetic resonance imaging data processing
#Text=Functional specialization in the human brain estimated by intrinsic hemispheric interaction
#Text=Abnormal default-mode network homogeneity in first-episode, drug-naive schizophrenia at rest
#Text=Spontaneous low-frequency fluctuations in the BOLD signal in schizophrenic patients: anomalies in the default network
#Text=Resting-state functional network correlates of psychotic symptoms in schizophrenia
#Text=Altered functional and anatomical connectivity in schizophrenia
#Text=Decreased default-mode network homogeneity in unaffected siblings of schizophrenia patients at rest
#Text=Heritability of changes in brain volume over time in twin pairs discordant for schizophrenia
#Text=The association between the Val158Met polymorphism of the catechol-O-methyl transferase gene and morphological abnormalities of the brain in chronic schizophrenia
#Text=Reduced prefrontal functional connectivity in the default mode network is related to greater psychopathology in subjects with high genetic loading for schizophrenia
#Text=Amplitude of low-frequency oscillations in schizophrenia: a resting state fMRI study
#Text=Early-stage visual processing deficits in schizophrenia
#Text=Aging gracefully: compensatory brain activity in high-performing older adults
#Text=Is there a cerebellar compensatory effort in first-episode, treatment-naive major depressive disorder at rest?
198-1	33141-33153	Correlations	_
198-2	33154-33157	and	_
198-3	33158-33174	anticorrelations	_
198-4	33175-33177	in	_
198-5	33178-33191	resting-state	_
198-6	33192-33202	functional	_
198-7	33203-33215	connectivity	_
198-8	33216-33219	MRI	_
198-9	33219-33220	:	_
198-10	33221-33222	a	_
198-11	33223-33235	quantitative	_
198-12	33236-33246	comparison	_
198-13	33247-33249	of	_
198-14	33250-33263	preprocessing	_
198-15	33264-33274	strategies	_
198-16	33275-33283	Cortical	_
198-17	33284-33288	hubs	_
198-18	33289-33297	revealed	_
198-19	33298-33300	by	_
198-20	33301-33310	intrinsic	_
198-21	33311-33321	functional	_
198-22	33322-33334	connectivity	_
198-23	33334-33335	:	_
198-24	33336-33343	mapping	_
198-25	33343-33344	,	_
198-26	33345-33355	assessment	_
198-27	33356-33358	of	_
198-28	33359-33368	stability	_
198-29	33368-33369	,	_
198-30	33370-33373	and	_
198-31	33374-33382	relation	_
198-32	33383-33385	to	_
198-33	33386-33397	Alzheimer's	_
198-34	33398-33405	disease	_
198-35	33406-33414	Spurious	_
198-36	33415-33418	but	_
198-37	33419-33429	systematic	_
198-38	33430-33442	correlations	_
198-39	33443-33445	in	_
198-40	33446-33456	functional	_
198-41	33457-33469	connectivity	_
198-42	33470-33473	MRI	_
198-43	33474-33482	networks	_
198-44	33483-33488	arise	_
198-45	33489-33493	from	_
198-46	33494-33501	subject	_
198-47	33502-33508	motion	_
198-48	33509-33513	REST	_
198-49	33513-33514	:	_
198-50	33515-33516	a	_
198-51	33517-33524	toolkit	_
198-52	33525-33528	for	_
198-53	33529-33542	resting-state	_
198-54	33543-33553	functional	_
198-55	33554-33562	magnetic	_
198-56	33563-33572	resonance	_
198-57	33573-33580	imaging	_
198-58	33581-33585	data	_
198-59	33586-33596	processing	_
198-60	33597-33607	Functional	_
198-61	33608-33622	specialization	_
198-62	33623-33625	in	_
198-63	33626-33629	the	_
198-64	33630-33635	human	_
198-65	33636-33641	brain	_
198-66	33642-33651	estimated	_
198-67	33652-33654	by	_
198-68	33655-33664	intrinsic	_
198-69	33665-33676	hemispheric	_
198-70	33677-33688	interaction	_
198-71	33689-33697	Abnormal	_
198-72	33698-33710	default-mode	_
198-73	33711-33718	network	_
198-74	33719-33730	homogeneity	_
198-75	33731-33733	in	_
198-76	33734-33747	first-episode	_
198-77	33747-33748	,	_
198-78	33749-33759	drug-naive	_
198-79	33760-33773	schizophrenia	_
198-80	33774-33776	at	_
198-81	33777-33781	rest	_
198-82	33782-33793	Spontaneous	_
198-83	33794-33807	low-frequency	_
198-84	33808-33820	fluctuations	_
198-85	33821-33823	in	_
198-86	33824-33827	the	_
198-87	33828-33832	BOLD	_
198-88	33833-33839	signal	_
198-89	33840-33842	in	_
198-90	33843-33856	schizophrenic	_
198-91	33857-33865	patients	_
198-92	33865-33866	:	_
198-93	33867-33876	anomalies	_
198-94	33877-33879	in	_
198-95	33880-33883	the	_
198-96	33884-33891	default	_
198-97	33892-33899	network	_
198-98	33900-33913	Resting-state	_
198-99	33914-33924	functional	_
198-100	33925-33932	network	_
198-101	33933-33943	correlates	_
198-102	33944-33946	of	_
198-103	33947-33956	psychotic	_
198-104	33957-33965	symptoms	_
198-105	33966-33968	in	_
198-106	33969-33982	schizophrenia	_
198-107	33983-33990	Altered	_
198-108	33991-34001	functional	_
198-109	34002-34005	and	_
198-110	34006-34016	anatomical	_
198-111	34017-34029	connectivity	_
198-112	34030-34032	in	_
198-113	34033-34046	schizophrenia	_
198-114	34047-34056	Decreased	_
198-115	34057-34069	default-mode	_
198-116	34070-34077	network	_
198-117	34078-34089	homogeneity	_
198-118	34090-34092	in	_
198-119	34093-34103	unaffected	_
198-120	34104-34112	siblings	_
198-121	34113-34115	of	_
198-122	34116-34129	schizophrenia	_
198-123	34130-34138	patients	_
198-124	34139-34141	at	_
198-125	34142-34146	rest	_
198-126	34147-34159	Heritability	_
198-127	34160-34162	of	_
198-128	34163-34170	changes	_
198-129	34171-34173	in	_
198-130	34174-34179	brain	_
198-131	34180-34186	volume	_
198-132	34187-34191	over	_
198-133	34192-34196	time	_
198-134	34197-34199	in	_
198-135	34200-34204	twin	_
198-136	34205-34210	pairs	_
198-137	34211-34221	discordant	_
198-138	34222-34225	for	_
198-139	34226-34239	schizophrenia	_
198-140	34240-34243	The	_
198-141	34244-34255	association	_
198-142	34256-34263	between	_
198-143	34264-34267	the	_
198-144	34268-34277	Val158Met	_
198-145	34278-34290	polymorphism	_
198-146	34291-34293	of	_
198-147	34294-34297	the	_
198-148	34298-34315	catechol-O-methyl	_
198-149	34316-34327	transferase	_
198-150	34328-34332	gene	_
198-151	34333-34336	and	_
198-152	34337-34350	morphological	_
198-153	34351-34364	abnormalities	_
198-154	34365-34367	of	_
198-155	34368-34371	the	_
198-156	34372-34377	brain	_
198-157	34378-34380	in	_
198-158	34381-34388	chronic	_
198-159	34389-34402	schizophrenia	_
198-160	34403-34410	Reduced	_
198-161	34411-34421	prefrontal	_
198-162	34422-34432	functional	_
198-163	34433-34445	connectivity	_
198-164	34446-34448	in	_
198-165	34449-34452	the	_
198-166	34453-34460	default	_
198-167	34461-34465	mode	_
198-168	34466-34473	network	_
198-169	34474-34476	is	_
198-170	34477-34484	related	_
198-171	34485-34487	to	_
198-172	34488-34495	greater	_
198-173	34496-34511	psychopathology	_
198-174	34512-34514	in	_
198-175	34515-34523	subjects	_
198-176	34524-34528	with	_
198-177	34529-34533	high	_
198-178	34534-34541	genetic	_
198-179	34542-34549	loading	_
198-180	34550-34553	for	_
198-181	34554-34567	schizophrenia	_
198-182	34568-34577	Amplitude	_
198-183	34578-34580	of	_
198-184	34581-34594	low-frequency	_
198-185	34595-34607	oscillations	_
198-186	34608-34610	in	_
198-187	34611-34624	schizophrenia	_
198-188	34624-34625	:	_
198-189	34626-34627	a	_
198-190	34628-34635	resting	_
198-191	34636-34641	state	_
198-192	34642-34646	fMRI	_
198-193	34647-34652	study	_
198-194	34653-34664	Early-stage	_
198-195	34665-34671	visual	_
198-196	34672-34682	processing	_
198-197	34683-34691	deficits	_
198-198	34692-34694	in	_
198-199	34695-34708	schizophrenia	_
198-200	34709-34714	Aging	_
198-201	34715-34725	gracefully	_
198-202	34725-34726	:	_
198-203	34727-34739	compensatory	_
198-204	34740-34745	brain	_
198-205	34746-34754	activity	_
198-206	34755-34757	in	_
198-207	34758-34773	high-performing	_
198-208	34774-34779	older	_
198-209	34780-34786	adults	_
198-210	34787-34789	Is	_
198-211	34790-34795	there	_
198-212	34796-34797	a	_
198-213	34798-34808	cerebellar	_
198-214	34809-34821	compensatory	_
198-215	34822-34828	effort	_
198-216	34829-34831	in	_
198-217	34832-34845	first-episode	_
198-218	34845-34846	,	_
198-219	34847-34862	treatment-naive	_
198-220	34863-34868	major	_
198-221	34869-34879	depressive	_
198-222	34880-34888	disorder	_
198-223	34889-34891	at	_
198-224	34892-34896	rest	_
198-225	34896-34897	?	_

#Text=Task-related activity in prefrontal cortex and its relation to recognition memory performance in young and old adults
#Text=Using structural neuroanatomy to identify trauma survivors with and without post-traumatic stress disorder at the individual level
#Text=abnormal causal connectivity by structural deficits in first-episode, drug-naive schizophrenia at rest
#Text=Short-term effects of antipsychotic treatment on cerebral function in drug-naive first-episode schizophrenia revealed by "resting state" functional magnetic resonance imaging
#Text=Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis
#Text=Functional effects of antipsychotic drugs: comparing clozapine with haloperidol
#Text=Cerebral metabolism and risperidone treatment in schizophrenia
#Text=Supplementary data
#Text=Supplementary data to this article can be found online at https://doi.org/10.1016/j.ebiom.2018.09.012.
199-1	34898-34910	Task-related	_
199-2	34911-34919	activity	_
199-3	34920-34922	in	_
199-4	34923-34933	prefrontal	_
199-5	34934-34940	cortex	_
199-6	34941-34944	and	_
199-7	34945-34948	its	_
199-8	34949-34957	relation	_
199-9	34958-34960	to	_
199-10	34961-34972	recognition	_
199-11	34973-34979	memory	_
199-12	34980-34991	performance	_
199-13	34992-34994	in	_
199-14	34995-35000	young	_
199-15	35001-35004	and	_
199-16	35005-35008	old	_
199-17	35009-35015	adults	_
199-18	35016-35021	Using	_
199-19	35022-35032	structural	_
199-20	35033-35045	neuroanatomy	_
199-21	35046-35048	to	_
199-22	35049-35057	identify	_
199-23	35058-35064	trauma	_
199-24	35065-35074	survivors	_
199-25	35075-35079	with	_
199-26	35080-35083	and	_
199-27	35084-35091	without	_
199-28	35092-35106	post-traumatic	_
199-29	35107-35113	stress	_
199-30	35114-35122	disorder	_
199-31	35123-35125	at	_
199-32	35126-35129	the	_
199-33	35130-35140	individual	_
199-34	35141-35146	level	_
199-35	35147-35155	abnormal	_
199-36	35156-35162	causal	_
199-37	35163-35175	connectivity	_
199-38	35176-35178	by	_
199-39	35179-35189	structural	_
199-40	35190-35198	deficits	_
199-41	35199-35201	in	_
199-42	35202-35215	first-episode	_
199-43	35215-35216	,	_
199-44	35217-35227	drug-naive	_
199-45	35228-35241	schizophrenia	_
199-46	35242-35244	at	_
199-47	35245-35249	rest	_
199-48	35250-35260	Short-term	_
199-49	35261-35268	effects	_
199-50	35269-35271	of	_
199-51	35272-35285	antipsychotic	_
199-52	35286-35295	treatment	_
199-53	35296-35298	on	_
199-54	35299-35307	cerebral	_
199-55	35308-35316	function	_
199-56	35317-35319	in	_
199-57	35320-35330	drug-naive	_
199-58	35331-35344	first-episode	_
199-59	35345-35358	schizophrenia	_
199-60	35359-35367	revealed	_
199-61	35368-35370	by	_
199-62	35371-35372	"	_
199-63	35372-35379	resting	_
199-64	35380-35385	state	_
199-65	35385-35386	"	_
199-66	35387-35397	functional	_
199-67	35398-35406	magnetic	_
199-68	35407-35416	resonance	_
199-69	35417-35424	imaging	_
199-70	35425-35437	Relationship	_
199-71	35438-35445	between	_
199-72	35446-35454	duration	_
199-73	35455-35457	of	_
199-74	35458-35467	untreated	_
199-75	35468-35477	psychosis	_
199-76	35478-35481	and	_
199-77	35482-35489	outcome	_
199-78	35490-35492	in	_
199-79	35493-35506	first-episode	_
199-80	35507-35520	schizophrenia	_
199-81	35520-35521	:	_
199-82	35522-35523	a	_
199-83	35524-35532	critical	_
199-84	35533-35539	review	_
199-85	35540-35543	and	_
199-86	35544-35557	meta-analysis	_
199-87	35558-35568	Functional	_
199-88	35569-35576	effects	_
199-89	35577-35579	of	_
199-90	35580-35593	antipsychotic	_
199-91	35594-35599	drugs	_
199-92	35599-35600	:	_
199-93	35601-35610	comparing	_
199-94	35611-35620	clozapine	_
199-95	35621-35625	with	_
199-96	35626-35637	haloperidol	_
199-97	35638-35646	Cerebral	_
199-98	35647-35657	metabolism	_
199-99	35658-35661	and	_
199-100	35662-35673	risperidone	_
199-101	35674-35683	treatment	_
199-102	35684-35686	in	_
199-103	35687-35700	schizophrenia	_
199-104	35701-35714	Supplementary	_
199-105	35715-35719	data	_
199-106	35720-35733	Supplementary	_
199-107	35734-35738	data	_
199-108	35739-35741	to	_
199-109	35742-35746	this	_
199-110	35747-35754	article	_
199-111	35755-35758	can	_
199-112	35759-35761	be	_
199-113	35762-35767	found	_
199-114	35768-35774	online	_
199-115	35775-35777	at	_
199-116	35778-35783	https	_
199-117	35783-35784	:	_
199-118	35784-35785	/	_
199-119	35785-35786	/	_
199-120	35786-35793	doi.org	_
199-121	35793-35794	/	_
199-122	35794-35801	10.1016	_
199-123	35801-35802	/	_
199-124	35802-35809	j.ebiom	_
199-125	35809-35821	.2018.09.012	_
199-126	35821-35822	.	_
